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Summary
There is an urgent need to develop novel therapeutic strategies for common 
solid tumours including small cell lung cancer where the five year survival rate is less 
than 5%. The natural product nordihydroguaiaretic acid (NDGA) (A) has been shown 
to block the growth of small cell lung cancer in vitro and in vivo.
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In order to realise the potential of NDGA as an effective anti-cancer agent we 
set up a collaboration with Dr. M. Seckl (Hammersmith Hospital) with the goal of 
producing a more potent analogue. Initially we concentrated on the synthesis of the 
racemate of NDGA (B) which would ascertain whether the stereochemistry of the 
methyl groups was important for activity. Our four step synthesis employed a pinacol 
coupling as the key step affording (B) in low overall yield. The preliminary test results 
showed (B) to be equipotent to NDGA suggesting that the stereochemistry of the 
methyl groups is not important for activity.
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To help in the determination of structural activity relationships we synthesised a 
series of analogues of NDGA having different bridging distances between the aromatic 
nuclei. The synthesis of a series of mono phenolic compounds was also undertaken 
following the same procedures. The diarylbutane derivative (C) was found to be 10 
fold more potent than NDGA in vitro suggesting that the methyl groups of (A) 
hindered its activity or that improved activity was due to decreased lipophilicity. A 
number of amide derivatives were also synthesised allowing access to more
conformationally restricted analogues. The test results showed that the secondary 
amide (D) was four times more potent than NDGA. However the corresponding N-Mq 
derivative was less active.
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The poor aqueous solubility of NDGA has hampered its development as an 
effective anti-cancer agent. With this in mind, we have been working on the synthesis 
of a water soluble conjugate of NDGA which would release the active component over 
a period of time. The tetra glycyl salt (E) was synthesised. This is water soluble as 
expected but has slighty less activity than the parent compound. On the other hand, the 
ammonium salt (F) was found to be water soluble and twice as potent as NDGA and is 
cuiTently undergoing in vivo testing.
1
Introduction
1.1 Cancer - What is it ?
The term cancer is derived from the Latin cancer and the Greek karkinos 
meaning crab and is so called as like a crab tumours have a central core and limbs 
through which the disease can spread throughout the body. Cancer is fundamentally a 
disease at the cellular level resulting in the uncontrolled cell proliferation of an 
abnormal cell which has broken free from the normal control mechanisms. A clear 
example of this is that a normal cultured cell will multiply only until a single layer has 
been formed whereas a cancer cell will continue to grow into a cell mass until the 
nutrients of the growth medium have been exhausted. Cancer cells are said to ignore 
density-dependent inhibition.
If a tumour remains at the original site, the lump is called a benign tumour. If 
untreated early the cancer cells can invade surrounding tissues, enter the circulation and 
set up secondary growths or métastasés. The tumour is now termed malignant and an 
individual with a malignant tumour is said to have cancer. In time the involvement of 
vital organs and general debility will lead to patient death.
1.2 The Cancer Problem
In developed countries cancer is probably the most feared disease of our time. 
It has afflicted our ancestors throughout human evolution with Egyptian medical tracts 
reporting diseases recognisable as cancer as long as 3500 years ago. As a cause of 
mortality it is second only to cardiovascular disease in the Western world. It is a 
chilling fact that one third of us will develop cancer at some stage in our lives and of 
these one half will die as a result. In the United States alone one person dies every 
sixty two seconds from the disease. 1 Cancer can occur at all ages but becomes more 
prevalent as one grows older undoubtedly due to the increased exposure to cancer 
causing agents (carcinogens).
On a brighter note, the amount of patients surviving for more than five years 
after diagnosis has been on the increase since the turn of the century. By the 1930s 
only one fifth of patients survived over five years and by 1990 this figure had risen to 
50%. Although the standard of cancer treatment is far from optimal there have been 
significant advances. These include the treatment of testicular cancer, Hodgkin's
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disease and Wilm's tumour although unfortunately these cancer types account for a 
relatively low proportion compared to the major common types including breast, lung 
and prostate cancers.
1.3 Cell Division and The Cell Cycle
It was initially thought that DNA replication was a continual process between 
the period of cell division (mitosis) but early in the 1950s it became possible to carry 
out some labelling experiments using the labelled nitrogenous base thymidine. Even in 
rapidily proliferating cells this revealed a distinct gap during and after DNA formation 
and led to the discovery of the cell cycle. The process of mitosis is now a well defined 
sequence of events that can be conveniently represented as shown in Figure 1.  ^The 
cycle has four distinct phases and the time taken for one complete cycle, Tc, varies 
from one cell type to another (Table 1).  ^The Tc of a rapidly dividing duodenum cell 
is ca. 18 h whereas the cell cycle of a liver cell is greater than 10,000 h.
Table 1 - The duration of the cell cycle for a variety of cell types (Hours)
Cell type Tc G l S G2 M
Marrow ~ 13 2 8 2 0.7
Ileum -  17 6 8 2 0.7
Duodenum ~ 18 7 8 2 0.7
Colon ~ 33 22 8 2 0.7
Tongue - 4 0 28 8 2 0.7
Esophagus ~ 181 170 8 2 0.7
Skin ~ 1,000 989 8 2 0.7
Liver > 10,000 >9,989 8 2 0.7
The Gi and G2 phases of the cell cycle are concerned with the synthesis of 
RNA, proteins and cytoplasmic organelles required for DNA replication and cell 
division. In the S phase the cell duplicates its DNA and the cycle is completed when 
mitosis forms two identical daughter cells in the M phase. The two daughter cells can 
now either be commited to further mitosis or enter a resting phase Gq. The process of 
events is highly regulated and controlled; however, once the cell enters the S phase it 
normally proceeds through the rest of the cycle. For the majority of cells the duration 
of the S, G2 and M phases tends to be fairly constant whatever the length of the cycle 
(Table 1) and the duration of the cycle seems to be controlled by the length of time 
spent in the resting Gq phase. A rapidly proliferating cell will have a short G i period 
whereas a slowly reproducing liver cell has a Gi period of more than 400 d.
It was initially thought that a tumour's growth arose from a complement of 
abnormal cells that proliferated at a higher rate than the surronding normal tissue. 
However, the average Tc of a human tumuor cell is 48 h and this, if anything, is 
fractionally longer than the Tc of a normal non-malignant cell type. If this was the only 
factor determining growth then the tumour would grow at the same rate or even slower 
than normal tissue and would pose little problem.
Figure 1 - The Cell Cycle
There are approximately 25 million cell divisions in the adult human every 
second and mistakes or malfunctions are very rare. Cells are constantly dividing to 
replace ones lost from injury or cell death to maintain a constant population but 
whereas normal cells remain in the G i phase until programmed to divide, a cancer cell 
has apparently lost this capacity and the control mechanisms that govern a normal cell 
are absent. This loss of control allows a tumour to continue growing and the normal 
mechanisms that control proliferation including the presence of growth factors, contact 
inhibition and programmed cell death (apoptosis) have little effect.
1.4 Cancer - The Causes
Tobacco smoking is the single largest cause of cancer and accounts for 30 % 
of all cancers and, including lung cancer, is responsible for cancers of the mouth, 
larynx, pancreas and kidney to name a few. The next most common cause of cancer 
concerns the way we live with risks associated with diet, alcohol use, sexual behaviour 
and exposure to sunlight. It is not surprising that high exposures to carcinogens 
whether it be through our occupational or social lives have been linked to human
cancers. Only 1-2 % of total cancers arise from inheritance although a high percentage 
of certain tumour types aie genetically determined. Examples in this aiea include 40 % 
of retinoblastomas and 20-40 % of Wilm's tumours which are linked to a genetic 
predisposition. The following three sub-sections discuss the factors that lead to cancer 
in more detail.
1.4.1 Chemical Carcinogenesis
In 1762 John Hill noticed a high incidence of nasal cancer among tobacco 
snuff users. The English physician Percival Pott discovered in 1775 a link between 
scrotal cancer and the exposure of chimney sweeps to soot and tar over many years. It 
had also been recorded by 1900 that workers in the coal tar and pitch industries stood a 
higher chance of developing skin cancer. Subsequent animal experiments carried out 
by two Japanese researchers confirmed the link between coal tar and cancer.^ Organic 
solvents such as benzene and toluene aie present in coal tar along with phenols, cresols, 
naphthalenes and aniline dyes, many of which are now proven carcinogens.^
The feature common to the diverse range of chemical carcinogens is their 
ability to generate reactive electrophilic forms that can be attacked by the numerous 
nucleophilic sites on DNA. These carcinogens either need to be metabolised by a 
variety of enzymes prior to reaction or may react directly like dimethyl sulfate 1 and 
uracil mustard 2 which are intrinsically electrophilic.
V°o
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The activation of the parent or procarcinogen to the active (ultimate) form may 
proceed directly or go through a number of less reactive intermediates called proximate 
forms (Figure 2).^ Detoxification products can also arise from this metabolism and 
are excreted from the body. The chief role of enzymes in these processes is to convert 
the foreign lipophilic agent into a more hydrophilic form that can be readily excreted 
and a consequence of this enzymatic manipulation can be the inadvertent production of 
a reactive product.
An example of such a process is shown in Figure 3  ^involving the polycyclic 
aromatic hydrocarbon (PAH) benzo[a]pyrene which is one of the carcinogens present 
in tobacco smoke. At first sight this compound looks unreactive but a series of 
enzymatic oxidation steps form the 7,8-dihydrodiol-9,10-epoxide which is the ultimate
HN
H
electrophilic form. This in turn can react with the 2-amino group of guanine residues in 
DNA.
Figure 2 - The metabolic activation and detoxification 
of chemical carcinogens.
I ProcaicinogenlI
Metabolic activalioii
Detoxification products|- <   | Proximate carcinogen]
Ul Li mate carcinogen Reaction at nucleopiiilic
electrophile sites in DNA
Initiation is the process whereby a cell is exposed to a limited dose of a 
carcinogenic substance but does not progress into a cancer cell without further 
alteration. Initiation is irreversible and an initiated cell can only be removed by DNA 
repair or cell death. An initiated cell may be converted into a cancer cell by a process 
called promotion which can arise from further exposure to the initiating agent or from 
an agent incapable of inducing a neoplastic transformation itself. A carcinogen that has 
the ability to both initiate and promote cancer is called a complete carcinogen.
Tobacco smoke is a complex mixture of more than 6000 substances and 
approximately 50 of these are carcinogenic including a variety of PAHs, aromatic 
amines and nickel containing compounds. Although the Control of Substances 
Hazardous to Health act (COSHH) was introduced in 1989 seeking to minimise 
exposure to potentially dangerous chemicals there are carcinogens present in the air we 
breathe and the water we drink and although their concentrations are low they must be 
taken into account. Food and drink have long being attributed to causing cancer and an 
link between alcohol and cancers of the mouth, pharynx, larynx and oesophagus was 
discovered more than 50 years ago.^ In summary, chemical carcinogens are widespread 
with the majority having been introduced into our environment by Man himself. Taking 
this into account the possibilities of drastically reducing the cancer problem by 
prevention of exposure are high.
1.4.2 Radiation Carcinogenesis
Humans are constantly being exposed to radiation from a variety of sources 
and it is an integral part of our environment. This radiation can be natural like cosmic
rays from outer space, ultraviolet rays from the sun and emissions from radioactive 
nuclei present in rocks and soil or it can arise from anthropogenic sources including 
medical X rays and industrial or military radioactivity. In addition to these an increase 
in our exposure to ultrahigh frequency soundwaves (ultrasound) may be linked to 
cancer.
Figure 3 - Metabolic activation of benzo[«]pyrene
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Solar Radiation and Cancer
Ultraviolet (UV) light is the primary source of skin cancer which is most 
prévalant for people living at tropical latitudes where the sun is at its most intense. Skin 
cancer is extremely common but rarely lethal due to non-melanoma type skin cancers 
being highly curable owing to their easy detection and slow metastasis. On the other 
hand melanoma is a much more serious form of skin cancer. Originating in pigment 
cells they are highly malignant and commonly metastasise long before recognition. 
Unfortunately the incidence of melanoma is on the increase throughout the world
probably due to increased sun bathing and tanning lamps and is responsible for 
perhaps 1-2% of cancer mortality in the United States.
UV light is absorbed by DNA and readily induces mutations by transforming 
molecules into a short-lived excited state that renders them chemically reactive. For 
example, excitation of pyrimidine bases (thymine or cytosine) allows them to either 
react with water thus forming pyrimidine hydrates or dimerise to give a chemically 
stable cyclobutane type linkage (Figure 4).^ The hydrated base can then eliminate 
water to give either the original pyrimidine or in the case of cytosine a deaminated 
derivative, in this case uracil. Interaction with the excited pyrimidine with other 
molecules including amino acids and proteins can give rise to DNA-protein cross links 
which could also explain the potent effects of UV radiation.
Figure 4 - Interaction of UV light with bases.
1. Altered base
NH;
-N H . HN'+ iiv
2. Dimérisation of tiiymine
HN' HN' NH
Ionising Radiation and Cancer
Ionising radiation is of a higher energy than UV and includes X rays and 
radiation arising from the radioactive decay of radioactive nuclei. This increased energy 
has the ability to break chemical bonds and cause genetic mutations within the DNA 
sequence. The first cancers resulting from exposure to X rays were observed only 
seven years after their discovery by Roentgen in 1895. Radiologists who used X rays 
extensively in the early 1900s had a three to four fold increased chance of developing 
leukaemia. Subsequent animal experiments revealed the induction of sarcomas in 
laboratory animals after radiation exposure. ^ 0
As a cell is composed of 80% water, ionisation results in water fragmentation 
giving rise to three reactive species namely the hydroxyl radical (OFF), the solvated 
electron and the hydrogen radical (H°). The radicals are short lived and readily 
dimerise to give hydrogen peroxide and hydrogen respectively; however they can
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damage a cell's DNA. (Figure This damage can lead to base alteration or loss 
and attack on the sugar phosphate backbone which can lead to single or double DNA 
strand breaks.
Figure 5 - Base damage and Ionizing radiation
(1) A liyclroxyl radical attacks tiiymine forming an altered base
O O
J- J-
(2 ) Cleavage of a gylcosidic bond resulting in pyrimidine base loss
” 1 ---------1----------------------------------------- “ 1----------1--------- T "
T C G "  T  C S
Radioactive elements
Radioactive elements are known to emit similar forms of radiation as X rays 
and their carcinogenic nature was known long before X rays were fully understood. 
Marie Curie who codiscovered the radioactive elements polonium and radium died 
from an anaemia undoubtedly resulting from her close association with these metals. 
Another example of radium carcinogenesis was observed in the 1930s when a group of 
young women developed bone cancer after ingesting radium from paint by licking 
brushes used to paint watch and clock dials. An increased risk for persons surviving 
the atomic bombs dropped during World War II over Hiroshima and Nagasaki is well 
documented.
1.4.3 Viruses and Cancer
Viruses are responsible for a number of disease types including cold sores, 
influenza, hepatitis and mumps. They are intracellular parasites which invade suitable 
host cells and use their cellular machinery to reproduce. Unlike the other disease 
causing viruses, cancer causing (oncogenic) viruses do not kill their host cell but alter 
their genetic program controlling differentiation and reproduction resulting in the onset 
of cancer. Structurally a virus is composed of one or a few tightly coiled nucleic acid 
molecules surrounded by a protein capsule. The nucleic acids within these proteins can 
be DNA or RNA although their mode of action is similar. On entry into the host cell 
the protein coat disappears, the nucleic acid is released into the cytoplasm and can 
become incorporated into the host's DNA now being part of its genetic makeup. After 
incorporation, some of the viral genes continue to be active and are copied into niRNA
molecules which in turn are translated into viral proteins. Some of these are able to 
change the activities of the infected cell so it becomes transformed or cancerous. 
Furthermore, these viral proteins can become incorporated into new viral particles able 
to leave and infect surrounding cells (Figure 6). ^  ^  Oncogenic RNA viruses behave in a 
similiar fashion although on entry to the host cell the viral RNA must make a DNA 
copy of itself utilising the enzyme reverse transcriptase.
Figure 6 - Events in the life of a oncogenic DNA virus
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There are four types of virus directly associated with human cancer (Table 
2). Unlike EBV and HTLV which are relatively uncommon, HBV induced 
hepatocellular carcinoma and HPV induced cervical carcinoma may account for 10- 
20% of overall cancer incidence. HIV also indirectly causes a high frequency of
Kaposi's sarcoma mainly attributed to the immunodeficiency suffered by the AIDS 
patient. It is suggested that worldwide viruses may account for 25% of the 80% of 
cancers derived from environmental factors.
Table 2 - Viruses Associated with Human Cancers
Virus Type of Cancer
Hepatitis B vims (HBV) Hepatocellular carcinoma
Human papilloma viruses (HPV) Cervical and other anogenital carcinomas, 
squamous cell skin earcinomas
Epstein-Barr virus (EBV) Burkitt's and other B-cell lymphomas, 
nasopharyngeal carcinaoma
Human T-cell lymphotropic virus 
(HTLV-I)
Adult T-cell leukaemia
Human immunodeficiency virus (HIV) Lymphomas, Kaposi's sarcoma, 
anogenital carcinomas
1.5 Cancer Treatment
Once a patient has been diagnosed with cancer the choice of treatment is 
dependent on the type of cancer and how far it has progressed. In most types of cancer 
the likelihood of a cure is dependent on early detection of the disease and before it has 
had time to spread. The unfortunate outcome common to the majority of cancers is that 
by the time of diagnosis the disease has already metastasised. The following sections 
survey the main methods available for cancer treatment today.
1.5.1 Surgery
Cancer surgery, which is known to date back to the ancient Greeks who 
amputated cancerous breasts, has evolved along with general surgery becoming safe 
and effective during this century with the aid of anaesthetics, antibiotics and blood 
transfusions. Although surgery can be an effective treatment with localised cancer cells, 
about 70% of eaneers by the time of detection have metastasised and cannot be cured 
by surgery alone. Nonmelanoma skin cancers, which do not readily metastasise, along 
with easily accessible cancers of the uterine cervix can be surgically removed and offer 
a high cure rate. Some benign tumours are only life threatening due to occupying 
inoperable locations, such as some brain tumours. Once the cancer has metastasised it 
becomes difficult to be sure that all the cancer cells have been eliminated by surgery.
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With this in mind, removal of an area of tissue, perhaps including regional lymph 
nodes which may be infected, is often undertaken in an attempt to eliminate all of the 
cancer cells.
Although surgery is a local treatment and is not totally effective in the majority 
of cases it does have its benefits. The removal of tumour specimens along with regional 
lymph nodes can play an important role in determining how far the cancer has 
progressed thus giving a valuable insight into the optimal therapy that should be 
administered. Even in advanced cases with a terminally ill patient removal of a tumour 
mass may significantly reduce pain and allow a greater quality of life. The combination 
of surgery along with other modalities (adjuvant therapy) such as those described 
below is the most common form of treatment today.
1.5.2 Radiation
Radiation therapy is similar to surgery being a local treatment although able to 
penetrate to areas of infected tissue inoperable by surgical procedures. It is therefore 
common for radiation therapy to be used in combination with surgery to eradicate 
cancer cells that have infected surrounding tissue outwith the main tumour mass. An 
example of this is in early breast cancer where routinely, surgical removal of the 
primary tumour and nearby lymph nodes is followed by radiation to kill remaining 
tumour cells.
Both X rays and radioactive nuclei, such as cobalt-60, are used in radiation 
therapy with their role being to damage DNA directly or by the production of free 
radicals within cells. This damage is most pronounced in rapidly proliferating cells but 
unfortunately, this includes cancer eells and some normal tissue cells. The sensitivity of 
some cells, such as blood-forming cells, the epethial cells that line the intestine, the cells 
that form hair and the cells of the reproductive organs, are responsible for some of the 
side effects of radiation therapy including anaemia, diarrhoea, hair loss and sterility. 
Radiation however is sometimes prefeiTed over surgery for treatment of local tumours. 
An example is laryngeal cancer which can effectively be treated by radiation whereas 
surgery would remove the vocal chords resulting in speech loss. Similarly areas that 
are difficult to operate on, such as the eyelid and tip of the nose, may be effectively 
treated by radiation.
In summary, radiation can extend the benefits of treatment offered by surgery 
in that it can penetrate further and kill cells in surrounding tissue that can not be 
reached by surgery. Radiation therapy selectively targets rapidly proliferating cells but 
includes some normal cells resulting in unpleasant side effects. The major drawback of 
the two therapies described above is that if a tumour has metastasised it can no longer 
be treated by local means and the use of chemotherapy to combat this is required.
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1.5.3 Chemotherapy
The third major strategy in the fight against cancer is the use of chemotherapy. 
The majority of chemotherapeutic agents exert their activity by damaging DNA or by 
interfering with cell division. The major advantage of chemotherapy is that, unlike 
surgery and radiation which are localised treatments, it can target metastatic growths 
throughout the body. Unfortunately, like radiation therapy, the drugs used are not 
specific in targeting only cancer cells and the attack on normal rapidly proliferating 
cells results in the same undesirable side effects. It is also possible that some cells 
within the tumour may become resistant to the particular drug as a result of a mutation. 
Although this is very rare, averaging only once in a million cells, a typical tumour is 
composed of billions of cells and it is conceivable that a mutation may occur allowing a 
single cell and its descendants to continue growing. Another problem facing 
chemotherapy is that some agents are carcinogenic themselves and the result of their 
use could be the development of another cancer at a later date. In spite of these 
problems chemotherapeutic agents are used widely in medicine today and the major 
classes including their mechanism of action are described in the following sections.
1.5.3.1 Nitrogen Mustards
The First World War saw the use of mustard gas (sulfur mustard) as a weapon 
used in trench warfare. It was later noticed that casualties suffered a distinct drop in 
their white blood cell count along with damage to both their bone marrow and 
lymphatic system. This observation posed the question that if this was the outcome in 
healthy subjects could it be used to treat those suffering from cancer and so led to the 
first study of cytotoxic agents in the early to mid 1940s. The agents tested were the 
nitrogen mustards which, although structurally resembling their sulfur counterparts, 
were considerably less irritant to normal tissue. Over the following twenty years more 
than three thousand agents were evaluated for testing and of these only about a dozen 
are in clinical use today.
Mechloroethamine 3 is a typical example of such a nitrogen mustard and its 
mechanism of action is shown in Figure 7.13 The formation of the highly reactive and 
electrophilic aziridinium ion is followed by reaction with a nucleophilic site on DNA. 
Formation of these covalent bonds is most common at the N-7 position of the purine 
base guanine. The distance between the two alkyl groups is such that the second 
chloroethyl group can react in a similiar fashion with a second guanine base on a 
complimentary DNA strand. The process is known as cross linking and prevents the 
DNA strands from separating at the time of DNA replication.
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Figure 7 - Nitrogen Mustards - Mechanism of Action
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Due to its severe toxicity and rapid action mechloroethamine 3 is not very 
clinically useful and is now confined for treatment of Hodgkin's disease and other 
lymphomas. Its rapid mode of action is exploited in the use of mechloroethamine in 
clinical emergencies such as superior vena cava obstruction by carcinoma of the 
bronchus.
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In an attempt to solve these problems the mustards melphalan 4 and 
chlorambucil 5 were synthesised in the UK in 1953. The rate of alkylation is 
considerably slower in these mustards as the nitrogen lone pair is delocalised into the 
ring system. This decreased activity allows time for absorption and distribution before 
extensive alkylation occurs and these drugs can be given orally unlike mechlorethamine 
which is administered intravenously. It was hoped that melphalan which closely 
resembles the amino acid phenylalanine would become concentrated in dividing cells 
where it could exert its activity. There is, however, no evidence suggesting this to be the 
case. It is however clinically useful for multiple myeloma and ovarian cancer whereas 
chlorambucil is used in the treatment of chronic lymphocytic leukaemia.
Cyclophosphamide 6 evolved as it was known that high concentrations of 
phosphoamidases were located in tumour cells. It was hypothesised that the drug
13
would remain inert until reaching the tumour site where it could be activated by a 
variety of enzymes. Experiments proved this not to be the case and initial metabolism 
in the liver was required prior to activity. A toxicity unique to cyclophosphamide is 
haemorrhagic cystitis due to excretion of the metabolites acrolein and 4- 
hydroxyphosphamide which have an irritant effect on the bladder mucosa. It has 
however proved to be one of the most successful nitrogen mustards being used in a 
large variety of cancers including carcinoma of the breast and carcinoma of the 
bronchus.
1.5.3.2 Nitrosoureas
This family of chemotherapeutic agents arose from the American National 
Cancer Institute’s drug development programme. The three most important drugs are 
bischloroethylnitrosourea (BCNU) 7, cyclohexylchloroethylnitrosourea (CCNU) 8 
and methyl-cyclohexylchloroethylnitrosourea (methyl-CCNU) 9. The mechanism of 
action of these drugs is not as clearly understood as the nitrogen mustards. Although 
the alkylating action of these drugs is thought to be the major cytotoxic action, 
inhibition of DNA polymerase prevents the repair of DNA strand breaks and RNA 
synthesis. Figure 8 outlines the mechanisms associated with the activity of 
n i t r o s o u r e a s . 4^ An important aspect common to the nitrosoureas, even those with only 
one chloroethyl moiety, is their ability to form interstrand cross-links in DNA. 
Chloroethylation is followed by the slow loss of chloride ion resulting in a second 
alkylation of a base in a complimentary strand.
Due to the lipophilicity of these agents, their ability to cross the blood-brain 
barrier has resulted in their use to treat cerebral tumours. They have also been used in 
the treatment of gastrointestinal adenocarcinoma, lung cancer and lymphoma but only 
in the last case have they been used regularly. A major side effect of the nitrosoureas is 
dose-related delayed bone marrow toxicity with the onset not appearing until four to 
six weeks after dosing. As a consequence of this the drug is given in a single dose and 
a second course is not administered for six weeks. Other common side effects include 
gastrointestinal disturbance leading to nausea and vomiting along with renal and 
hepatic damage.
1.5.3.3 Other Alkylating Agents
The aziridines are a group of agents that closely resemble the aziridium ion 
formed from the nitrogen mustards (Figure 7). Examples include thiotepa 10 and 
mitomycin (mitomycin C) 11 with the latter isolated from Streptomyces species. Their
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mechanism of action is similar to the mustards although, as the aziridine moieties are 
not charged, they are more reactive at an acid pH.
Figure 8 - Nitrosoureas - Mechanism of Action
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Thiotepa is rarely administered systematically due to bone marrow depression 
although it is administered topically to treat papillary carcinoma of the bladder. 
Mitomycin, which is activated by quinone reduction, is a DNA cross-linker. The 
aziridine and carbamate groups are the sites of alkylation and are activated after 
quinone reduction by elimination of methanol.
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Mitomycin has shown activity against a variety of tumour types including 
cancers of the stomach, lung and breast. The major side effect is delayed, cumulative 
myelosuppression.
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The alkane sulfonates, such as busulfan 12, are bifunctional alkylating agents 
through cleavage of the alkyl-oxy bonds giving rise to an interstrand cross-link. Its 
major activity is in the management of chronic myeloid (granulocyte) leukaemia with 
the principal side effects derived for bone marrow suppression.
1.5.3.4 Non Classical Alkylating Agents
The potential of using platinum compounds came from the work of Rosenberg 
and co-workers who demonstrated that certain transition metal complexes could inhibit 
bacterial division under the effects of an electric field. They discovered that it was 
actually electrolysis products from the platinum electrode that were causing this 
inhibition and in 1970 they demonstrated the efficacy of several platinum complexes 
against certain tumour types in mice.
H ,N  Cl
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Although a number of platinum complexes were shown to be active 
experimentally, cisplatin 13 and carboplatin 14 are the only two approved for clinical 
use. The complexes that show anti-tumour activity all contain chloride, bromide or 
malonate leaving groups and not groups, such as nitrate, which are too labile and would 
be useless in vivo. Another observation is that since the ?ra/i.s-isomers tested were all 
ineffective, the cA-configuration is needed for activity but the reasons for this are not 
known. Unlike other alkylating agents, the complexes interact with DNA causing 
intrastrand links predominately between the N-1 atoms of neighbouring guanines. This 
results in a distortion of the DNA chain and is sufficient to inhibit DNA synthesis.
Cisplatin is one of the most frequently used anti-cancer drugs, frequently in 
combination therapy with other drugs, and treats a variety of tumour types, most 
notably testes, lung and bladder. Major toxic effects include nephrotoxicity, peripheral 
neuropathy and ototoxicity with nephrotoxicity being dose-limiting. Cisplatin is 
regularly administered in combination with sulfur containing compounds, such as 
thiosulfate, which do not readily penetrate cells but are excreted by the kidney where 
they can react with any residual drug. Carboplatin was introduced in an attempt to 
lower the side effects arising from the use of cisplatin. Although it exhibited the same 
spectrum of activity and significantly reduced the side effects, its dose-limiting toxicity 
was myelosuppression. Its use is thus confined as an alternative to cisplatin in patients
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who have pre-existing renal dysfunction or patients with a clear disposition for 
neurotoxicity or ototoxicity.
1,53,5 Antimetabolites
The first clinical tests of antimetabolites were carried out by Farber and co­
workers in 1948 and were the second generation of anti-cancer drugs to be discovered. 
In preparation for cell division, a cell must build up a complement of nucleic acids and 
proteins and the antimetabolites interfere with this by either of the following pathways. 
Some of the drugs prevent the syntheses of DNA by poisoning the enzymes required 
to synthesise the nucleotide building blocks of DNA. This occurs during the S period 
of the cell cycle (Figure 1) and cells that cannot complete the cycle will ultimately die. 
Alternatively, some antimetabolites are so similar in structure to normal purines and 
pyrimidines they are able to compete for places in the nucleotide pathway. Although 
many antimetabolites have been evaluated for anti-cancer activity, only a handful are in 
clinical use today. The principal toxicities attributed to all these agents is 
myelosuppression and gastrointestinal disturbances.
Methotrexate
In an attempt to lower the side effects of aminopterin 15, methotrexate 16 was 
introduced after the pioneering work of Faber et al.^^ proving to be equipotent but less 
toxic. The vitamin folic acid 17 plays a pivotal role in the synthesis of purine and 
pyrimidine nucleotides needed for the biosynthesis of DNA. To perform its function 
as a coenzyme, folic acid must be reduced in two successive steps utilising the enzyme 
dihydrofolate reductase (DHFR). It is this final reduced form that can transfer single 
carbon units in a variety of metabolic processes (Figure 9).^^
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As methotrexate is similai' in structure to folic acid its efficacy as an anti-cancer 
agent is attributed to folate antagonism. In addition, substitution of the 4-hydroxyl 
group of folic acid with the amino moiety results in a 100,000 times greater affinity for 
DHFR. The methotrexate-DHFR complex is almost inseparable once formed leading 
to enzyme inactivation resulting in the airest of purine and pyrimidine biosynthesis.
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Figure 9 - Dihydrofolate reductase 
in folic acid metabolism
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Methotrexate has been used to treat a variety of diseases, achieving its greatest 
success in the treatment of choriocarcinoma, a highly malignant cancer that arises from 
the placenta during pregnancy, with a high percentage of women cured. It was first 
used in the treatment of acute leukaemia and is also used in combination with other 
drugs for the adjuvant therapy of breast cancer. It has also found value in the treatment 
of some solid tumours and is particularly active against squamous cell carcinomas.
5-Fluorouracil
The development of 5-flurouracil as an anti-cancer agent arose from the 
observation in 1954 that the uptake of uracil in rats with chemically induced hepatomas 
was greater than that of normal cells. This suggested a distinct difference in the 
biochemistry of these two cell types which could be exploited to target tumour cells 
selectively. 5-Fluorouracil 18, which is structurally very similar to uracil 19, can inhibit 
cell division in the following two ways. Firstly, the enzyme thymidilate synthetase, 
which converts deoxyuridilic acid to thymidilic acid, plays an important role in 
pyrimidine synthesis. 5-Fluorouracil is known to block this enzyme preventing their 
formation therefore arresting the production of DNA. Secondly as a consequence of 
the structural similarity of 5-fluorouracil with uracil, it can become incorporated into 
RNA in place of uracil affecting RNA maturation and processing adversely.
5-Fluorouracil has found extensive use in the treatment of a variety of solid 
tumours most notably the adenocarcinomas of the gastrointestinal tract and breast 
cancer. It is commonly administered in combination with other agents some of which 
are not toxic but are known to modulate the effects of 5-flurouracil.
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Cytosine Arabinoside
Cytosine arabinoside (ara-C) 20 is metabolised to its triphosphate prior to 
exerting its activity. It is a competitive inhibitor of the enzyme DNA polymerase, 
required for the binding of thymine to DNA during reproduction, resulting in the 
inhibition of DNA formation and repair. Ara-C can also become incorporated into the 
DNA chain making it more likely to degrade and prevent replication.
Ara-C is particularly useful for the treatment of myelogenous leukaemia but 
has found no clinical use against solid tumours. The dose-limiting toxicity is 
neurological disorders which aie most common in older patients.
Purine antagonists
This class of chemotherapeutic agents, such as 6-mercaptopurine and 6- 
thioguanine, exert their activity by firstly undergoing an enzymatic conversion into their 
active forms then inhibiting a number of enzymes utilised in the early stages of purine 
biosynthesis. The net result is that the synthesis of DNA is inhibited due to a lack of 
the purine bases adenine and guanine. The major clinical use of these agents is in the 
treatment of leukaemia and in paiticular acute lymphatic leukaemia.
1.5.3.6 Noiico valent DNA-Binding Drugs 
Anthracyclines
The anthracycline antibiotics were initially studied in the late 1950s being 
isolated from a variety of strains of Streptomyces. Daunorubicin 21 was discovered in 
1963 and its potent antileukaemic activity sparked a rush to discover other 
anthracyclines with doxorubicin 22 isolated in 1969. Structurally these compounds 
have a four ring structure linked, via a glycosidic bond, to the amino sugar 
daunosamine.
The exact mechanism of the activity of these compounds is not clear but is due 
partly to intercalation. The molecular structure of the anthracyclines allows the planar 
ring system to insert between the hydrophobic faces of the base pairs in DNA causing 
a local unwinding of the helix. This intercalation interferes with the activity of the
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enzyme Topoisomerase II which can result in protein-linked double strand breaks. As 
a result of DNA being twisted extensively, enzymes called Topoisomerases are 
required to untwist certain regions for processes such as transcription, replication and 
other essential functions. They are able to break the DNA strands, allow the necessary 
processes to take place and then reseal the breaks. The enzymes are divided into two 
classes type-I and type-II enzymes which break one strand and two strands of the 
DNA double helix respectively.
In addition to intercalation, the cytotoxicity of the anthracyclines is due to the 
formation of free radicals which predominantly cause single strand breaks. The 
quinone moiety common to the anthracyclines can undergo a one or two electron 
reduction, utilising a variety of quinone reductases, resulting in the formation of 
superoxide (Figure 1 0 ) . This superoxide can dismutate forming hydrogen peroxide 
which in combination with an iron chelated drug complex can form hydroxyl radicals. 
The cardiotoxicity shown by these drugs is directly attributed to this free radical 
formation.
Figure 10 - Superoxide anion formation
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Doxorubicin has a wide range of activity against a variety of solid tumours 
including carcinoma of the breast and lung. Daunorubicin is of limited clinical 
usefulness and mainly used for the treatment of acute myelogenous leukaemia. In 
addition to cardiotoxicity, both cause severe bone marrow suppression, nausea, 
vomiting and alopaecia.
Non-anthracycline Antibiotics
Mitoxantrone belongs to the anthracenedione class of chemotherapeutic agents 
and, although maintaining the planar polyclic aromatic ring system needed for 
intercalation, does not contain the sugar moiety. Interestingly, due to an apparent 
inability to generate free radicals, it does not possess the cardiotoxicity of the
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anthi’acyclines. It is however of less clinical use than doxorubicin although used in the 
treatment of leukaemias and lymphomas along with advanced breast cancer.
Other examples include actinomycin-D, the bleomycins and mithramycin 
isolated from a variety of fungi. These agents, which have complex structures, appear to 
inhibit tumour growth by a vaiiety of pathways including intercalation and free radical 
formation causing single and double strand breaks. They are used for a number of 
cancers including paediatric tumours, choriocarcinomas, soft tissue sarcomas, testicular 
teratomas and lymphomas. Myelosuppression and gastrointestinal disturbances are the 
major side effects excluding the bleomycins which shows little or no 
myelosuppression with the major side effect being pulmonary toxicity.
1.5.3.7 Topoisomerase II Inhibitors
As mentioned earlier, Topoisomerase II is an enzyme is used to break DNA 
strands temporarily allowing vital processes such as replication to occur before 
resealing the double helix. Etoposide 23 and teniposide 24 are semisynthetic 
derivatives of the naturally occurring lignan podophyllotoxin 25, itself a microtubule 
inhibitor. It was expected that etoposide would inhibit microtubule function also but, as 
with teniposide, its major activity arises from Topoisomerase II inhibition. ^ 9
OH
HO!
HO
MeO' OM e
OH
MeO' OM e
OM e
When the Topoisomerase II first associates with DNA a non covalent complex 
is formed termed noncleavable, as removal of the enzyme at this point would result in 
no strand breaks. Only when the enzyme has cleaved the DNA strands is the complex 
cleavable as removal of the enzyme would result in a permanent double strand break. 
This complex is however short lived, in the absence of inhibitors, and after a 
topological change has been effected the breaks are resealed with subsequent release of 
the free enzyme. Etoposide is known to stabilise this cleavable complex thus preventing 
processes such as replication and ultimately regeneration of the DNA and free enzyme. 
As a result of the longer lifetime of the cleavable complex, the drug-complex may then 
undergo spontaneous dénaturation resulting in permanent double-strand breaks at vital
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sites leading to cell death. In addition inactivation of the protein kinase p34, which 
plays an important role in the G2 phase of the cell cycle prior to mitosis, may account 
for the efficacy of these agents.20 It is thought that the observed arrest of cells in the 
G2 phase, after treatment with etoposide, may be attributed to inhibition of the p34 
kinase.
Etoposide has found clinical use towards a variety of tumour types most 
notably testicular cancer and has a role to play in the management of small cell lung 
cancer. The major clinical uses of teniposide are in the treatment of lymphocytic 
leukaemia, neuroblastomas in children and brain tumours in adults with the major 
toxicity of both these agents being due to myelosuppression.
1.5.3.8 Microtubule Inhibitors 
The Vinca Alkaloids
Microtubules are involved in a variety of cellular functions including mitosis, 
transport of solutes, cell movement and maintaining the structure of the cell. They are 
composed of the protein tubulin and exist in an equilibrium between free tubulin 
dimers and assembled polymers. An integral part of mitosis is the polymerisation of 
tubulin dimers to form microtubules. These then align themselves at opposite poles of 
the cell and pull apart the two sister chromatids of the chromosome prior to 
cytoplasmic division (cytokinesis).
The Vinca alkaloids vincristine 26 and vinblastine 27 were isolated from the 
Madagascan periwinkle plant Catharanthus roseus. Their antitumour activity, 
discovered about thirty years ago, arises from their ability to bind to free tubulin 
dimers. A consequence of this binding is the disruption in the equilibrium between 
microtubule polymerisation and depolymerisation. The concentration of free dimers 
available for polymerisation is significantly reduced resulting in a shift of equilibrium 
towards disassembly and anest of cells during mitosis.
Vincristrine has proved useful in the management of leukaemias and 
lymphomas and for the adjuvant therapy of some solid tumours, particularly breast 
cancer. It shows little myelosuppression with its major toxicity being neurotoxicity. 
Vinblastine has found clinical use in the treatment of Hodgkin’s disease although it is 
significantly more myelosuppressive than vincristine which is its dose limiting factor. 
Taxol 28, unlike the other microtubule antagonists, is known to disrapt the equilibrium 
in favour of the assembled micro tubule s. As a result of Taxol treatment, the 
microtubules are stabilised and conditions that normally cause their disassembly, such 
as a high concentration of calcium, are less successful leading to an abnormal bundle
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of microtubules. In addition, stabilisation results in a lower concentration of free 
tubulin dimers required for polymerisation.
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The development of Taxol as a clinical agent has been hampered by a lack of 
suitable material. Until recently the major source of Taxol was from the bark of the 
slow growing yew Taxus brevifolia^^, but it can now be accessed semi-synthetically 
from the analogue 10-deacetyl baccatin III itself isolated from the needles of a related 
tree. As a result of its potential clinical value, its total synthesis has been reported by 
the groups of Holton^^, Nicolaou^^, D a n i s h e f s k y ^ ^  and Mukaiyama^^.
Although still in early clinical development, Taxol has been used to treat 
refractory ovaiian cancer and was approved for the treatment of breast cancer in 1994. 
The dose-limiting toxicity for Taxol is neutropenia although other major side effects 
due to hypersensitivity, such as breathing difficulties and hypotension, are common. As 
a result of this the search for analogues showing reduced toxicity and increased water 
solubility has been reported.^^
1.5.3.9 Hormone Therapy
The use of chemotherapeutic agents in this area arose from the observation that 
certain tumour types, originating from hormone responsive tissues, maintain their 
sensitivity to hormones and can be selectively targeted. The most common cancers that 
are activated by hormones are those arising from sexually differentiated tissues, such 
as breast, endometrium and the prostate. Their growth and function is maintained by 
the continual supply of sex hormones, steroidal substances produced predominantly in 
the ovaries of females and the testes of males.
The production of sex hormones is a highly regulated pathway originating in 
the brain where the production of Gonadotrophin Releasing Hormone (GnRH) effects 
the release of a second hormone, Leuteinising Hormone (LH) from the anterior 
pituitary gland. This in turn stimulates estrogen production and the synthesis of 
androgens, such as testosterone in the testes of males. These hormones are able to 
regulate their own concentration by inhibiting the production of GnRH and LH by a
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process known as negative feedback. There is a variety of ways in which hormone 
therapy can treat cancers by interfering with this pathway and they are discussed below 
for two specific examples, prostate and breast cancer.
Prostate Cancer
The incidence of prostate cancer in men is second only to lung cancer. The use 
of hormone therapy developed after the pioneering work of Huggins and Clark in 
1940. They reported that after castration or estrogen treatment, the hyperplastic prostate 
of a dog had reduced in size.27 Prostate cancers are hormone responsive and are 
known to be stimulated by androgens like testosterone. The production of these 
androgens can be indirectly inhibited by the administration of oestrogens, such as 
diethylstilbestrol 29, which primarily inhibits the production of LH from the pituitary 
gland. Due to the cardiovascular side effects associated with high dose estrogen use, 
today the approach is to use GnRH analogues. These initially increase the 
concentration of LH but with continued therapy, they inhibit LH release by reducing 
the number of receptors in the pituitary thereby reducing androgen production. In 
addition the use of antiandrogens, such as flutamide 30 often in combination with 
therapies discussed above, can prevent the binding of androgens to their tumour 
receptor site thus causing a remission in the tumour. It should be noted however, that 
none of these treatments are curative although they can significantly reduce tumour 
growth, pain and increase the patient's quality of life.
HO' 0 ,N
29 30
,NMc2
31
Breast Cancer
In 1896 Beats on noticed a regression in advanced breast cancer in young 
women after they had their ovaries removed.^^ It was later shown in the 1960s that a 
number of breast cancers possessed receptors for the hormone estrogen, which when 
activated stimulated the proliferation of the epithelial cells of the breast. The 
antiestrogen tamoxifen 31 was discovered by research into new oral contraceptives but 
was found to have activity towards breast cancer. It is known to exert its activity by 
binding to the receptors of the tumour cells but does not activate them properly 
preventing the release of essential growth factors. In addition, tamoxifen shows a weak
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oestrogen like effect which results in an increase in the enzyme called sex hormone 
binding globulin. This results in a reduction of the concentration of free oestrogen 
available to bind with the receptors in the tumour cells. The net effect is that tamoxifen 
antagonises oestrogen-induced effects thereby inhibiting the growth of oestrogen 
dependent tumours. Breast cancer may also be treated by interfering with the patient’s 
endogenous oestrogen production. The agent aminoglutethimide was originally 
introduced as an anti-epileptic drug although was withdrawn due to the inhibition of 
steroid biosynthesis in the adrenal glands. Its activity against breast cancer is due to 
inhibition of the enzyme aromatase, a vital enzyme in the biosynthesis of androgens 
and estrogens from cholesterol.
1.6 Cancer And The Future
Chapter 1 has given a brief overview into the mechanisms, causes and 
treatments of cancer. With few exceptions, our treatment to date can best be described 
as palliative with our practical gains towards a cure minimal. The majority of 
chemotherapeutic agents indiscriminately attack cancerous cells along with healthy 
tissues resulting in high toxicity and stress to the patient. During the last few decades 
we have gained substantial knowledge towards understanding cancer including, how 
carcinogens affect DNA, mutate critical control genes and ultimately convert normal 
cells into cancerous cells. Using this knowledge one could envisage the use of rational 
drug design to annul these side effects and permit substantial progress towards a cure.
It should come as no surprise that mortality arising from cancer could be 
drastically reduced by the way we live our lives. It is estimated that ca. 33% of all 
cancers in the United States are due to tobacco use. It is also known that high fat diets, 
excessive alcohol consumption along with the voluntary exposure to uv radiation 
contribute highly to the incidence of cancer. An important tool in our fight against 
cancer must therefore be to educate people early about the importance of maintaining a 
healthy lifestyle along with being vigilant for the early warning signs of cancer. It is 
clear that each one of us can drastically reduce our risk of developing cancer by using 
our own initiative.
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The Isolation. Stereochemistry and Proposed Mechanism of Action of NDGA
2.1 Introduction
The compound nordihydroguaiaretic acid (1), commonly abbreviated to 
NDGA, is a phenolic lignan found in the resinous extracts of many plants most 
notably Larrea divaricata. Of the three possible stereoisomers, depicted in Figure 11, 
NDGA is isolated with the optically inactive meso configuration (1). This Chapter 
opens with a discussion into the isolation of NDGA from natural sources and 
highlights how the configuration was established. The rest of the Chapter concentrates 
on the proposed mechanism of action of NDGA and how one may utilise these actions 
to produce an effective anti-tumour agent.
Figure 11 - The Three Stereoisomers of NDGA
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2.2 Isolation of NDGA
NDGA has been isolated from the resinous extracts of many plants most 
commonly Larrea divaricata, also known as the creosote bush. This name is derived 
because of an abundance of resinous coated leaves and twigs which have a strong 
creosote odour when wet or burned. The creosote bush, which is indigenous to the 
south western United States, is one of the most drought tolerant plants of the region. 
Its morphology makes is ideally suited to survive periods of drought of up to two years 
and individual plants are known to live for long periods; often 100-200 years. It has 
been used medicinally for thousands of years by native Americans for a variety of
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ailments. A tea made from the boiled leaves is reported to be effective towards 
cramping pains, allergic problems and to eliminate parasites. The dried powdered 
leaves are used to treat inflammation and minor wounds.
The first isolation of NDGA (1) from the creosote bush was reported by 
Waller and Gisvold in 1 9 4 5 . The phenol (1) was isolated from an alcoholic extract of 
powdered plant material and its structure was confirmed from a series of chemical tests 
and synthesised derivatives.
As a result of the anti-oxidant activity of NDGA towards foodstuffs and 
pharmaceutical preparations^^; a reliable method for the extraction of NDGA from the 
creosote bush was patented by Gisvold in 1945.^0 This procedure involved the 
percolation of plant material with an aqueous hydroxide solution at ambient 
temperature which was then acidified to release the crude component. The solid mass 
obtained was taken up in diethyl ether and a second base extraction followed by 
acidification afforded NDGA in batches of varying purity. It is worthy of note that 
starting from 6 kg of plant material the method provided 150 g of NDGA representing 
2.5% of the total weight of starting material used.
2.3 Determination of Stereochemistry
The tetramethyl ether of NDGA was first synthesised by Schroeter and 
Lichtenstadt in 1918 via the reduction of the dimethyl ether of guaiaretic acid.37 The 
authors assigned the compound (m.p. 100-101 °C) the meso configuration as a 
consequence of the inability of a diamino derivative to be resolved. Later Haworth et 
rzZ.38 prepared the same compound (m.p. 101-102 °C) by a similiar reduction 
procedure and assigned the compound as the racemate. As a result of these findings; 
Schrecker set about the synthesis of both the meso and racemic stereoisomers of the 
tetramethyl ether of NDGA and confirmed that Schroter’s inactive tetramethyl ether 
did in fact possess the meso configuration.
The lengthy reaction sequence, depicted in Scheme 1, started with a 
condensation of vératraldéhyde with diethyl succinate employing sodium methoxide as 
base. The unsaturated acid (34) was reduced with Raney nickel at elevated temperature 
affording the saturated meso acid (35) in moderate yield. Acid (35) was then cyclised 
following the procedure of Haworth and W oodcock^^ affording the racemic anhydride 
(36 ) in high yield. The assignment of the stereochemistry arose from the fact that 
hydrolysis of (36) afforded a different acid than (35) which could be resolved into its 
component isomers with strychnine. LiAlHq reduction of anhydride (36) afforded the 
diol (37) which was converted into the bis tosylate (38) in excellent y ie ld .33 Finally 
LiAlHq reduction of the tosyl groups of (38) afforded the racemic tetramethyl ether of 
NDGA (39) which gave a melting point of 70.4 -71.2 °C.
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The meso configuration of acid (35) was confirmed by reduction to the 
diaryIbutane in a manner analogous to that used for the anhydride (36). This material 
gave a melting point of 101.5-102 °C which was in agreement with the materials 
synthesised by Schroeter^^ and Haworth.^^
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In 1972 Perry et al. reported experiments designed to offer unequivocal 
evidence for the meso configuration of NDGA.42 Méthylation of commercially 
available NDGA afforded the tetramethyl ether of (1) in excellent yield (Scheme 2) 
which gave a melting point in agreement with data reported e a r l i e r . ^ B r o m i n a t i o n  
in acetic acid afforded the aryl bromide (41) in high yield. A single crystal X-ray 
analysis of this heavy atom derivative confirmed that NDGA (1) had the meso 
configuration.^'^
2 .4  P ro p o s e d  M e c h a n is m  o f  A c tio n
The rational design of novel anti-cancer agents is likely to arise from a better 
undestanding of the biology of these diseases. Among the many defects which have 
been identified in cancer cells, we are becoming increasingly aware of the importance 
of growth factors which may drive the proliferation of tumour cells in 
autocrine/paracrine loops. The mechanism for driving tumour growth has been 
extensively studied in small cell lung cancer (SCLC) which secrete and respond to 
multiple neuropeptide and certain polypeptide growth factors. However, many other 
tumuor types respond to such agents. As an example, the polypeptide growth factor 
stem cell factor and its receptor c-kit are co-expressed in nearly all SCLC cell lines but 
are also widely distributed in gynaecological malignancies. Consequently the 
development of small molecule inhibitors which block the growth signals of agents 
such as c-kit, may provide a novel therapeutic approach.
2.4.1 Small Cell Lung Cancer
There is an urgent need to develop novel therapeutic strategies for most 
common solid tumours including small cell lung cancer for which the five year survival 
rate is less than 5%. SCLC represents about 20% of all lung cancers and is named for 
the size of the cancerous cells. Although small, these cells can multiply rapidly forming 
large tumours which can spread to lymph nodes and other organs such as the brain, 
bones and liver. SCLC is almost always caused by smoking and it is very rare for a 
non-smoker to suffer from this cancer type.
2.4.2 5-Lipoxygeiiase
5-Lipoxygenase is one of a family of enzymes that metabolise arachidonic acid 
to hydroperoxyeicosatetraenoic acids (HPETEs) (Figure 12). Each enzyme catalyses 
the insertion of an oxygen moiety at a specific position in the arachidonic acid (AA) 
(42) backbone. In addition to 5-lipoxygenase two other enzyme types in this family are
29
known, namely 12- and 15-lipoxygenase with the prefix referring to the position on the 
AA backbone they oxygenate. 5-Lipoxygenase forms 5-HETE, the precursor of the 
leukotrienes which are potent bioactive compounds involved in inflammation, allergy 
and several deteriorative disorders.
Figure 12 - 5-lipoxygenase metabolic pathway
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5-Lipoxygenase is an iron containing enzyme that must be activated to the 
Fe^+ state before oxygenation of AA (Figure 12). Upon activation, Fe^+ specifically 
oxidises the 5,8 diene system of AA to generate a pentadienyl radical with the iron 
being reduced to the Fe^+ state. This radical then stereospecifically reacts with 
molecular oxygen at C-5 to generate the 5-5"-hydroperoxy radical which undergoes 
electron transfer and protonoylsis regenerating the active Fe^+ and 5-HPFTF. This in 
turn is converted into 5-HETF from which leukotrienes are formed.
2.4.3 Inhibitors of 5-lipoxygenase
Inhibitors of the 5-lipoxygenase pathway can be classified under three 
headings depending on their alleged mechanism of enzyme inhibition.
2.4,3.1 Redox Inhibitors
These compounds typified by ICI207968 (43) can potentially interact with a 
number of points on the enzyme mechanism (Figure 12). For example, they may act
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by reducing the active Fe^+ to the inactive Fe^+ or reduce one of the radical 
intermediates, thus leaving iron in the inactive Fe^+ state. Redox inhibitors however 
show poor selectivity for 5-lipoxygenase, often being weak or inactive enzyme 
inhibitors in vivo when dosed orally. Indeed, ICI207968 caused methaemoglobin 
formation in blood which precluded its development for clinical use.
2.4.3.2 Iron Ligand Inhibitors
One of the most powerful metal binding groups is the hydroxamic acid moiety 
which has received a lot of research for inclusion in potential 5-lipoxygenase 
inhibitors. This lead to the discovery of Zileuton (44) by the Abbott group. It is a 
selective 5-lipoxygenase inhibitor showing no activity towards the 12- and 15- 
lipoxygenase enzymes. In addition to their metal binding properties hydroxamates and 
A^-hydroxyureas also possess weak redox potentials and there is increasing evidence 
that their activity is derived wholely or in pait to these effects.
Ph
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2.4.3.3 Non-redox Inhibitors
As discussed above, many 5-lipoxygenase enzymes have the potential to 
participate in redox reactions or to interact with iron. However, the diffuse structure 
activity relationships of such compounds coupled with the absence of 
enantiospecificity suggested they did not interact strongly with the enzyme. This lead 
to a drug hunting programme by ICI with the goal of developing an active site 5- 
lipoxygenase inhibitor although devoid of redox and iron ligand properties. This led to 
the discovery of ICID2138 (45) as a selective 5-lipoxygenase inhibitor. In leukotriene 
dependent models of inflammation and bronchoconstriction, ICID2I38 was 
approximately 10 fold more potent than Zileuton (44) and as a consequence of this 
encouraging profile ICID2138 has entered clinical trials.
2.4.3.4 Inhibition of 5-lipoxygenase by NDGA
NDGA (1) has been reported to be a selective lipoxygenase inhibitor and 
blocks SCLC growth in vitro and in vivo.^^ The preliminary data observed by Seckl et
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al.^^ agree with these findings but they noticed that NDGA is a better inhibitor of 
SCLC growth than other more potent lipoxygenase inhibitors. Their results also 
suggest that NDGA has an alternative mechanism of action in SCLC cells. NDGA 
appears to inhibit c-kit directly, the receptor for stem cell factor, which is a prominent 
autocrine growth factor for neaiiy all SCLC cell lines.
2.4.4 Conclusions
In additon to NDGA’s novel mechanism of action there are also several other 
compelling reasons to initiate an urgent and rapid investigation of NDGA as a new lead 
compound in cancer therapeutics. Firstly, NDGA has been shown to be active in vivo, 
blocking the growth of SCLC xenografts and human pancreatic xenografts. 
Nevertheless, NDGA has poor water solubility and chemical modifications are required 
to generate a compound that would be clinically effective. Secondly, the structure of 
NDGA is distinct from other lipoxygenase inhibitors and has not yet been exploited. 
Moreover, a patent search has revealed no granted patents on the anti-cancer effects of 
NDGA and so it is likely that any clinically relevant compounds generated in this 
reseai'ch would be patentable.
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The Synthesis of (±)-NDGA
3.0 Introduction
There have been several syntheses of the natural product nordihydroguaiaretic 
acid (NDGA) (1) reported in the literature. However in most cases they involve long 
reaction sequences or low yielding reactions. The synthesis of (±)-NDGA (32) has not 
received nearly the same amount of attention with only one total synthesis reported in 
the literature. This chapter opens with a review of the methods reported for the 
synthesis of the diasterisomers of NDGA including a brief discussion of the pros and 
cons of each synthetic sequence. The rest of the chapter outlines our attempts to 
synthesise (±)-NDGA (32) culminating in our successful total synthesis of a 
compound that was a lot more synthetically challenging than one would first envisage.
3.1 Previous Syntheses of NDGA.
3.1.1 Schroeter s partial synthesis of m^so-NDGA.
The first reported partial synthesis of meso-NDGA (1) was reported by 
Schroeter et in 1918 employing the dimethyl ether of (-)-Guaiaretic acid (46) 
isolated from Guaiacum officinale L. The catalytic reduction of (46) was carried out 
over Nickel affording the diary Ibutane (47) in 67% yield (Scheme 2). Déméthylation 
was effected in refluxing hydroiodic acid affording m^yc-NDGA (1) in 59% yield.
Scheme 2
Mel
Mel Tetraliii, 6 8 % RO'
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The partial synthesis of NDGA reported by Schroter et al. is overall low 
yielding employing a starting material that is not readily available. Indeed, the 68% 
yield reported for the reduction relates to a lower melting material and a further
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recrystallisation is required, however no yield is reported for this step. The group 
should however be credited with the first synthesis of me^tP-NDGA (1).
3.1.2 Haworth’s total synthesis of meso-NBGA,
In 1934 Haworth and co-workers^^ reported a series of experiments aimed at 
synthesising compounds of the guaiaretic acid type (48) culminating in the synthesis 
of NDGA. The lengthy reaction sequence, depicted in Scheme 3, starts with a 
Reformatsky reaction of veratraldehyde with ethyl-2-bromopropionate in refluxing 
benzene which afforded the unsaturated ester (49) in excellent yield.
Scheme 3
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The ester was transformed into the saturated ester (50) via a series of 
hydrolysis, reduction and estérification steps although no yield was given for this 
series of synthetic transformations. The condensation of (50) with 3,4- 
dimethoxyphenylacetonitrile (51), itself aquired in 40% yield, was carried out in the 
presence of potassium ethoxide in refluxing benzene. The intermediate nitrile was
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gently hydrolysed to the primary amide (52) employing a mixture of AcOH and HCl at 
low temperatures. Basic hydrolysis and concomitant decarboxylation afforded ketone 
(53) in moderate yield. Haworth reported that attempts to boil amide (52) in 
concentrated HCl gave impure ketone (53) which could not be purified. Méthylation 
was effected using méthylmagnésium iodide to give a secondary alcohol which 
underwent an elimination reaction on mild base treatment at elevated temperatures 
affording guaiaretic acid dimethyl ether (46) in poor yield. Catalytic hydrogenation 
over palladium afforded the tetramethyl ether of NDGA (47) in good yield. The ether 
was demethylated to give m^^o-NDGA (1) which did not depress the melting point of 
a sample obtained from the natural source.
The reaction sequence employed by Haworth et al. is quite long at seven steps 
not taking into account numerous intermediates that were not isolated. With a couple of 
exceptions the reactions are low yielding and require harsh reaction conditions. 
Although the final product is obtained in overall low yield, the authors should be 
credited with the first total synthesis of a compound that until then had only been 
available from the natural source.
3.1.3 Liebermaii's total synthesis of meso-NDGA.
Scheme 4
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The key step in the synthesis of me^o-NDGA by Lieberman and co-workers^^ 
was the homo-coupling of the Grignard reagent derived from 2-broraosafrole (54)
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using 0.5 equivalents of iodine in diethyl ether. The low yielding reaction afforded the 
bis dimethylene ether of NDGA (55) as a heavy oil presumably composed of a mixture 
of diastereoisomers. A similar coupling was reported much later by Gunasekaran and 
Balasubramanian^O using the reagent 2-^-butyk3-phenyloxaziridine (56) affording the 
mgj-o-tetramethyl ether of NDGA (47) in 51% yield. The low yield again could be 
attributed to the formation of two diasteroisomers although the authors gave no 
indication of this in the paper.
Returning to Lieberman's synthesis, subsequent cleavage of the 
methylenedioxy groups of (55) via the carbonate (57) afforded NDGA in a 2% overall 
yield as needles that did not depress the melting point of a sample obtained from the 
natural source.
Although Lieberman's synthesis is short with only four synthetic steps, overall 
it is very low yielding and without the aid of modern spectroscopic techniques it is 
difficult to ascertain when the diastereoisomeric purity was introduced.
3.1.4 Pearls total synthesis of mg^o-NDGA.
Because there was no commercially viable process to synthesise NDGA its 
extraction was expensive and far from satisfactory, Pearl patented a synthesis of 
NDGA in the early 1950s.41 Although the process was reported as being successful 
starting from a variety of oxybenzaldehydes, the synthetic route from vanillin is 
representative as depicted in Scheme 5.
Reaction of the anion of nitroethane with vanillin followed by elimination of 
water gave the nitrostyrene (58) which after reduction and hydrolysis with Fe- 
FeClg/c.HCl afforded the phenylacetone (59) as a viscous oil. The pinacol coupling of 
the phenylacetone (59), discussed more thoroughly in Section 3.3.2, was effected 
using a sodium amalgam under aqueous conditions affording the pinacol (60) as a 
viscous oil, presumably as a mixture of diasterioisomers. Pearl reported that attempted 
déméthylation of the pinacol using acidic reagents resulted in rearrangements giving 
rise to unwanted ketone by-products. As a consequence, the methyl ethers of (60) were 
cleaved under basic conditions at high temperature to give the highly hydroxylated 
compound (61). Elimination of water from the tertiary alcohols was achieved by 
heating (61) in the presence of acetic anhydride and acetyl chloride to give the phenolic 
butadiene (62) presumably as a mixture of geometrical isomers, after saponification of 
the phenolic esters arising during the elimination conditions. The final step involved a 
catalytic hydrogenation of the butadiene over palladium on charcoal affording NDGA 
(1) as colourless crystals melting at 185-186.5 °C in agreement with data for the 
natural product.
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Although the experimental section appearing in the Patent is clear and should 
be easy to follow, the only methods of characterisation of the intermediates are boiling 
points or in the case of solids, a melting point. The scheme is quite long at seven steps 
and the lack of reported yields makes it difficult to determine the effectiveness of this 
synthetic sequence. Although not reported, it would be sensible to presume that a 
mixture of isomers was formed in the pinacol, elimination and hydrogenation reactions. 
In the final reaction the catalyst was simply filtered off and the organic solution was 
concentrated to a small volume whereupon crystals of NDGA were deposited. No 
reference was made to the mother liquors and the fact that no yield was given may 
indicate that all three diasterioisomers were present in the mixture and it is fortuitous 
that the 7?îe.so-diasterioisomer was deposited.
3,1.5 Perry's total synthesis of m i^SO-NDGA.
An efficient synthesis of NDGA by Perry et appeared in the literature
in the early 1970s in an attempt to provide a commercially viable source of NDGA. 
Research up to that date had been non-productive and the creosote bush had remained 
the only commercial source of NDGA. The synthetic sequence employed by Perry and 
co-workers is depicted in Scheme 6.
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The acylation of 1,2-dimethoxybenzene with propionyl chloride was effected in 
quantitative yield affording the ketone (63) which was brominated in refluxing CHCI3 
again in excellent yield. A highly diastereoselective coupling reaction of the sodium 
enolate of (63) with bromoketone (64) in refluxing liquid ammonia afforded the 
racemic diketone (65) in high yield and a mechanism to rationalise this result is 
discussed in Section 3.2. The cyclodehydration of diketone (65) could be conviently 
carried out by refluxing a DCM solution of (65) in the presence of methanolic HCl 
affording the furan (66) in excellent yield. The furan was hydrogenated and cleaved 
over powdered palladium oxide utilising high pressure and elevated temperatures. 
Using this procedure the tetramethyl ether of NDGA (47) could be isolated in a crude 
yield of 78%. This material was demethylated with HBr affording NDGA (1) as cream 
crystals in 66% yield after thi’ee recrystallisations from 20% aqueous AcOH. The final 
product was reported to be identical in all respects with the purified natural product.
This six step synthetic sequence to NDGA would at first sight seem excellent 
giving high yields of product incorporating short reaction times but the following 
points should be noted. The yields given in Scheme 6 are not analytical ones and often 
the yields are composed of several crops of material with differing melting points. It is 
common that the authors report an analytical melting point but do not give a yield of 
final pure product. The hydrogenation of the furan (66) to give the tetramethyl ether
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(47) requires quite harsh conditions and the product was only isolated in 78% crude 
yield with a melting point of 91.5-95 °C. The same compound was made by the 
authors by methylating commercial NDGA with a view to working out the 
configuration of a dibromo derivative.^^ The tetramethyl ether from this reaction, after 
several recrystallisations from MeOH, had a melting point of 101-102 so it is clear 
that the crude material from the hydrogenation was not analytically pure. Nonetheless 
the route developed by Perry and co-workers is by far the best synthesis of meso- 
NDGA appearing in the literature to date giving the natural product in good overall 
yield.
3.1.6 Parkhurst’s total synthesis of (±)-NDGA,
Scheme 7
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The same racemic diketone (65) synthesised by Perry et aL^'^ was employed as 
a starting material in the synthesis of (±)-NDGA (32) by Parkhurst and P a r d i n i . 4 4  
This diketone was reduced to the diol (67) presumably as a mixture of 
diastereoisomers in quantative yield. Méthylation was effected using sodium hydride 
and an excess of methyl iodide in DMF at ambient temperature affording the 
hexamethyl ether (68 ) in excellent yield. The benzylic ethers were cleaved by 
dissolving metal reduction at -78 °C giving the racemic tetramethyl ether (39) in 
quantative yield. The authors reported that use of low temperature and short reaction 
times was critical to avoid partial reduction of the aromatic nuclei giving rise to
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complex mixtures. Déméthylation was affected in high yield using hydrobromic acid at 
high temperatures in a sealed tube affording (±)-NDGA (32) as a solid.
The synthetic sequence employed by Parkhurst and Fardini affords racemic 
NDGA in seven steps in excellent yield. There was however no mention in the paper of 
purification of the intermediates or the final product and no characterisation was 
reported with the exception of a melting point of the final product.
3.1.7 Rao’s partial synthesis of (-)-NDGA.
The partial synthesis of a single enantiomer of NDGA has been reported by Rao and 
Chattopadhyay45 while investigating the regioselective cleavage of the methylenedioxy 
group of the natural product (-)-austrobailignan-5 (69) (Scheme 8).
Scheme 8
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Reaction of (69) with p-thiocresol and sodium hydride in refluxing DMF 
afforded the phenol (70) in high yield. The direction of the cleavage was determined by 
synthetic manipulation of (70) to ethylvanillic acid (71) giving physical properties 
identical to an authentic sample. Hydrolysis of (70) with dilute HCl afforded 
enantiopure NDGA (32) as a colourless glass in high yield. Unfortunately, the authors 
did not report any characterisation of the phenol (32) although they described the 
synthesis of both its tetraacetate and tetramethylether which were partially 
characterised.
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3.2 Towards the synthesis of (±)-NDGA
A search of the literature had presented us with a variety of pathways from 
which to choose a suitable synthesis allowing access to our target compound (32). We 
decided the method of Perry42,43 (Scheme 6) was an excellent pathway to follow for a 
variety of reasons. The experimental section was clear and well documented, the yields 
reported were excellent and the starting materials readily available. We felt that once the 
racemic diketone (65) was isolated, it could be directly reduced to the racemic 
diarylbutane which could be deprotected using standard procedures. This section 
describes our initial attempts to achieve our goal.
3.2.1 Synthesis of (±)-NDGA - First approach
The acylation of veratrole (72) was carried out following the method of Perry et 
alA'^ with best results achieved using freshly distilled propionyl chloride and 
aluminium chloride ground to a fine powder under a nitrogen atmosphere. The ethyl 
ketone (63) was obtained as large shiny crystals in high yield with analytical data in 
agreement with those reported (Scheme 9). An IR stretch at 1662 cm'^ confirmed the 
presence of the carbonyl group with the regiochemistry of the addition apparent from 
the 1h NMR spectrum. Two doublets with coupling constants of 8.3 and 1.9 Hz along 
with a doublet of doublets giving identical J  values in the aromatic region clearly 
indicated the 1,3,4 subsitution pattern of the ring. We felt that the bromination 
conditions reported by Peny for (63) were severe and as a consequence an alternative 
method was developed. First attempts concentrated on the dropwise addition of 1.4 
equivalents of bromine to a stirred solution of (63) in CHCI3 at rt under nitrogen. After 
the mixture was stirred overnight, TLC showed two spots with one running very close 
to the starting material and one with lower polarity. Separation by silica gel flash 
chromatography afforded the desired bromoketone (64) in c c l  60% yield as an off- 
white solid. The less polar material was shown by ^H NMR spectroscopy and MS to 
be the dibromo derivative with both a-hydrogens exchanged. In later experiments, we 
found that addition of a stoichiometric amount of bromine in portions, with the reaction 
monitored regularly by TLC, ensured formation of only the monobromo ketone after 
ca. 30 min. Although the starting material and product had almost identical Rf values, 
the former gave an intense red colour when stained with vanillin whereas the product 
gave no reaction and thus one could easily determine at what point all the starting 
material had been consumed. Using this methodology we were able to isolate the a- 
brom oketone (64) as feathers in high yield avoiding the need for column 
chromatography. A highly deshielded methine quartet at 5 5.31 in the ^H NMR
41
spectrum together with an identical melting point to that reported confirmed the 
proposed structure.
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The key step in the synthesis was the highly diastereoselective coupling of the 
sodium enolate of (63) with the a-bromoketone (64) in liquid ammonia carried out by 
employing the method of Peny et al^'^ Initial attempts involved the transfer of reagents 
as THF solutions for ease and control of addition, however only moderate yields were 
obtained using this method. When the reagents were added as solids, via a solid 
addition funnel, the pure racemic diketone (65) could be isolated as crystals in high 
yield after recrystallisation from MeOH. The crude product contained up to 10% of the 
me^'o-diastereoisomer as indicated by a doublet in the ^H NMR spectrum at 5 1.13. 
This minor diastereoisomer could however be removed by a single or more commonly 
two recrystallisations from MeOH affording (65) in high yield giving a melting point 
and ^H NMR spectrum in agreement with those reported. A mechanism attempting to 
rationalise this result is depicted in Figure 13.
Formation of the enolate of (63) should give predominantly the (Z)-enolate 
with reaction of either enantiomer of (64) from above or below possible. It would 
however be sterically more favourable when the aroyl group of (63) is furthest away 
from the aroyl group of (64), and the methyl group of (63) is towards the oxygen of
(64) rather than the aryl group. Thus in the example given, displacement of the bromine 
with concominant inversion would lead to one enantiomer of the diketone (65).
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I -ikcwi.sc nnd with C(|iial pinhahilily attack may nccur fioin llir oj'posilc (acc leading to 
the otiici cnantiotncr with the net result being the (nrmali(tn of (he tacernic dikclone.
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riie symmetry of (65) was indicated hy the NMR spectra with the 
spectrum showing eleven peaks including the ketone at (> 203 and the secondary 
methyl groups appearing as a doublet at 5 1.31 in the  ^II NMR spectium (Figure Id).
Figure 14 - Ul NMR spectriiiii of (lie niceniic diketone
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The single ot-piolon was not icaclily visible in I be speed nin allbongb close 
inspection of the two singlets arising from the met by I cibeis levealed an integialion ol 
seven protons. It was clear that the methine piolon lesonance was being masked by the 
ethers and this was proved by h l - h l  NMK spin decoupling expeiimenls. Iiiadalion 
over the methyl ethers region resulted in the secondai y methyl doublet collapsing to a 
singlet clearly indicating the presence of the methine lesonance in (his legion. An IR 
stretch at 1660 cm’ * and a parent ion peak o f . h S h  in (he mass speednm weie also 
consistent with the desired structnic.
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With the laccmic dikctone in hand we felt that ieduction of the catbonyl gioups 
of (65) to the coiresponding methylenes followed by déméthylation would furnish out 
taiget cotnpound. It was expected that the (eduction could be accomplished in a single 
step using catalytic hydrogenation over palladium in AcOII. Ihe leaction went 
smoothly at atmospheric pressuie and ambient tempcratnre to give a single less polai 
spot on I FC. I he crystalline pioduct obtained was not the desired tetramethyl ether 
(39) but in fact the natural product (±)-veiaguensin (73) initially isolated in the ( t )- 
form from the plant O co lca  ir/Y/.gr/rv/.v/.v'^ ’^ and later synthesised by Ahrned ef I he
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isolated product gave a melting point and NMR spectrum in agreement with those 
reported.47 It was clear from the spectrum, shown in Figure 15, that we had isolated 
the unsymmetric diastereoisomer with two doublets arising both from the methyl 
groups and the methine protons next to the oxygen of the furan ring along with four 
separate methyl ether singlets. Furthermore the NMR spectrum of the crude 
product showed some extra minor doublets presumably arising from the other two 
symmetric diastereoisomers; however no attempt was made to isolate these 
compounds. It had been reported by Biftu et al.^^ that direct reduction of the diketone
(65) could be achieved by using a high catalyst to substrate ratio in EtOH. Biftu et a l 
reported that using a low catalyst concentration resulted in the formation of the 
tetrahydrofuran (73) and encouraged by this we decided to adopt his reaction 
conditions. However on several occasions we were unable to repeat his work and even 
on increasing the catalyst concentration further we isolated solely the tetrahydrofuran 
with no signs of the desired diarylbutane (39) detected by TLC or ^H NMR 
spectroscopy.
The direct hydrogenation was also attempted at 7 barr in a Baskerville 
hydrogenator; however only the tetrahydrofuran was isolated. Attempts using 
alternative catalysts including Raney nickel, palladium oxide, rhodium on carbon and 
platinum (IV) oxide were not successful. Ammonium formate transfer hydrogenation^^ 
was also unsuccesful with the tetrahydrofuran being the major product isolated.
Perry and co-workers reported the hydrogenation of the all cA-tetrahydrofuran 
(74) to mgjo-NDGA tetramethylether (47) using PdO in THF (Scheme 10).42 
Encouraged by this result we decided to adopt these conditions and apply them to our 
diastereoisomeric tetrahydrofuran (73); however several runs failed to give any product 
with only stalling material recovered.
Scheme 10
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Disappointed by these results and being temporarily unable to attempt the 
hydrogenations at increased pressures we turned our attention to alternative 
methodologies. Attempts to form the bis-dithiane (75) which could be cleaved with 
Raney nickel (Scheme 11) allowing access to the tetramethylether (39) could not be
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effected due to the difficulty in the formation of (75). The crude product which could 
be crystallised from MeOH gave a very complex NMR spectrum and could not be 
identified.
An attempted Wolff-Kischner reduction gave a complex mixture of products 
identified by TLC and NMR spectroscopy as did the general method of Lau et 
employing a AlCl3-^ u N H 2 .BH3 system. No reaction was evident from TLC 
using the general procedures of Lau and Satoh using the Znl2 -NaCNBH3^  ^ and 
NaBH4-PdCl2^  ^systems, respectively.
Scheme 11
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At this point we decided that reduction of the diol (67), easily accessible 
following the procedures of Biftu^^ or Parkhurst44^ would allow access to the 
tetramethyl ether (39) after diol reduction. The reduction with LiAlH^ went in 
quantative yield (Scheme 12) affording the diol (67) as a mixture of three 
diastereoisomers identified by NMR spectroscopy. Biftu et al. reported the 
isolation of the racemic unsymmetrical diastereoisomer (67) after crystallisation of the 
crude product from CHCI3-hexane but did not give a weight or yield isolated.
Figure 16 - The three diastereoisomers of alcohol (67)
OH
OH OH
OH
OH
Ar = 3,4{OMe)Ph
A I r  NMR spectrum of our crude material showed (67) to be the major 
diastereoisomer formed with two doublets for the secondary methyl groups along with 
two deshielded benzylic methine doublets at 5 4.38 and 4.59. In addition to this 
compound, the NMR spectrum showed two extra doublets in both of these regions
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parent ion peak of ni/z  IVt) in the mass speclinm were also consislent with the 
proposed slrnctiire.
I he proporlion of Ihe major diaslerenismiier cnirld rrol he signilieanlly 
increased hy reeryslallisalion from a var iely of solvents wilhoiil a major loss of rnaleiial 
and so, we decided to cany Ihe diol (67) lor ward as a diaslereoisornei ic mixlure. 
C'alalylic hydrogenation of the diol (67) was carried ont in AcOII al almospheiic 
pressure affording a product that gave a homogeneous less polar spot hy IIX ' 
However, crystallisation of the residue from MeOH did not afford Ihe expected 
diarylbutane (39) hut the natural product (±)-galhulin (78) in low yield. A rn.p. and Ml 
NMK spectrum (Ingiire 17) were in agreement with Ihe data reported for the natural 
product isolated from l i in iau tcw dni hacculd  Kail.  ^  ^and later M vrisfica  
Figure 17 - Ul NMR speeti uiii of (±)-galbnlin
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A second crop of material, which was deposited after the mother li(|irors had 
heerr placed in a freezer overnight, was shown to he the desired diarylbutane (39) hy 
hi  NMK spcclro.scopy although contaminated with (±)-galhitlin. Several attempts to
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remove this contaminant by chr omatography or recrystallisation proved unsuccesful, so 
we decided to carry out the deprotection allowing access to our target compound after 
suitable purification. The methyl ethers were cleaved with boron tribromide^^ in 
quantitative yield affording a crude oil that showed no signs of the arylmethyl ethers in 
the Iff NMR spectrum. The product however proved very difficult to crystallise often 
oiling out of solution and we could not obtain an analytically pure sample by column 
chromatography.
Scheme 12
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We decided at this point to return to the reduction of the diol (67) and alter our 
reaction conditions with the aim of producing an analytically pure sample of the 
diarylbutane (39) which could be further manipulated. We found that the catalytic 
hydrogenation in AcOH was independent of the catalyst concentration with the 
cyclisation by-product (78) consistently formed. The reaction was also carried out in a 
variety of solvents, however this lead to poor conversion and often a range of 
compounds detected by TLC. Alternative catalysts were tried including Pt02, PdO, Rli- 
C and Raney nickel; however these reactions suffered from the production of a variety 
of compounds detected by TLC and were not further pursued.
We decided to repeat the work reported by Biftu et as depicted in Scheme 
13 and although the authors started with piperonal (79), we started with commercially 
available 3,4-methylenedioxypropiophenone (80) thus eliminating two steps from the 
synthetic sequence.
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Scheme 13
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The bromination was carried out using our modified conditions to synthesise 
(64) and afforded the bromoketone (81) in good yield with a melting point and 
NMR spectrum in agreement with those reportedriS  The coupling reaction in liquid 
ammonia afforded the pure racemic diketone (82) giving analytical data also in 
agreement with those reported. The methine proton of (82), which was masked by the 
methyl ethers in (65), could be observed in the NMR spectrum as a multiplet at ô 
3.80-3.89 and an IR stretch at 1670 cm"l was observed for the aryl ketone 
functionality. Attempted direct hydrogenation of (82) was unsuccesful giving similar 
results as those discussed for (65) with tetrahydrofuran formation predominating. 
Lithium aluminium hydride reduction afforded a solid in quantitative yield composed 
of a mixture of three diastereoisomers as shown by NMR spectroscopy. 
Recrystallisation from CHClg-hexane afforded the pure unsymmetric diasterisomer 
(83) in moderate yield giving analytical data in agreement with those reported .48 The 
authors reported the reduction of the diol (83) to the diarylbutane (84) using catalytic 
hyrogenation in AcOH but we were unable to obtain a pure sample using this method. 
A crude NMR of the partly solid residue showed the desired product but like the 
tetramethyl ether analogue (39) it was slightly contaminated with a cyclisation by­
product suspected to be the tetrahydronaphthalene. We were unable to obtain an 
analytical pure sample by chromatography and felt deprotection would present us with 
the same purification problems as discussed previously.
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Before deciding to abandon this route, and having some diol (67) in hand, we 
attempted some alternative methods. The conversion of an alcohol into a tosylate or 
mesylate followed by reaction with a hydride source is a common way to reduce 
alcohols. We were however unable to form the tosylate and although mesylation 
conditions consumed all the starting material by TLC, the NMR spectrum of the 
crude product was very complex and we felt that cyclisation and elimination reactions 
hampered the isolation of the bis-mesylate. An attractive method for the indirect 
reduction of alcohols is the radical reduction of a xanthate and we attempted this 
approach on our diol (67) as depicted in Scheme 14.
Scheme 14
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The classical method for the synthesis of a xanthate involves the deprotonation 
of the alcohol, reaction with dry carbon disulfide and trapping the resultant anion with 
methyl iodide. Unfortunately although all the starting material was consumed a 
NMR spectrum of the crude sample showed a complex mixture that was not further 
investigated. Another approach using phase transfer conditions by the method of Lee et 
al.^^ gave a similar result. Our final attempt concentrated on repeating the work of 
Parkhurst who was able to cleave the dimethyl ether of (68) using dissolving metal 
reduction (Scheme 7).^4 This approach however was not pursued as we isolated only 
starting diol (67) after following the reported méthylation conditions.
3.2,2 (±)"NDGA - The Stobbe Condensation route
The alkylation of the butyrolactone (87) with 3,4-dimethoxybenzyl bromide 
(93) has been reported by Landais et al.^^ to afford exclusively the tmuj:-lactone (87) 
in high yield (Scheme 15). We decided to adopt this aproach especially as the authors 
had described the reduction of the corresponding 3,4,5-trimethoxylactone (89) to the 
diarylbutane (91) as depicted in Scheme 15.^^
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Me
OMe NaOMe, MeOH 
A, 1.5 h, 40%
Me'
Me'
COjMe
CO2H
H 2 . Pd-C, MeOH 
rt, 17 h, 84%
Me'
Me
CO?Me
CO2H
1. KOH, EtOH
2. CaCl2, NaBH^
3. MCI, 46%
1.LDA, THF, -78 °C
2. 93, THF, -78 °C, 3 h
Met
Met
OM e
OMe
Met
Met
OMe
OMe
Met1.M sC l.Py
2. LiAlH 4 , THF
Mel MetMeO'
0 " C -^  I t
1 h, 50%Mel Met!)0 (R=H)91 (R=OMe) 93OMe
OMe
The Stobbe condensation of veratraldehyde with dimethyl succinate was 
effected using sodium methoxide in MeOH at reflux temperatures. The unsaturated 
ester (85) was obtained as bright yellow crystals giving analytical data in agreement 
with those re p o rte d .T h e  NMR spectrum showed a highly deshielded benzylic 
singlet at § 7.87 along with four separate singlets for the remaining aliphatic protons. 
The catalytic hydrogenation went smoothly at atmospheric pressure affording the 
saturated ester (86) as a white powder giving a melting point and a NMR spectrum 
in agreement with those reported.^^ The benzylic singlet was no longer observed and a 
single methine proton appeared as a complex multiplet along with two methylene 
resonances which were now diastereotopic. The chemoselective reduction of the 
saturated half-ester (86) was carried out on the potassium salt of the acid with calcium 
borohydride affording the lactone (87) in moderate yield as an oil after column 
chromatography. A NMR spectrum was in agreement with that reported^^ and an 
IR stretch at 1778 cnr^ confirmed the proposed structure.
With the lactone in hand we turned our attention to the synthesis of the 
benzylic bromide (93). Torrado and Imperiali synthesised bromide (93) using a PPhg-
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NBS system in DCM in high yield as an an intermediate in their synthesis of 
nonstandard amino acids^^ and we decided to repeat their work. The reaction went well 
by TLC with all the starting material consumed but we were not able to obtain an 
analytically pure sample. The product when passed through a flash column as 
described suffered from decomposition and only a very low yield of material was 
recovered. Enders et al.^^ required the similiar benzylic bromide (94) as an electrophile 
in their total synthesis of (+)-(5)-[6]-gingerol (95) (Scheme 16) and we decided to use 
the conditions on commercially available veratryl alcohol (92). The reaction with 
phosphorous tribromide in dry ether went smoothly affording the desired bromide (93) 
as a fluffy solid in moderate yield after recrystallisation from Et20-hexane. A melting 
point and NMR spectrum were in agreement with those reported.^b The bromide 
was not very stable at rt and gradually turned black over a couple of days and as a 
consequence was stored under an inert atmosphere in a freezer prior to use.
Scheme 16
O OHMel Br
HO'
With both coupling partners now in hand we turned our attention to the 
alkylation following the procedure reported by Landais et However although all 
the starting material had been consumed by TLC, a NMR spectrum of the crude 
material showed a complex mixture which was not further investigated. The authors 
reported that the use of lithium hexamethyldisilylamide resulted in increased yields; 
however this approach was not attempted. This disappointing result coupled with the 
long-winded reaction sequence persuaded us to abandon this approach. We realised at 
this point that we had spent a considerable length of time on the synthesis of racemic 
NDGA trying to follow reported procedures. We felt that a retrosynthetic analysis of 
(32) could help us towards our goal and present us with a novel approach to this 
synthetically challenging compound.
3.2.3 A Retrosynthetic analysis of (±)-NDGA
A retrosynthetic analysis of (±)-NDGA is depicted in Figure 17. It was clear 
that the final step in any synthesis would involve the cleavage of phenolic protecting 
groups and we felt that the racemic diarylbutane (39) was a suitable precussor to our 
target. This compound could arise from the catalytic hydrogenation of the (E)-alkene
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(96) which we envisaged arising from the coupling of the aryl Grignard reagent (97) 
with the allylic bromide (98), itself a product of bromine addition to the commercially 
available buta-l,3-diene (99).
Figure 17
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A similiar synthetic pathway had been reported by Filler and Choe<^ 2 the first 
step in the synthesis of octafluoro[4,2]paracyclophane (103) (Scheme 17). The 
pentafluoro Grignard reagent (101) was successfully coupled with the allylic bromide 
(100) in moderate yield and this further encouraged us to adopt this approach.
Scheme 17
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3.2.4 (±)-NDGA - The Grignard route
The bromination of the butadiene (Scheme 18) was carried out by the method 
of Sweeting and Johnson^^ affording the bromide (98) in moderate yield as shiny 
crystals. The melting point was in agreement with that reported and the NMR 
spectrum revealed two singlets at ô 1.90 and 4.07 integrating for three and two protons 
respectively. The NMR spectrum showed three resonances including a quaternary 
peak at 5 132 and a parent ion at m/z 242 in the mass spectrum also agreed with the
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proposed structure. We also found the material to be a strong lachrymator as reported 
by the authors.
Scheme 18
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With the bromide (98) in hand, we turned our attention to the synthesis of the 
Grignard reagent derived from commercially available 4-bromoveratrole (104). The 
reaction was attempted using scrupulously dry glassware and magnesium ribbon that 
had been washed thoroughly with ether and dried under vacumn. We however 
witnessed no sign of reaetion on addition of an ethereal solution of (104) to the 
magnesium ribbon under nitrogen, Sonication or gentle reflux failed to initiate the 
reaction as did the addition of a few drops of 1,2-dibromoethane. The reaction was also 
attempted in dry THF and even use of activated magnesium, obtained by stirring the 
ribbon under nitrogen overnight, was unsuccessful. We suspected that the aryl iodide 
(105) would form the Grignard reagent more readily as a consequence of easier 
insertion of the metal into the halide bond. With this in mind, iodide (105) was 
synthesised following the general procedure of Skulski and c o - w o r k e r s . from 
commercially available veratrole (72) using an iodine-lead tetraacetate system (Scheme 
19). The reaction is believed to follow the pathway outlined with oxidation of the iodine 
to give the electrophile which reacts with the activated aromatic nucleus in the usual 
fashion.
Scheme 19
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The consumption of iodine during the reaction was clearly evident with the 
reaction mixture turning from a deep red-black colour to a light yellow solution after
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several hours. The iodide (105) was obtained in good yield and of the two possible 
regioisomers substitution at the 4-position was apparent from the NMR spectrum. 
In addition to two methyl ether singlets, the spectrum revealed two doublets and one 
doublet of doublets in the aromatic region giving clear evidence for the regiochemistry 
proposed. A parent ion at m/z 264 in the mass spectrum and a melting point in 
agreement with that r e p o r t e d ^ 4  were also consistent with the proposed structure. 
Unfortunately following the same conditions used for the arylbromide we were not 
able to effect any Grignard formation.
Rieke and Bales^^ have reported the formation of a highly reactive magnesium 
source showing enhanced reactivity towards Grignard formation by using alkali metal 
reduction of magnesium salts in THF. We however were unwilling to attempt this 
procedure for safety reasons but in a final attempt to achieve our goal we attempted a 
transmétalation of magnesium from commercially available isopropylmagnesium 
chloride (106) in THF as outlined in Scheme 20. It was envisaged that due to the 
enhanced stability of the aryl Grignard over the aliphatic reagent that one could 
transmetalate under mild conditions and react this with our bromide (98). As a trial we 
decided to attempt such a transmétalation and react the derived Grignard reagent with 
water resulting in overall reduction of (104) to veratrole (72) (Scheme 20). The crude 
product was however shown to be starting material by ^H NMR spectroscopy and 
further runs at 0 °C even using the iodide (105) failed to effect reduction of the aryl 
halide bond.
Scheme 20
l .T H F ,-7 8 °C , 1 h
M e c A ^  MgCI 2.H;6 M eO '"^^
104 lOfi 72
3.2.5 Attempts employing other metals
Disappointed at the stubbornness of bromide (104) to form the Grignard 
reagent we turned our attention to the synthesis of the organolithium species generated 
by the insertion of lithium into the metal halogen bond of (104) using M-butyllithium. 
Our first attempt was a trial reaction using the dialdehyde (107) as an electrophile 
which we had at our disposal (Scheme 21). Addition of one equivalent of 77-Buli to a 
solution of 4-bromoveratrole (104) in THF at -78 °C followed by 0.5 equivalents of 
aldehyde (107) resulted in smooth conversion to the diol (108) in quantitative yield. 
TLC showed all the starting material had been consumed and revealed a single more 
polar spot near the baseline which was stained red with vanillin spray. The ^H NMR
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spectrum showed the desired structure exsisting as a mixture of diastereoisomers that 
was not further purified.
Scheme 21
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Encouraged by this result and confident that metal halogen exchange had been 
effected we decided to carry out the work as depicted in Scheme 22. Addition of 1.1 
equivalents of n-BuLi to a solution of (104) in THF at -78 °C followed by reaction 
with the allylic bromide (98) proceeded smoothly giving a single more polar spot by 
TLC. The crude reaction product was passed through a short silica column to afford a 
crystalline product which gave a very simple NMR spectrum. The spectrum 
revealed two doublets and a doublet of doublets in the aromatic region along with two 
methyl ether singlets but did not show expected resonances for the aliphatic protons of 
(96). The NMR spectrum also showed no signs of aliphatic functionality and gave 
eight resonances including the two methyl ethers at ô 56. A parent ion at m/z 274 in the 
mass spectrum along with the NMR data confirmed the presence of the 
tetramethoxybiaryl compound (109), a product of homocoupling of the organolithium 
species. Interestingly, the coupling of aryl Grignard reagents has been reported by 
Taylor et al.^^ using unsaturated 1,4-dihalocompounds. The authors report the use of 
l,4-dichlorbut“2-ene and 1,4-dichlorobut-2-yne as being successful giving high yields 
of coupled product however no reaction is observed with fmn.y-1,4-dibromobut-2-ene. 
Although it was not further investigated, we feel that under our conditions bromide (98) 
was acting in a similiar fashion to that reported, by excepting an electron thus forming 
the stable aiyl radical which then underwent homocoupling.
Scheme 22
l.H-BuLi, THF 
-78 “C. 10 min MelMel
2. 98, THF, -78 °C 
rt, 1 h MelMel 104
OMe
OMeMel OMe
OMeMeO 109
56
Attempts to transmetallate from lithium to copper using the reagent lithium 
thienyl“2-cyanocuprate^'7 was unsuccesful along with attempts to form the organozinc 
using anhydrous zinc chloride. The crude reaction product from each reaction was 
shown to be a complex mixture of products by NMR spectroscopy and were not 
further investigated.
Returning to the retrosynthetic analysis of (±)-NDGA (Figure 17) it was 
expected that symmetrical alkene (96) could arise from a McMurry type coupling of 
commercially available 3,4-dimethoxyphenylacetone (110) (Figure 18). The remainder 
of this chapter opens with a brief review of some low valent titanium reagents useful in 
organic synthesis concluding with our succesful total synthesis of (±)-NDGA utilising 
such a reagent in a key step.
Figure 18
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3.3 Successful synthesis of (±)-NDGA
3.3.1 Low Valent Titanium Reagents
The use of low valent titanium reagents for the reductive coupling of aldehydes 
and ketones to alkenes arose independently from the labs of Tyrlik and 
Wolochowicz^^, Mukaiyama et al.^^ and McMuiry and Fleming^O the early 1970s. 
Mukaiyama et al. used a reagent prepared from the reduction of titanium (IV) chloride 
with zinc giving good yields of coupled products. Their reactions afforded the 
corresponding pinacols at low temperatures whereas alkenes were isolated when the 
reaction mixtures were heated at reflux. In the case of aliphatic aldehydes and ketones 
the major products isolated were the pinacols with small ammounts of alkenes formed 
even under refluxing conditions. McMurry and Fleming developed a reagent derived 
from the reduction of titanium (III) chloride with LiAlH4 and succesfully coupled a 
series of aromatic and aliphatic carbonyl compounds. In contrast to the other methods 
discussed the authors reported the successful coupling of aliphatic ketones to alkenes 
using this reagent system. McMurry and co-workers have demonstrated considerable 
effort in an attempt to produce a reagent that shows consistency in the coupling
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procedure for a wide variety of substrates. This has resulted in the coupling of 
carbonyl compounds to alkenes being widely referred to as “The McMurry 
Reaction”.
Shortly after their original paper McMurry and Fleming reported an improved 
procedure which used three equivalents of potassium metal to reduce the titanium (III) 
chloride.'^l This was later followed by a more thorough report concentrating on the 
reduction of TiClg with both potassium and lithium including a thorough investigation 
into the reaction mechanism.^^ These procedures superceded their original work as the 
ability to repeat their results was dependent on the batch of TiClg used. The use of an 
alkali metal as a reductant however was shown to be consistent for three separate 
batches used and even the highly hindered olefin tetraisopropylethene (111) could be 
isolated in moderate yield by this route (Scheme 23). Several years later McMurry et 
alJ^  reported an optimised procedure for titanium- induced carbonyl-coupling 
reactions. The reagent system used was TiCl3(DME)i.5 / Zn-Cu and was reported as 
being particularly effective as even old batches of TiClg could be converted into the 
blue crystalline TiClg/DME solvate which showed enhanced reactivity. As an example 
of the reagent's effectiveness the authors reported the isolation of hindered olefin (111) 
in 87% yield which was a significant increase to that previously reported.^l
Scheme 23
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Many other research groups have reported the succesful use of low valent 
titanium reagents. Corey et alP^ introduced the reagent TiClq -Mg(Hg) which could 
effectively couple carbonyl compounds to produce pinacols at low temperature in high 
yield. The authors claimed that this reagent was more consistent than the original 
system developed by Mukaiyama et al.^^ showing enhanced reactivity towards 
aliphatic ketones. They also reported that a reagent derived from 
cyclopentadienyltitanium trichloride-LiAlHq was equally effective for a variety of 
processes. In refluxing THE TiCl4-Mg(Hg) allowed access to alkenes derived from 
both aromatic or aliphatic p re c u rso rs .T h e  addition of pyridine to TiCl4-Zn was 
reported as being effective for the reductive coupling of a wide variety of aliphatic 
ketones affording alkenes in moderate y ie ld s .T a lu k d a r  et alJ^  have recently 
reported an especially reactive system derived from TiCl3-Li in combination with 
iodine. The reagent effects the coupling of both aliphatic and aromatic carbonyl
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compounds to alkenes at low temperatures in contrast to conventional methodology. In 
one example acetophenone could be successfully transformed to the coiTesponding 
stilbene (112) at -40 °C in good yield, (Scheme 24).
Scheme 24
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The use of low valent titanium reagents is not confined solely to intermolecular 
couplings with many examples of intramolecular reactions appearing in the literature. 
The skeleton of the taxane diterpene taxusin (113) has been successfully constructed 
employing an intramoleculai' coupling reaction by Kende et al?^ (Scheme 25).
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The use of low valent titanium reagents has also found widespread application 
in the field of natural product synthesis typified by the synthesis of bicyclogermacrene 
(114) by McMurry and Bosch^G" (Scheme 25). Mixed coupling of carbonyl
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compounds is also possible when one carbonyl component is in excess and its olefin 
dimer is readily separable from the product mixture. Alternatively if the reduction 
potential of the carbonyl components are quite different mixed coupling can be 
synthetically useful. This is particulary true for diaryl ketones where the second 
reduction potential is less negative than the first reduction potential of the ketones. The 
initial step is thus a two electon transfer to the diaryl ketone yielding a dianion which 
adds in the conventional fashion producing a pinacol which is further deoxygenated. 
This procedure was used by Coe and Scriven in a new stereoselective synthesis of the 
antitumuor agent Tamoxifen (31).^  ^The reaction sequence (Scheme 25) was a suitable 
route towards a series of Tamoxifen analogues by simply altering the alkoxy group on 
the benzophenone nucleus.
3.3.2 Mechanism of the Reductive Coupling
The accepted mechanism of the reductive coupling of carbonyl compounds to 
alkenes is depicted in Figure 19. The initial step is a one electron transfer from the 
titanium species to the carbonyl group affording a radical anion which dimerises to 
give the primary pinacol product (115). The use of low temperatures ensures that the 
pinacol (115) is the final reaction product with no deoxygenation to the corresponding 
alkene.
Figure 19 - Mechanism of Reductive Coupling
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McMuiTy et alP'^ envisaged four possible mechanisms for the deoxygenation 
of the intermediate pinacol (Figure 19) and devised a series of experiments aimed at 
distinguising between them. Paths A and B were similiar in that both involved a five
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membered-ring intermediate with both oxygens bound to a common titanium atom. It 
was feasible that this intermediate could break down by a concerted (Path B) or non­
concerted pathway (Path A) in which the two C -0 bonds were broken at different 
times. However when a diol of known stereochemistry like mgj'o-5,6-dihydroxydecane 
(117) was subjected to the coupling conditions a mixture of geometrical isomers was 
isolated in good yield suggesting that the deoxygenation was in fact non-concerted 
(Scheme 26). Path C assumed that the two oxygens were not bound within a five- 
membered intermediate but bound to two separate titanium atoms.
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These pathways were distinguised by realising that reduction of cis-9,10- 
decalindol (118) proceeded smoothly affording the octahydronaphthalene (119) in 
high yield however the ^mnA-diastereoisomer (120) gave no reaction (Scheme 26). It 
was clear that due to the close proximity of the oxygen atoms in the cA-isomer, a five- 
membered ring intermediate could be formed which would further break down. If path 
C was a viable mechanism one would expect the tmns-isom&v to be reduced as unlike 
path A the oxygens do not need to be close in space. However as no reduction was 
observed it was clear that path C did not represent a viable reaction mechanism. Path D 
differs from path A in that one assumes that the reaction is occurring in a 
heterogeneous phase on the surface of an active titanium particle. The pathways were 
distinguised by considering the reaction rate for the deoxygenation of the cis-
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camphanediol (121) versus that for a mixture of the rm^j-isomers (122 + 123). If a 
five-membered ring intermediate was involved one would expect the cz^-isomer to 
deoxygenate rapidly with respect to the tmns-isom&ïs where the oxygen atoms are 
further apart in space. McMurry et al. found however that the isomers were reduced at 
an equal rate strongly suggesting that a five-membered ring intermediate was not 
involved (Scheme 26).
As a consequence of their experiments the authors concluded that the 
intermediate pinacol was deoxygenated in a heterogeneous fashion on the surface of a 
broad titanium particle affording the alkene (116).
3.3.3 First Attempts at Reductive Coupling
During their investigation on the intramoleculai- oxidative coupling of aromatic 
compounds, Carroll et al.^^ required the diarylbutane (126) arising from the reductive 
coupling of 3,4,5-trimethoxyphenylacetone (124) (Scheme 27). The mixture of 
geometrical isomers formed could be easily separated by recrystallisation from EtOH 
affording pure (F)-alkene (125) in good yield. Catalytic hydrogenation of (125) in 
MeOH over palladium on charcoal afforded (±)-(126) in high yield. Encouraged by 
this result on a very similiar substrate coupled with the fact that 3,4- 
dimethoxyphenylacetone (110) is commercially available we decided to adopt this 
methodology.
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Addition of a THE solution of (110) to the Mg(Hg)-TiCl4 system at 0 °C 
followed by 17 hours at reflux was carried out as reported^! on a 2.57 mmol scale 
(Scheme 28). The crude product was obtained as a heavy amber coloured oil which
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was crystallised from EtOH affording orange crystals in 38% yield. It was clear 
however by TLC and NMR spectroscopy that this product was not the expected 
alkene (96). TLC revealed a single less polar spot that was not stained by acidified 
KMnÜ4 and the NMR spectrum was more complicated than one would expect. 
Two singlets at 5 2.07 and 2.28 were observed each integrating for three protons along 
with four separate methyl ether resonances. A multiplet integrating for two protons 
along with a doublet and three separate singlets, each integrating for one proton, were 
recorded in the aromatic region of the spectrum. A parent ion at m/z 352 was observed 
in the mass spectrum and the NMR spectrum showed eighteen peaks excluding 
the methyl ethers which appeared as a single resonance. The spectrum indicated the 
presence of six CH groups and six quaternary carbons in the aromatic region along 
with two separate methyl resonances at 5 17.2 and 5 22.1. It was clear from the 
analytical data that the product we had isolated was in fact l-(3,4-dimethoxyphenyl)- 
2,3-dimethyl-6,7-dimethoxynaphthalene (127). The naphthalene (127), which had 
previously been synthesised using an alternative route by Muller and Vajda, gave a 
melting point in agreement with that reported.^2 We decided to repeat the reaction 
monitoring regularly by TLC although not heating at reflux which we felt was giving 
us this curious result. After stirring overnight at ambient temperature TLC showed no 
starting material and two distinct spots neither of which was stained by KMnOq. The 
crude product was purified by silica gel flash chromatography and naphthalene (127) 
was isolated in 41% yield along with an unknown compound in low yield which was 
clearly not alkene (96) by NMR spectroscopy. As a consequence of not being able 
to repeat the work of Carroll et on our substrate, we turned our attention to 
alternative methods.
Scheme 28
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Addition of three equivalents of lithium to a stirring suspension of TiCl3 in dry 
DME followed by heating at reflux resulted in a colour change of purple to a deep
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black heterogeneous mixture. Ketone (110) was added to the cooled solution and 
reflux maintained for 16 hours following the general procedure of McMurry et alP'^ 
The crude product was shown however to be a complex mixture by NMR 
spectroscopy and was not further investigated. The same result was observed when 
potassium metal was used in place of lithium. The TiCl3-LiAlH4 reagent, introduced 
by McMurry and Fleming^®, was also investigated and the crude product showed 
several spots by TLC with no starting material evident (Scheme 29). A Iff NMR of 
the crude mixture showed it to be predominately alcohol (128) clearly arising as a 
result of a conventional L1A1H4 type reduction. Silica gel flash chromatography (2:1 
hexane-EtOAc) allowed us to isolate a further three compounds in very low yield. The 
first was identified  by  ^H and  ^ ^ C NMR spectroscopy as 3,4- 
dimethoxyphenylpropane (129) isolated as an oil, a product of deoxygenation of the 
intermediate radical anion. A second fraction gave a solid in low yield which was 
identified by NMR spectroscopy as the desired alkene although present as a 
mixture of geometrical isomers in ca. 1:1 ratio. Two singlets around 5 1.7 combined 
with a further two around 5 3.5 arising from the methyl and methylene groups 
respectively were consistent with the proposed structure. The spectrum was similiar to 
that of the trimethoxy analogue (125) reported by CaiToll et al.^^ and a TLC sample 
was intensely stained by KMn04. The final fraction ran close to the baseline on TLC 
and was stained red when developed with vanillin. A %  NMR spectrum revealed the 
product to be a diastereoisomeric mixture of pinacols (130) which was later confirmed 
during its synthesis by an alternative route (Section 3.3.4). The reaction could not be 
optimised and use of an alternative batch of TiCl3 failed to overcome the problem.
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Encouraged by the fact that we had managed to synthesise (96) albeit in very 
low yield we attempted to use the optimised procedure for carbonyl coupling reported 
by McMurry et alJ'^ The Zn-Cu couple was synthesised as reported; however attempts
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to form the crystalline TiClg (DME) 1.5 were disappointing. TiClg was suspended in 
dry DME and heated at reflux under an argon atmosphere for two days as reported. 
We however isolated an off-white solid after filtration in contrast to a blue crystalline 
substance reported by the authors. It was clear from this result along with the 
proceeding experiment (Scheme 29) that our TiCl] was clearly ineffective for this type 
of chemistry and we sought an alternative approach.
3.3,4 A Successful Coupling Procedure
Takeya et al.^^ required alkene (125) for the synthesis of some racemic 
dibenzocyclooctadiene lignans. It was prepared by a two step process via an 
intermediate pinacol which was deoxygenated affording a mixture of alkenes which 
could be readily separated (Scheme 30).
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TiClq was added drop wise to a stirring solution of ketone (110) in THE 
resulting in a yellow-green suspension to which was added activated zinc dust 
portionwise. On heating, the mixture became a deep red homogeneous solution which 
was heated at reflux for 3 hours as reported. The crude product, isolated as an oil, was
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crystallised from Et20 affording pinacol (130) in high yield (Scheme 30). Integration 
of the methyl group singlets in the NMR spectrum revealed a mixture of 
diastereoisomers in ca. 1:1 ratio.
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Deoxygenation of the pinacol mixture (130) was carried out as reported 
following the general procedure of Josan and E a s t w o o d . ^  solution of (130) in 
triethyl orthoformate was heated at 180 °C in the presence of benzoic acid while 
allowing EtOH to distil from the reaction mixture. TLC revealed a single less polar 
spot which was stained by acidified KMn04. The crude product was recrystallised 
from EtOH affording the novel (E)-alkene (96) in relatively good yield. At this point 
we tentatively assigned (96) the fmzi^'-configuration in accordance with the result 
reported for the trimethoxy a n a l o g u e ^ ^  ^nd this was later confirmed by hydrogenation. 
It was interesting that crystallisation of the mother liquor afforded the cA-alkene (131) 
as a solid in low yield whereas the trimethoxy analogue is reported as an oil. Several 
recrystallisations were however needed to obtain an analytically pure sample, showing 
no (E)-alkene in the ^H NMR spectrum, resulting in this low yield.
We felt that it would be synthetically more attractive if the separation of 
isomers could be effected at an earlier stage. We serendipitously discovered that
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recrystallisation of the pinacol mixture (130) from EtOH afforded the pure meso 
pinacol (132) in 22% yield which was fully characterised (Scheme 31). A futher crop 
of material was isolated in 39% yield and was shown by ^H NMR spectroscopy to be 
a mixture of the racemic and meso pinacols (133) in a 2:1 ratio. Deoxygenation of 
(133) afforded the pure (E)-alkene (96) in good relative yield which was fully 
characterised. With (96) in hand we turned our attention to reduction of the double 
bond following the successfully reported methods for the trimethoxy analogue.
Carroll et a/.^l has reported the reduction of alkene (125) using palladium on 
charcoal in MeOH affording the racemic diarylbutane (126) in excellent yield (Scheme 
27). A mixture of our alkene (96) was thus stirred under a hydrogen balloon over Pd-C 
overnight. TLC of the mixture showed a very close running spot to starting material 
that was not stained by KMnOq and the filtered residue was concentrated to give a 
semi-solid. ^H NMR spectroscopy showed a more complex spectrum than one would 
expect with an apparent triplet at Ô 0.84 along with four separate resonances for the 
diastereotopic benzylic protons of (39). It was clear that we had formed a mixture of 
the (±)-and me^'o-diarylbutanes which could not be separated by chromatography or 
recrystallisation. By comparison of our ^H NMR spectrum with the one reported for 
the meso-compo\md^ the ratio was found to be 3:2 in favour of the racemate (39).
The same result was obtained when the reaction was carried out in AcOH or 
EtOAc even at reduced temperatures. We suspect that this curious result is a 
consequence of our alkene (96) being able to adopt a planar conformation. 
Isom érisation of the double bond into the benzylic position would be 
thermodynamically favourable due to overlap of the 7 t electrons of the double bond 
with the aromatic n  system. In contrast, the trimethoxy analogue (125) should 
experience steric hindrance between the methyl group of the aliphatic chain and the 
methoxyl group on the ring (Figure 20). As a result of this, we expect that the aromatic 
ring could pucker out of planarity thus reducing the probability and rate of 
isomérisation with respect to double bond reduction.
The hydrogenation of (96) in EtOAc over 5% rhodium on charcoal gave only 
starting material. However when the reaction was performed in AcOH, there was a 
slight conversion into product. It was encouraging that by ^H NMR spectroscopy we 
could see little of the meso~a\kenQ and this prompted us to attempt the reaction at a 
higher pressure. Reduction of (96) in AcOH at an initial pressure of 6 ban* gave a 
mixture chiefly composed of the racemic diarylbutane (39).
67
Figure 20
Mel
Mel
Favoured due to 
extensive orbital overlap
OMe
OMe
Mel
Mel
OMe
OMe
Mel
Mel
Unfavoured due to 
poor orbital overlapO—
125 Mel OMe
OMe
Mel
Mel
O—
Mel OMe
OMe
Close inspection of the NMR spectrum revealed some starting material 
along with the me^ço-diarylbutane (47) although the ratio had dropped significantly 
from 1:9 in favour of the racemate. There was also signs of extra resonances in the 
aliphatic region of the spectrum which we assumed to be a result of aromatic ring 
reduction. The reaction was also performed at 7 barr in an attempt to consume all the 
starting material. Unfortunately a NMR spectrum of the crude residue showed no 
signs of aromaticity and a large multiplet in the aliphatic region, clearly a result of 
aromatic ring reduction. The use of Raney nickel as a catalyst failed to give any useful 
result with little consumption of the starting material. It was clear from NMR 
spectroscopy of the crude product that isomérisation had been effected persuading us 
that high pressure hydrogenation would not give a useful result.
Takeya et al. have reported that hydrogenation of (£')“l,4-bis-(3,4,5- 
trimethoxyphenyl)-2,3"dimethylbut-2-ene (125) using platinum (IV) oxide afforded the 
racemic diarylbutane (126) in high yield.^3 Encouraged by this result we decided to 
adopt their reaction conditions and repeated their work on our very similiar substrate. 
Our initial attempt concentrated on stirring a solution of the (E)-alkene (96) in AcOH 
over P t02 under hydrogen at atmospheric pressure overnight. To our surprise the 
NMR spectrum showed no resonanees for aromatic protons and a large multiplet in the 
aliphatic region. This was consistent with aromatic ring reduction as we had 
experienced using rhodium on carbon at an increased pressure. We decided to repeat 
the reaction and monitor the consumption of starting material regularly by TLC. After 
one hour no starting material was evident and a homogeneous compound was observed 
which did not give an intense yellow spot when developed by acidified KMn04 stain. 
The crude residue was shown to be a 10:1 ratio of diastereoisomers of (39) in favour
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of (lie racemate. I hcrc was also evidence of aromatic ring reduction. However this 
contaminant could be removed by silica gel chromatography alToiding pure (39) albeit 
as a ratio of diastereoisomers. We found that attempts to crystallise pure racemic (39) 
out of the mixture could only be effected by slow evaporation of a saturated MeOH 
solution. Attempts to induce crystallisation by scratching or cooling enriched the 
concentration of the racemate, however it was not iliastcreoisomeiically pure. We 
isolated the pure lacemic diarylbutane (39) as needles in low yield that gave a melting 
point and h i  NMK spectrum (Kigurc 21) in agiecment with those repoited."^  ^ I he 
 ^ NMR spectrum showed the expected eleven resonances and a paient ion at tu/z. 
358 in the mass spectrum was consistent with the proposed structure.
Figure 21 - *11 NMR spcclniin of (±)-diaryll)utaiic (39)
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1 he dcproleclion of (39) to give our target compound thankfully went 
uneventfully affoiding (32) as a tan coloured solid in high yield. As reported 
previously (Section 3.1.6), this compound has leceived little interest in the literature 
and only a melting point is piesented. We herein icport full chaiacterisation for (32) 
including a melting point which was is agreement with that leported."^ '* I he *11 NMR 
spectrum shown in Figure 22 is clearly in agreement with the proposed structure. A
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low licid 311 cioublcl at 6 0.72, a III imilliplcl and two III doublet of doublets were 
observed for the methyl, metbinc and methylene protons of the aliphatic sidechain 
respectively. I hc sustitution patterns of the aromatic nuclei was clear as were the two 
phenolic protons which appeared as two broad doublets around 8.4. 'I hc IK spectrum 
showed two distinct phenol stretches at 3377 cnr  ^ and 3474 cnr * along with two 
stretches in the 1500'1600 cnr * region for the aiomatic nuclei. Nine peaks in the * 
NMK spectrum coupled with a parent ion at ni/z 302 in the mass spectrum confirmed 
that we had succcsfully isolated our target molecule in high purity.
I'igiirc 22 - *11 NMK spectrum of (±)-NI)(iA
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3.3.5 Synthesis of meso - NDGA
Having the pure pinacol (132) in hand we decided to carry out the 
synthesis of /;/c.w-NDGA ( I )  as outlined in Scheme 32.1 he .vv//-deoxygenation was 
carried out as reported previously affording the novel (Z)-alkene (131) as crystals in 
good yield. Catalytic hydrogenation over Kt()2 presented us with the same problems 
we had encountered with the (/T)-alkene (96). Kecrystallisation of the crude residue 
from McOI I gave the /nr.vo-diarylbutane (47) as a 19:1 ratio of diastereoisomers (h i
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NMR) in moderate yield. A further recrysallisation was needed to obtain pure (47) 
albeit in a lower yield. The combined mother liquors were shown by NMR 
spectroscopy to be mainly the me^o-compound (47), however no suitable material 
could be recovered. Déméthylation was carried out in refluxing hydrobromic acid 
affording NDGA (1) as tan coloured crystals in good yield. A NMR spectrum and 
melting point were in agreement with those reported for the natural product,42
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3.3.6 Alternative reduction attempts
Due to the disappointing yields obtained for the reduction of the (JE)- 
alkene (96) we were keen to attempt an alternative method which would result in no 
isomérisation or ai'omatic ring reduction.
3.3.6.1 Diimide chemistry
Diimide (134) is an unstable compound that is generated in situ and 
used for the hydrogenation of non-polar multiple bonds. It is generally formed by the 
oxidation of hydrazine and its derivatives and has been shown to hydrogenate double 
bonds in a Ay/r-fashion. The mechanism of hydrogenation, depicted in Figure 23, 
involves a synchronous delivery of hydrogen through a cyclic transition state. Diimide 
does not lead to isomérisation of double bonds and its high functional group selectivity 
gives it some advantages over many catalytic processes.
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Figure 23 - Mechanism of Diimide Reduction
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Our first attempt used the general method of Wade and Amin 
employing a EtOAc-hydroxylamine sy s te m .T h e  crude product, isolated as a solid, 
was shown by NMR spectroscopy to be only starting material with no signs of the 
reduced product. The same result was obtained using the general procedure of 
Moriarty et al.^^ using hypervalent iodine oxidation of hydrazine to generate diimide. 
We then turned our attention to more conventional methods; however the thermal 
decomposition of tosylhydrazine afforded only staring material as did the acid 
catalysed decomposition of potassium azodicarboxylate. It has been documented in the 
literature that increased substitution around the double bond is consistent with lower 
yields of reduced product being i s o l a t e d . ^ ^ Q  feel as a consequence of seeing no 
reduced product in the crude NMR spectra, that the tetra substituted double bond 
of (96) is simply too hindered to undergo this type of chemistry.
3.3.6.2 Hydroboration-Protonolysis
Takeya et al.^^ required the threo-buimol (135) for the synthesis of 
some dibenzocyclooctadiene lignans (Scheme 33). It was obtained from the (E)-alkene 
(125) by a conventional hydroboration procedure. We realised that the intermediate tri- 
organoborane could be trapped with AcOH allowing access to the racemic diaiylbutane 
(39) using the procedure of Brown and Murray.
Hydroboration of (96) was carried out as reported; however the H2O2- 
NaOH mixture was replaced with an excess of AcOH and the mixture was heated at 
reflux overnight. A NMR spectrum of the crude residue showed no starting 
material however there was no sign of the racemate (39) and the reaction was not 
further investigated. It is worthwhile to note that Brown and Murray found that when 
the boron atom was attached to a highly branched alkyl group protonolysis did not 
proceed even under drastic co n d itio n s .T h ese  findings pursuaded us not to pursue 
this type of chemistry.
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3.3.7 Conclusion
We have spent a considerable amount of time on the synthesis of the 
racemic diastereoisomer of NDGA (32) resulting in a four step synthesis through 
which we isolated our target in low overall yield. The initial route we decided to follow 
(Section 3.2.1) was particulary disappointing as the racemic diketone (65) could be 
isolated in high purity with the stereochemistry of the methyl groups successfully in 
place. It is interesting that the simaliar substrate (136) was reduced to the diarylbutane 
with great difficulty (Scheme 3 4 ) . The Wolff-Kischer and Clemmensen reduction 
gave no useful product nor did a variety of hydrogenation experiments. The authors 
isolated (126) in low yield via reduction of the derived dithioacetal clearly giving 
further evidence of the difficulty associated with the reduction of these types of 
systems.
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Our succesful synthesis of racemic NDGA (32) is overshadowed by the 
problems associated with the hydrogenation of the hindered (E)-alkene (96). It is 
surprising that the trimethoxy analogue is reported to be succesfully hydrogenated 
without any signs of isomérisation or over reduction. The first step can be carried out 
on a large scale using cheap readily available materials giving a mixture of pinacol 
diastereoisomers that can be partially separated. No attempt was made to carry this 
reaction out asymmetrically as a result of little work reported in the literature. The 
pinacol coupling of aromatic and a,P-unsaturated aldehydes using a titanium (III)- 
magnesium (II) complex has been reported to afford pinacols with a high threo- 
selectivity.^^ There is however no reaction reported with aliphatic substrates warning us 
not to attempt these conditions. Our route also allows access to /M^^o-NDGA (1) 
giving material of higher purity than that obtained commercially. There is however still 
problems associated with the alkene reduction. However we have to date not discovered 
a suitable system to overcome this problem.
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Synthesis of NDGA Analogues
4.1 Introduction
We were interested in the synthesis of a series of NDGA analogues which 
could help in the determination of structure activity relationships. The first set of 
compounds synthesised is depicted in Figure 24 which although sharing the bis 
catechol functionality, differed in the distance between the aromatic nuclei. We also 
synthesised a range of mono phenolic compounds in an attempt to ascertain whether 
the catechol functionality was important for activity. The presence of an amide linkage 
between the aromatic nuclei would give a more conformationally restricted analogue 
which might show enhanced activity. With this in mind, synthesis of a series of amides 
was also undertaken containing both catecholic and phenolic aromatic nuclei. This 
chapter describes our work undertaken in achieving our aims concluding with a series 
of preliminary test data.
Figure 24
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4,1.1 A Common Synthetic Route
A series of diphenyl alkanediamines have been synthesised by Fliender et 
as potential fibrinolytic agents. The key step in their synthesis was the alkylation of an 
aromatic dithiane with a suitable dihaloalkane (Scheme 35). We felt that this method 
was ideal for our needs as reduction of the dithiane functionality followed by 
deprotection would furnish our target compounds. Furthermore, simply altering the 
substituents on the aromatic nucleus along with utilising a variety of commercially 
available dihaloalkanes would give rise to a range of NDGA analogues.
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The required 2-(3,4-dimethoxyphenyl)dithiane (137) was successfully 
synthesised in high yield following the procedure of Seebach et for the 
corresponding 2-phenyl analogue (Scheme 36). The product was obtained as shiny 
crystals giving a melting point in agreement with that r e p o r t e d ,^4 The Iff NMR 
spectrum revealed a 2H and 4H multiplet in the aliphatic region along with a deshielded 
methine singlet at Ô 5.13 giving further evidence for the proposed structure. With 
dithiane (137) in hand, we turned our attention to the coupling procedure following the 
reported method of Fliedner et al.^^ Addition of one equivalent of 7T-BuLi to a cooled 
solution of dithiane (137) in THF gave a yellow solution to which was added 0.5 
equivalents of 1,3-dibromopropane drop wise. After the mixture was left at 0 °C 
overnight, TLC indicated no starting material and a homogeneous slower running spot. 
We were not able to obtain a suitable sample by recrystallisation, as reported, so the 
crude residue was purified by silica gel flash chromatography affording the 
bis(dithiane) (138) as a solid in moderate yield. (138) gave a melting point in 
agreement with that r e p o r t e d ^ ^  and a ^H NMR spectrum was consistent with the 
proposed structure.
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Reduction of the bis(dithiane) (138) was attempted in refluxing EtOH over 
Raney Ni, however TLC of the reaction mixture after heating overnight showed only 
starting material. The same result was observed using freshly prepared W2-Raney Ni
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and even carrying the reaction out under a hydrogen atmosphere showed no product 
formation by TLC. It was suspected that the catalyst was inactive, however when a 
small sample was allowed to dry out under controlled conditions, it sparked violently 
and caught fire so it was clearly active. Attempted reduction of dithioacetal (137) was 
also unsuccessful prompting us to abandon this common synthetic route.
4.1.2 Synthesis of a C3-Bridge analogue
A series of dibenzoylmethane derivatives have been synthesised by Choshi et 
al. as potential inhibitors of the mutagen 2-nitrofluorene.^^ The key step in their 
synthesis was the coupling of an aromatic ester with a substituted acetophenone using 
sodium hydride in refluxing benzene. We decided to repeat their method and the 
synthesis of the C3 bridge analogue (143) is depicted in Scheme 37.
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3,4-Dimethoxybenzoic acid was esterified as reported^^ affording the ethyl 
ester (139) as a colourless oil in moderate yield. A 3H triplet and 2H quartet in the 
NMR spectrum along with a characteristic ester resonance at ô 167 in the NMR 
spectrum confirmed the proposed structure. The coupling of ester (139) with 3,4- 
dimethoxyacetophenone (140) was carried out as reported although benzene was 
replaced by toluene for toxicity reasons. The crude product was recrystallised from 
EtOH affording the P-diketone (141) as bright orange crystals giving analytical data in 
agreement with those reported.^^ The low yield was disappointing, however pure (141) 
could be simply obtained by a single recrystallisation of the crude residue avoiding the 
need for column chromatography. An olefinic and broad hydroxyl proton at 5 6.8 and
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ô 14.4, respectively, in the %  NMR spectrum indicated that (141) exists exclusively as 
the enol form in neutral solution. A characteristic stretch at 1600 cm“l for an enolised 
1,3-diketone and a parent ion at m/z 344 gave further evidence for the proposed 
structure. Catalytic hydrogenation of diketone (141) was carried out in MeOH over 
palladium affording the diarylpropane (142) in good yield. This compound has been 
synthesised by Tamura et alP'^ by an alternative route and gave a melting point in 
agreement with that reported. The ^H NMR spectrum revealed a 2H multiplet and a 4H 
triplet for the methylene and benzylic methylene protons respectively. The IR spectrum 
showed no stretches in the carbonyl region and a parent ion at m/z 316 in the mass 
spectrum confirmed that reduction had been successful. Boron tribromide 
déméthylation was carried out following the general procedure of McOmie et The 
crude product showed a polar homogeneous streaky spot by TLC that was intensely 
stained by I2 . This product could not be purified by recrystallisation so was subjected 
to silica gel flash chromatography affording diarylpropane (143) as a solid in excellent 
yield, giving a melting point in accordance with that r e p o r t e d . T h e  ^H NMR 
spectrum showed no resonances for the methyl ethers while the nM R spectrum 
showed the expected eight resonances. Broad phenolic stretches at ca. 3500 cm"l in 
the IR spectrum coupled with a parent ion at m/z 260 in the mass spectrum were also 
consistent with the proposed structure.
4.1.3 Synthesis of a C4-Bridge analogue
Gisvold et al.^^ have reported the synthesis of the diarylbutane (149) which 
showed antiseptic and antioxidant activities comparable with those of NDGA. Their 
synthesis was however low yielding using harsh conditions and we decided to try an 
alternative approach. Another procedure reported by Tamura et involves a total of 
eight synthetic steps and we felt this was too long and cumbersome to repeat.
Scheme 38
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In planning our own synthesis of (149) we felt that a 1,4-diketone could be 
synthesised easily by modifying our first approach to NDGA (Chapter 3). Our 
experience in the difficulty associated with the reduction of such systems however, 
persuaded us not to attempt such a pathway. Our successful synthesis of diarylbutane 
(149) using a Wittig olefination as the key step is depicted in Scheme 39.
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The phosphonium salt (144) was readily available from the substitution of 3,4- 
dimethoxybenzyl alcohol (92) with triphenylphosphine hydrobromide in refluxing 
acetonitrile (Scheme 38). The product was isolated as crystals in high yield and was 
subsequently fully characterised. The NMR spectrum of (144) showed a 
deshielded methylene doublet at ô 5.32 and a 15H multiplet in the aromatic region for 
the three phenylphosphine groups. A singlet at ô 22.4 in the NMR spectrum and a 
doublet at 6 30.6 in the NMR spectrum were all in agreement with the proposed
structure. Our initial synthetic attempts towards aldehyde (146) followed the reported 
procedure of Padwa et reducing acid (145) with borane followed by oxidation
using PCC in DCM. Although the borane reduction went quantitatively giving a single 
slower running spot by TLC, the oxidation step using freshly prepared PCC was 
problematic and low yielding. The crude residue was subjected to flash column 
chromatography affording aldehyde (146) as a pale yellow oil in only 48% yield. 
LiAlHq reduction of acid (145) followed by distillation afforded the corresponding 
alcohol in moderate yield. Swern o x i d a t i o n g a v e  aldehyde (146) in excellent 
yield as a colourless oil that was pure enough to use without further purification. Two 
triplets at ô 2.77 and 2.91 and a broad singlet at 5 9.62 for the aldehyde proton were 
observed in the NMR spectrum. The expected eleven peaks were recorded in the 
l^C  NMR spectrum including the carbonyl resonance at ô 202 which were in
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agreement with data r e p o r t e d . 99 With both coupling partners successfully synthesised, 
we turned our attention to the Wittig olefination.
Addition of 1.1 equivalents of n-BuLi to a cooled suspension of (144) gave a 
deep red homogeneous solution to which aldehyde (146) was added dropwise. After 
stirring at rt for Ih, TLC showed a single close running spot which was stained red by 
vanillin unlike the aldehyde which gave a blue colouration. The majority of the 
triphenylphosphine oxide byproduct could be removed by stirring the crude residue in 
chilled ether and filtering before final purification was achieved by silica gel flash 
chromatography. Alkene (147) was isolated as a solid in high yield with no attempts 
made to separate the geometrical isomers. Integration of the pertinent peaks in the 
NMR spectrum revealed a ratio of 1.9; 1 in favour of the cis isomer. The two isomers 
could be easily distinguised by the J  value for the doublet of triplets arising from the 
homobenzylic methine proton with the cis isomer giving J  values of 11.6 and 7.1 Hz 
and the trans isomer 15.8 and 6.8 Hz. The NMR spectrum was predictably quite 
complex, however the aliphatic methylene groups were observed as four distinct 
resonances between 5 30.9 and 36.0 and a parent ion at m/z 328 was also consistent 
with the proposed structure. In any event, control in the Wittig olefination was 
irrelevant towards our target as catalytic hydrogenation over palladium afforded the 
diarylbutane (148) as crystals in high yield giving a melting point in agreement with 
that reported.98 The symmetry of the system was clearly evident from the NMR 
spectra with the ^H spectrum revealing two triplets in the aliphatic region and the 
spectrum showing the expected ten resonances. The IR spectrum showed three 
stretches in the aromatic region and a parent ion at m/z 330 in the mass spectrum 
showed that hydrogenation had been successful. Although the general déméthylation 
method of McOmie et al.^^ was successful, we later found that refluxing hydrobromic 
acid was just as effective although cheaper and easier to carry out on a large scale. The 
phenolic diraylbutane (149) was obtained in high yield as fawn crystals giving a 
melting point in agreement with that reported by Gisvold et No signals for the 
methyl ethers were observed in the ^H NMR spectrum and two broad singlets at Ô 8.6 
and 8.7 were indicative of the phenolic groups. These were also observed as broad 
phenolic stretches at ca. 3500 cm"^ in the IR spectrum and confirmed by a peak at m/z 
274 in the mass spectrum.
In summary, the synthesis of the phenolic diarylbutane (149) was achieved in 
five steps using cheap readily available starting materials with a good overall yield of 
35%,.
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4.1.4 Synthesis of a Cs-Bridge analogue
The Friedel-Crafts acylation of veratrole with glutaryl dichloride had been 
reported as problematic by Fliedner et al.^^ and an alternative approach was required. 
Haworth and Lamberton required the diarylpentane (153) while investigating its 
vesicant p r o p e r t i e s .^02 The route used is depicted in Scheme 40 which we were happy 
to follow with a few modifications.
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The aldol condensation of veratraldehyde with acetone was carried out as 
r e p o r t e d  1^2 affording the unsaturated ketone (150) as bright yellow feathers in high 
yield. A melting point was in agreement with that reported and the E ~ configuration of 
the double bond was apparent from the ^H NMR spectrum, showing two IH doublets 
with a J  value of 15.8 Hz. Catalytic hydrogenation over palladium was effected at 
atmospheric pressure affording the saturated ketone (151) in moderate yield. In one 
run TLC of the reaction mixture after 3 h revealed no starting material and two spots 
with one slower running and the other faster running than the starting material. The 
lower spot was stained red by vanillin and was expected to be the alcohol in agreement 
with data reported by Haworth and L a m b e r t o n .  Recrystallisation of the crude 
residue afforded the saturated ketone (151) in only 39% yield. However, we found that 
the mother liquors could be concentrated and oxidised back up to the ketone (151) 
using a standard Jones oxidation protocol. Using this method a further 30% of 
material could be recovered bringing the total yield up to a more respectable 69%. In 
latter experiments we discovered that monitoring the reaction regulai'ly by TLC ensured 
formation of the ketone (151) as the major component after only 1 h. Using this
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procedure we isolated ketone (151) in 56% yield as crystals that gave a melting point in 
agreement with that r e p o r t e d .^ O l  olefinic signals were observed in the NMR 
spectrum and a 4H multiplet was recorded in the aliphatic region for the methylene 
funtionalities.
Scheme 41
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Haworth and Lamberton isolated the diarylpentane (152) in 50% yield by the 
Clemmensen reduction of (151) although no experimental detail was given. For 
toxicity reasons we were not keen to repeat this so initially opted for the general 
procedure reported by Hutchins et This route, depicted in Scheme 41, involved 
the reduction of an intermediate tosylhydrazone with sodium cyanoborohydride under 
acidic conditions. Although the reaction afforded (152) after column chromatography 
in moderate yield, we had problems in obtaining a sample free of the high boiling (245 
°C) sulfolane solvent. A Wolff-Kischner reduction was carried out employing the 
modified general procedure of Haung-Minlon. ^  04 The reaction involved heating ketone 
(151) at an elevated temperature with hydrazine hydrate in the presence of potassium 
hydroxide (Scheme 40). The diarylpentane (152) was isolated as a solid in moderate 
yield giving a melting point in agreement with that reported. The pertinent features 
in the ^H NMR spectrum were a 4H triplet at Ô 2.56 and two further muliplets in the 
aliphatic region integrating for a total of six protons. Boron tribromide déméthylation 
following the general procedure of McOmie et gave the phenolic diarylpentane 
(153) in excellent yield giving a melting point in agreement with that reported. There 
were no resonances in the methyl ether region of the ^H NMR spectrum and two 
broad stretches at ca. 3500 cm"l in the IR spectrum gave strong evidence for the 
phenolic moieties. The expected nine resonances were observed in the NMR 
spectrum and a parent ion at m/z 288 in the mass spectrum was consistent with the 
proposed structure.
4.1.5 Synthesis of a C6-Bridge analogue
The Friedel-Crafts acylation of veratrole with freshly distilled adipoyl 
dichloride (Scheme 42) was carried out as reported by Fliedner et aZ.94 using 
anhydrous chloroform in place of tetrachloroethane. The diketone (154) was isolated 
as feathers in high yield giving a melting point in agreement with that reported.94 The
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regiochemistry of the addition was apparent from the NMR spectrum which 
showed two IH doublets and a IH doublet of doublets in the aromatic region. The 
NMR spectrum revealed the expected eleven resonances including the carbonyl 
functionality at ô 199. A parent ion at m/z 386 in the mass spectrum was consistent 
with incorporation of the two aromatic nuclei.
Scheme 42
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Diketone (154) has reportedly been reduced by Clemmensen and Wolff- 
Kischner reduction by Gisvold et and Tamura et alP'^ respectively. We found that 
catalytic hydrogenation of (154) in AcOH over palladium offered milder reaction 
conditions affording the diarylhexane (155) as plates in moderate yield. A melting 
point was in agreement with that reported and a new 2H triplet at Ô 2.55 in the ^H 
NMR spectrum was observed for the benzylic methylene group. Boron tribromide 
déméthylation was effected following the general procedure of McOmie et al.^^ 
affording the phenolic diarylhexane (156) in excellent yield giving a melting point in 
agreement with that reported. Broad stretches at ca. 3500 cm “Mn the IR spectrum 
were consistent with methyl ether cleavage as were the ^H and ^^C NMR spectra 
which showed no resonances for the methyl ethers. The mass spectrum revealed a 
parent ion at the expected m/z 302 and a combustion analysis offered further evidence 
for the purity of the compound.
4.1.6 Synthesis of a C7-Bridge analogue
The synthetic route towards the diarylheptane (159) was essentially that used 
for the diarylhexane (156) however pimeloyl dichloride was utilised as the linker in the 
Friedel-Crafts acylation (Scheme 43). Diketone (157) was isolated as crystals in 
moderate yield giving a melting point in agreement with that reported.94 The low yield 
can be attributed to problems associated with crystallisation of the crude residual oil 
from a variety of organic solvents. In any case we felt we had isolated sufficient 
material to continue without having to subject the mother liquors to column
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chromatography. As seen previously for (156) the NMR spectrum revealed a 
symmetrical compound showing a 1,3,4-substitution pattern on the aromatic nuclei. A 
parent ion at m/z 400 in the mass spectrum revealed that double addition had been 
successfully accomplished.
Scheme 43
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Diketone (157) was sufficiently soluble to allow catalytic hydrogenation over 
palladium to be carried out in MeOH affording the saturated diarylheptane (158) as 
crystals in high yield. Kakemi et have prepared diaiylheptane (158) by a catalytic 
hydrogenation of diketone (157) in AcOH and our material gave a melting point in 
agreement with that reported. A new benzylic methylene triplet in the ^H NMR 
spectrum coupled with no absorption observed for the carbonyl functionality in the IR 
spectrum were consistent with successful reduction. Finally, boron tribromide mediated 
cleavage of the methyl ethers was carried out following the general procedure of 
McOmie et The phenolic diarylheptane (159) was isolated as an off-white 
powder after column chromatography in moderate yield. A melting point was in 
agreement with that r e p o r t e d a n d  ^H and NMR spectroscopy highlighted the 
absence of the methyl ether functionalities. A broad stretch at 3400 cm“ ^  in the IR 
spectrum along with a parent ion at m/z 316 in the high resolution mass spectrum were 
consistent with the proposed structure.
4.1,7 Synthesis of a conformationally restricted analogue
It has been reported by Matsuda and Yamada that the conformationally 
restricted analogue (162) showed enhanced anti-oxidant properties over NDGA in 
foodstuffs. We were interested to see if this finding could be extended to our field 
and set about the synthesis of (162) as outlined in Scheme 44.
Our initial attempts at the Fredel-Crafts acylation of veratrole with 
commercially available teraphthaloyl chloride (160) followed the general procedure 
used for the synthesis of diketones (156) and (159). TLC of the crude residual showed
84
only starting material. However, when the reaction was carried out at elevated 
temperatures acylation was successful. The diketone (161) was isolated in moderate 
yield as lemon coloured crystals giving a melting point in agreement with that 
r e p o r t e d .  106 The structure was further confirmed by NMR spectroscopy showing 
two doublets and a doublet of doublets for the electron rich aromatic nuclei along with 
a 4H singlet at ô 7.85 for the protons of the central aromatic ring.
Scheme 44
C l A IC I3 , C H C I3 
A, 4  h, 5 5 %
OMe
OMe
1. H2 , Pd-C ,THF 
rt, 72 h
2. BBi-3 ,D CM  
-78 °C  rt
2h, 65% from 161
HO.
HO
OH
OH
Diketone (161) was rather insoluble in common catalytic hydrogenation 
solvents such as MeOH, EtOH and AcOH, however the reduction could be succesfully 
carried out in THF. The crude residue so obtained could not be crystallised from a 
variety of solvents so it was decided to carry the mixture through for déméthylation 
without purification. Boron tribromide déméthylation^^ afforded the bis-catechol (162) 
as a cream coloured powder that gave a melting point in agreement with that 
reported. There were no signs of the methyl ether functionality in the ^H NMR 
spectrum, however a 4H singlet was now observed at ô 4.83 for the methylene protons 
arising during the reduction step. The structure was further confirmed by NMR 
spectroscopy showing a methylene resonance at Ô 41.8 and broad phenolic stretches 
were observed in the IR spectrum around 3500 cm"^. Finally a parent ion at m/z 322 in 
the high resolution mass spectrum gave further evidence for the proposed structure,
4.2 Synthesis of Phenols
4.2.1 Sythesis of a C4-Bridged Phenolic compound
The synthesis of the C4-bridged phenol (170) was essentially that used for the 
C4~bridged catecholic compound (149) with a few exceptions (Scheme 45).
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Retiuction of /i-anisaldehytie (163) with L1A1H4 afforded an oil that was 
homogeneous and slower running by TLC and was stained red with vanillin spray. The 
crude product was treated directly with triphenylphosphine hydrobromide in refluxing 
CHgCN affording the phosphonium salt (164) as a solid in 78% yield over the two 
steps. The structure of the salt was verified by a variety of spectroscopic techniques 
most notably NMR spectroscopy. A 2H doublet at 5 5.26 with a coupling constant of 
13.7 Hz was observed in the NMR spectum for the benzylic methylene group. A 
fine coupling of the doublet, arising from the aromatic proton meta to the methoxyl 
group, with a coupling constant of 2.1 Hz gave further evidence of triphenylphosphine 
incorporation. The benzylic methylene group of (164) also appeared as a doublet at 6 
30.5 in the NMR spectrum, however this carbon-phosphorus eoupling was not 
unique with the majority of the resonances appearing as doublets. A significant 
example was the deshielded carbon bonded directly to the methoxyl group which 
appeared as a doublet at 5 160 with a 7cp of 3.7 Hz. Johnson and Kyllingstad 
synthesised phosphonium salt (164) using an alternative approach, during their 
investigations into the stereochemistry of the Wittig reaetion^^^, and our material gave 
a melting point in accordance with that reported.
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Aldehyde (166) was synthesised in a two step process starting from 
commercially available 3“(4-methoxyphenyl)propionic acid (165). Reduction of (165) 
with LiAlH4 gave an intermediate alcohol which was homogeneous by TLC and pure 
enough by NMR spectroscopy to be used without further purification. Oxidation 
to the aldehyde (166) was carried out employing PDC, freshly prepared on a 0.25 mol 
scale by the method of Corey and Schmidt. Aldehyde (166) was isolated as an oil in 
moderate yield over the two steps after purification by column chromatography. The 
pertinent spectroscopic data were an IR stretch at 1732 cm"l, a IH triplet at Ô 9.80 and 
a carbonyl resonance at 8 202 in the ^^C NMR spectrum. Semmelhack et 
required aldehyde (166) during their synthesis of alnusone and our material gave 
spectroscopic data in agreement with those reported. The proposed structure was 
further confirmed by a parent ion at m/z 164 in the high resolution mass spectrum. 
With both coupling partners in hand, we turned our attention to their coupling 
employing a Wittig olefination.
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Addition of 1.1 equivalents of /r-Buli to a suspension of phosphonium salt 
(164) in THF resulted in a blood red solution to which was added aldehyde (166) at 0 
°C. The reaction was shown to be complete by TLC after 30 min showing a slightly 
slower running compound which was stained red by vanillin unlike aldehyde (166) 
which gave a blue colouration. The crude residue was recrystallised from MeOH 
affording the pure (E)-alkene (167) as plates in 45% yield. The compound was fully 
characterised. The stereochemistry was clearly evident from the NMR spectrum 
showing a doublet {J ~ 15.8 Hz) and a doublet of triplets {J -  15.8 and 6.8 Hz) in the 
olefinic region for the benzylic and homo-benzylic methine protons respectively. The 
concentrated mother liquors were purified by flash chromatography affording an oil in 
30% yield chiefly composed of the (Z)-alkene (168). The exact ratio of isomers was 
calculated by integration over the doublet of triplets arising from the homo-benzylic 
olefin proton in the ^H NMR spectrum and was shown to be 12:1 in favour of the (Z)- 
isomer. While investigating a novel approach to aryltetralin lignans Pelter et 
claim to have isolated alkene (167) as an undesirable reaction product (Scheme 46).
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TFAA catalysed cyclisation of the quinoiie-metliide ketal (171) gave alkene (167) in 
55% yield however the use of BF3.Et20 resulted in smooth conversion to the desired 
aryltetralin (172). On the basis of their reported NMR spectrum run in CDCI3 we 
suspect that the authors have isolated an alternative compound and not alkene (167). In 
their spectrum they report the methylene protons as a muliplet at ô 1.2-1.8 and the 
olefin and aryl protons as a multiplet at ô 6 .6-7.8 , Our spectrum reveals a different 
compound with the methylene protons appearing as two distinct multiplets between ô 
2.4 and 6 2.7 and the olefin and aryl protons giving distinct resonances between ô 6.1 
and Ô 7.3.
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Catalytic hydrogenation of the (E)-alkene (167) over palladium afforded the 
diarylbutane (169) as plates in moderate yield. Richardson and Reid have synthesised 
(169) by a more laborious route allowing access to phenol (170) required for 
bactericidal testing, m  Diarylbutane (169) gave a melting point in agreement with that 
reported and the resultant symmetry of the system was apparent from the NMR spectra 
with the l^C  spectrum revealing the expected seven resonances. Kadkhodayan et a l  
have reported the synthesis of (169), along with a series of bis-para-anisylalkanes, 
utilising a copper catalysed coupling of suitable dihaloalkanes with aryl Grignard 
r e a g e n t s . T h e  NMR spectrum, which was in agreement with that reported^ 
showed two distinct resonances for the methylene groups along with two doublets in 
the aromatic region for the AA’BB’ system. Catalytic hydrogenation of the (Z)-isomer 
(168) also gave diarylbutane (169) in moderate yield. Spectroscopic data were identical 
to those of the material isolated from the (E)-isomer. Boron tribromide déméthylation 
afforded the phenolic diarylbutane (170) as fawn crystals in high yield giving a melting 
point in agreement with that reported. ^  The NMR spectrum showed no signs of 
the methyl ethers being replaced with a broad phenol singlet at ô 9.1. This finding was 
reinforced by IR spectroscopy which showed a broad stretch at 3410 cm“l.
4.2.2 Sythesis of a Cs-Bridged Phenolic compound
The aldol condensation of anisaldehyde with acetone in the presence of NaOH 
afforded the unsaturated ketone (173) in high yield as bright yellow feathers. Two 
olefinic doublets in the NMR spectrum with a coupling constant of 15.8 Hz 
confirmed the (E)-stereochemistry of the double bond. A resonance at ô 189 for the 
carbonyl moiety was observed in the NMR spectrum and a melting point was in 
agreement with that r e p o r t e d . Catalytic hydrogenation of an intensely yellow 
solution of (173) in EtOAc gave a colourless solution from which was isolated the 
saturated ketone (174) in good yield after workup. The two olefinic doublets were now 
absent in the ^H NMR spectrum being replaced with two methylene triplets in the 
aliphatic region of the spectrum confirming successful reduction. The identity of (174) 
was further confirmed by NMR spectroscopy showing two methylene singlets at 
Ô 45.2 and ô 29.3 for the benzylic and homo-benzylic methylene groups, respectively. 
Wolff-Kishner reduction of ketone (174) was carried out as reported for the catecholic 
analogue (151). The protected diaryIpentane was isolated as a colourless oil in low 
yield after purification by silica gel flash chromatography offering a ^H NMR 
spectrum in agreement with that r e p o r t e d .  H2 The structure was further confirmed by 
NMR spectroscopy which revealed the expected eight peaks including three 
methylene resonances in the aliphatic region. The ^H NMR of the crude reaction 
product showed the diarylpentane along with another product suspected of being the 
intermediate hydrazone. Integration over the pertinent peaks revealed a ratio of ca. 1:1 
and we feel that a longer reaction time would allow cleavage of this intermediate 
resulting in a higher yield. In any case, we felt enough material had been isolated to 
continue with the synthesis and the reaction was not repeated at this stage. Finally the 
aryl methyl ethers were cleaved with boron tribromide affording the phenolic 
diarylpentane (175) as an off-white solid in good yield. In addition to (175) giving a 
melting point in agreement with that of Richardson and R e i d ^  the NMR 
spectrum confirmed the identity of (175) showing no resonance for the aryl methyl 
ethers and a broad phenolic singlet at ô 9.1. The identity of (175) was further 
confirmed by NMR, IR spectroscopy and accurate mass spectrometry.
4.2.3 Sythesis of a C6-Bridged Phenolic analogue
The synthetic route for the synthesis of the bis-anisylhexane derivative (178) 
was identical to that used for the catecholic analogue (156) and is depicted in Scheme 
48. Friedel-Crafts acylation of anisole with freshly distilled adipoyl dichloride was 
carried out following the method of Fliedner et al.^^ affording the 1,6-diketone (176)
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as crystals in excellent yield. The stereochemistry of the addition was readily apparent 
from the %  NMR spectrum showing two doublets ( /  = 8.9 Hz) in the aromatic region 
for the AA’BB’ system. The NMR spectrum showed the expected eight peaks 
including the carbonyl resonance at ô 199.
Scheme 48
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Catalytic hydrogenation was effected in AcOH over palladium at ambient 
temperature affording the saturated diarylhexane derivative (177) as plates in moderate 
yield. A melting point and ^H NMR spectrum were in agreement with that reported by 
Kadkhodayan et Boron tribromide déméthylation afforded the phenolic
dianisylhexane (178) in excellent yield and gave a melting point consistent with that 
r e p o r t e d , ^ T h e  proposed structure was further confirmed by NMR, IR and 
accurate mass spectrometry.
4.3 Synthesis of amides
Our experience in designing new analogues of biologically active compounds 
suggests that more rigid compounds with fewer degrees of freedom and restrictions in 
the number of possible conformations adopted are often superior in biological activity. 
With this in mind synthesis of a series of amide analogues was undertaken utilising 
readily available starting materials. Our preliminary test data identified the diaiylbutane 
derivative (149) as being ten fold more active than NDGA and as a consequence of 
this, we decided to maintain the four atom unit between the aromatic nuclei.
4,3.1 Synthesis of Secondary Amides
The coupling of 3,4-dimethoxybenzylamine (179) with 3,4-dimethoxy 
phenylacetic acid (180) was successful affording amide (181) as fine needles in 64% 
yield (Scheme 49), We investigated two coupling agents for this transformation, 
namely DCC and its water soluble derivative EDCI with the latter giving superior 
yields. Unlike the insoluble DCU by-product resulting from DCC coupling, the urea 
by-product from EDCI could easily be removed by an aqueous wash thus simplifying
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purification. Amide (181) has previously been synthesised by Battersby et via 
the acid chloride while investigating the biosynthesis of alkaloids. Our material gave a 
melting point in agreement with that reported and the identity of (181) was further 
confirmed by a variety of spectroscopic techniques. An IR stretch at 1639 cm"l and a 
quaternary resonance at ô 172 in the NMR spectrum confirmed the presence of 
the amide moiety. The NMR spectrum showed a broad singlet at 5 5.79 for the 
amide proton along with a 2H doublet at 5 4.34 which collapsed to a singlet after 
shaking the sample with D2O.
Scheme 49
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Deprotection of (181) was carried out using boron tribromide affording the 
novel phenolic amide (182) as a beige solid in low yield. TLC (2:1 EtOAc-acetone) of 
the reaction mixture after 1 h at rt showed no staring material and a streaky spot at Rf 
0.4 which was intensely stained with iodine. The reaction was worked up in the usual 
fashion however we obtained a relatively poor crude yield (52%) from which pure 
novel (182) was isolated in only 23% yield. The amide bond was shown to be intact 
with an IR stretch at 1600 cm"l along with a resonance at 5 171 in the NMR 
spectrum. In the NMR spectrum four distinct peaks were observed for the phenols 
at Ô 8.7 to Ô 8.9 and the amide proton now came into resonance at Ô 8.2, presumably a 
consequence of hydrogen bonding.
The amide coupling of 3,4-dim ethoxyaniline (183) with 3-(3,4- 
dimethoxyphenyl)propionic acid (184) was again achieved in best yield using the 
EDCI-DMAP system as depicted in Scheme 50. The novel amide (185) was obtained 
in moderate yield as pale pink needles and was fully characterised. The pertinent 
spectroscopic data included two methylene triplets in the aliphatic region of the 
NMR spectrum along with an amide resonance at ô 171 in the NMR spectrum.
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An IR stretch at 1655 cm"l was representative of the amide moiety and a parent ion at 
m/z 345 in the high resolution mass spectrum confirmed the identity of amide (185).
Scheme 50
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We suspected that the low yield experienced for the déméthylation of (181) 
could be attributed to partial amide bond cleavage and decided to attempt the 
deprotection of (185) at a reduced temperature. Addition of boron tribromide to a 
solution of (185) in DCM at -78 °C was carried out as normal except that the reaction 
mixture was allowed to warm slowly to 0 °C and not room temperature. TLC (EtOAc- 
acetone {2:1} + 2% AcOH) after 30 min showed no starting material and the reaction 
was worked up in the usual way. Using this procedure we obtained a better yield 
(64%) of the crude product from which was isolated the novel phenolic amide (186) as 
an off-white solid in moderate yield. Four phenolic singlets around Ô 8.7 were again 
observed in the NMR spectrum along with a deshielded singlet at 6 9.5 for the 
amide proton. The amide bond of (186) was shown to be intact with a resonance and 
stretch at ô 170 and 1636 cm'^ in the l^C NMR and IR spectrum respectively.
Synthesis of amide (189) was readily achieved in good yield employing the 
commercially available acid (187) and amine (188) as depicted in Scheme 51. This 
compound has previously been synthesised in 60% yield by Landais and Robin using 
an alternative a p p r o a c h .   ^15 material gave a melting point, IR and NMR 
spectrum in agreement with that reported and was further characterised by ^^C NMR 
and high resolution mass spectrometry. The deprotection of (189) was carried out as 
normal however we were unable to obtain a sample of suitable purity for testing. Crude
(190) was obtained as a foam in excellent yield that could not be recrystallised from a 
variety of solvents or suitably purified by column chromatography. The reaction was
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attempted on numerous occasions, however a NMR spectrum of the residue 
revealed extra resonances in the aromatic region.
Scheme 51
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We suspected these extra peaks were a result of amide bond cleavage however 
we were unable to obtain a sample free of these impurities. We expected a change of 
protecting groups would alleviate this problem especially choice of one that could be 
removed under mild conditions. As a consequence of no suitably protected starting 
materials being commercially available, we decided to await the test results of the 
isomeric amides (182) and (186) before employing a new approach.
4.3.2 Synthesis of Tertiary Amides
The tertiary amide (194) is a structural analogue of NDGA and we were 
therefore keen to investigate its synthesis. The secondary amine (192) was not 
commercially available and was thus synthesised from 3,4-dimethoxybenzaldehyde
(191) using a reductive amination procedure. Addition of 1.1 equivalents of an 8M 
ethanolic solution of methylamine followed by heating at reflux resulted in smooth 
conversion to the intermediate imine. A Iff NMR spectrum of the yellow syrup thus 
obtained showed no starting material and a deshielded singlet at ô 8.2 for the benzylic 
proton. Catalytic hydrogenation was carried out over palladium at 4 atm. affording the 
methylamine (192) as a colourless oil after distillation. The structure of (192) was 
confirmed by a variety of spectroscopic techniques most notably NMR spectroscopy. 
Singlets integrating for 3H and 2H at ô 2.46 and 5 3.69, respectively, were observed in 
the Iff NMR spectrum and are consistent with the proposed structure. Amine (192) 
has previously been synthesised by Neidigh et and our material gave a Iff NMR 
spectrum in agreement with that reported.
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Coupling of amine (192) with the commercially available acid (180) was 
conveniently achieved employing EDCI in the presence of 10 mol % DMAP affording 
the novel amide (193) as shiny crystals (Scheme 52). The rotameric nature of the 
tertiary amide (193) was evident from NMR spectroscopy. The NMR spectrum 
showed two distinct singlets at 5 4.49 and ô 4.52 for the methylene protons adjacent to 
the nitrogen in a ratio of ca. 3:2. The exsistence of rotamers also gave rise to a 
complicated NMR spectrum showing doubling of peaks including eight 
resonances for the carbons in the central bridge. The identity of (193) was further 
confirmed by an amide stretch at 1631 cm"l in the IR spectrum coupled with a parent 
ion at m/z 359 in the high resolution mass spectrum. Boron tribromide déméthylation 
afforded the novel phenolic amide (194) as shiny crystals in good yield. The rotameric 
nature of (194) was even more pronounced in the NMR spectrum which showed 
twin singlets for both the methylene groups and methyl protons. A broad muliplet at ô 
8 .7-8.9 was observed for the phenols, which were confirmed with a broad stretch at 
3406 cm"l in the IR spectrum. The structure of (194) was further confirmed by 
NMR and high resolution mass spectrometry.
In an attempt to ascertain the importance of the catecholic functionality, we 
undertook the synthesis of the mono-phenolic amide (198) employing the route used 
for the synthesis of the catechol derivative (194). Reductive amination of p~ 
anisaldehyde (195) with methylamine afforded the secondary amine (196) in high yield 
after distillation (Scheme 53). The amine (196) offered a NMR spectrum in 
agreement with that reported by Neidigh et who had employed an alternative 
synthesis. EDCI coupling of amine (196) with 4-methoxyphenylacetic acid (197) gave 
the protected rotameric amide that was used without further purification.
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Boron tribromide déméthylation gave the amide (198) as a foam that refused to 
crystallise from a variety of solvents. Column chromatography (EtOAc-acetone {2:1}) 
gave a hydroscopic solid that was further purified by recrystallisation affording the 
novel phenolic amide (198) as a flaky solid in low yield. A broad resonance at 6 9.2 in 
the Iff NMR spectrum was indicative of the phenols and a quaternary peak at 5 171 in 
the ^3(2 NMR spectrum was observed for the amide moiety. Further characterisation 
included stretches at 3365 and 1624 cm"^ in the IR spectrum coupled with a parent ion 
at m/z 271 in the high resolution mass spectrum,
4.3.3 Synthesis of amide (194) - An alternative approach
At this juncture we decided to investigate the synthesis of (194) employing an 
alternative protecting group that could be cleaved under mild conditions. We decided 
that the benzyl protected group would be suitable for our needs as it is readily cleaved 
by catalytic hydrogenation at atmospheric pressure. This would also allow a further 
series of compounds containing acid sensitive functionalities between the rings, 
including amide (190), to be synthesised in the future.
Our alternative synthesis of the tertiary phenolic amide (194) is depicted in 
Scheme 54 starting with the synthesis of the secondary amine (201). Benzyl protection 
of commercially available 3,4-dihydroxybenzaldehyde (199) was carried out following 
the method of Barrero et Protected aldehyde (200) was isolated as lemon
coloured crystals in moderate yield giving a melting point in agreement with that 
reported. Two singlets at 5 5.21 and ô 5.26 were observed for the benzylic protons in 
the Iff NMR spectrum confirming the proposed structure. Reductive amination of 
(200) with methylamine was carried out as normal, however the intermediate imine was 
reduced with an excess of NaBHq in refluxing EtOH. The secondary amine (201) was
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isolated in high yield as a light yellow oil that was pure enough to use without further 
purification. A NMR spectrum of (201) was again identical to that reported by 
Neidigh et for material made by an alternative procedure and our sample was 
characterised by IR, MS and NMR spectroscopy.
Scheme 54
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Synthesis of the acid portion (204) was carried out following the reported 
procedure of He et utilising commercially available 3,4-dihydroxyphenylacetic 
acid (202). The intermediate benzyl ester (203) was smoothly hydrolysed with 
ethanolic NaOH affording the protected acid (204) in high yield which gave a melting 
point in agreement with that r e p o r te d .T w o  benzylic singlets were observed in the 
1h  NMR spectrum and integration over the pertinent peaks was consistent with 
successful ester cleavage. The amine (201) and acid (204) were successfully coupled 
employing EDCI in the presence of 10 mol% DMAP affording the novel amide (205) 
in good yield after column chromatography. It was surprising that this compound was 
isolated as an oil refusing to crystallise when its tetramethyl ether analogue (193) was 
isolated as a solid. In any case the structure was confirmed by a variety of 
spectroscopic techniques including a ^H NMR spectrum as shown in Figure 25. Twin 
peaks for the methyl and two methylene groups of the central bridge of (205) are 
clearly a result of amide rotamers in a ratio of ca. 4:3. Numerous peaks are observed 
for the benzylic singlets around Ô 5.1 and two resonances at 5 171.5 and 6 171.8 were 
observed in the NMR spectrum for the amide moiety. Catalytic hydrogenation of
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(205) over pallacliiifii al almosplicric pressure ariorded (he phenolic amide (194) in 
higii yield. I his compound gave a homogeneous spot by 11.C which co spoiled with a 
reference sample. I he melting point was identical to the material obtained from the 
tetramethyl ether.
Figure 25 - Ml NMK spcclriiiii of prolccled niiiidc (205)
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III the synthesis of the tertiary amide (194), using the benzyl protecting group 
offers no distinct advantage over the methyl ether approach. In fact the yields obtained 
from the methyl ether route (Scheme 52) are good and because the starting materials 
are commercially available, this route would be favoured in this case. However the 
chemical stability of the methyl ether protecting group requires the use of quite harsh 
reaction conditions for its removal, thus limiting the functionality available between the 
aromatic nuclei. Indeed, we have found attempts to cleave methyl ethers with BBr3 on 
substrates that contained ester, alkene and alcoholic linkages resulted in decomposition 
giving complex h i NMR spectra. In these cases the use of a benzyl protecting group 
could offer a distinct advantage although the starting materials would not be 
commercially available. Although not investigated, the synthesis of the secondary
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amides (Section 4.3.1) would benefit from this approach undoubtedly resulting in 
easier purifications and improved yields. We suspect that the use of the benzyl ether 
protecting group is pivotal in the development of a larger range of analogues including 
compounds containing acid labile groups in the future.
4.4 Biological Test Results
The compounds synthesised throughout this project have been screened for 
their ability to inhibit SCLC cells in vitro by Dr. Michael Seckl at the Medical 
Oncology Department of Charing Cross Hospital (subsequently Hammersmith 
Hospital), London. The preliminary test data are presented in Table 3.
4.4.1 Method of T e s t i n g i ^ o
Cell Culture : SCLC cell lines H-69 were maintained in RPMI 1640 
supplemented with 10% (v/v) fetal bovine serum (heat inactivated at 57 °C for 1 h) in a 
humidified atmosphere of 10% CO2 / 90% air at 37 °C. They were passaged every 7 
days. For experimental purposes, the cells were grown in HITESA which consisted of 
RPMI 1640 supplemented with lOnM hydrocortisone, 5qg/ml insulin, 10 jig/ml 
transferrin, lOnM oestradiol, 30nM selenium and 0.25% bovine serum albumin.
Liquid Culture Assay : SCLC cells, 3-5 days post passage, were washed and 
resuspended in HITESA. Cells were then aliquoted in 24 well Falcon plates at a 
density of 50,000 cells in 1 ml HITESA in the presence or absence of increasing 
concentrations of NDGA analogues. One and two weeks later, cell number was 
determined from a mininum of 3 wells per condition using a Coulter counter, after cell 
clumps were disaggregated by passing the cell suspension 5 times through a 19 and 
subsequently 21 gauge needle. These times were chosen to coincide with log phase and 
plateau phase growth of the cells.
4.4.2 Preliminary Results
The racemate of NDGA (32) was found to be only slightly more active than 
me^o-NDGA (1) suggesting that then orientation of the secondary methyl groups is 
not important for activity. This theory was further justified when the Cq-bridged 
analogue (149) was discovered to be greater than ten times more active than NDGA. 
The other analogues of this series were found to be relatively inactive with the 
exception of the C^-bridged analogue (156) which was found to be equipotent with 
NDGA. The C5 and C6-bridged phenolic compounds were approximately equipotent 
to NDGA however the Cq-bridged phenol (170) lacked activity. It is interesting to
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point out that although the mono phenolic compounds gave a similiar effect over one 
week they were more active over two weeks suggesting a greater stability. The results 
obtained from the amide analogues have been particularly encouraging with the 
majority showing enhanced IC50 values over NDGA. The phenolic tertiary amide 
(198) was found to be inactive interestingly in accordance with the result observed for 
the phenolic diarylbutane (170).
Table 3
NDGA Analogue Number IC 50 (ftmol)
y x r c o : : NDGA (1) 3.5
(±) - 32 3
Catechol Derivatives
HO OH
143 >100
OH
149 0.3
153 >3
156 3.5
HCr OH
159 35
Phenolic Derivatives ' -T:.
170 8
175 3.5
HO OH
178 3
Secondary Amides .
x n r ' x t : 182 0.8
H
186 1.5
Tertiary Amides
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JU. ^  0 Me U HGT OH 194 3
JJ ^  O Me U .A
OH
198 >100
4.4.3 Future Work
There is a large diverse range of NDGA analogues that can be envisaged with 
the ultimate goal of producing a more potent anti-cancer agent. Within our group we 
are actively investigating the synthesis of polyhydroxylated compounds which could 
provide a more potent analogue. The methylene groups between the aromatic nuclei 
could be replaced with heteroatoms such as NH, O or S offering hydrogen bonding 
sites which could be important for activity. In the case of amines their derived salts 
could allow access to a more water soluble analogue and such a compound type is 
synthesised in C hapter 5. The encouraging test results observed with the amide 
analogues suggests that the synthesis of conformationally restricted compounds 
should be further investigated. Included in this group could be esters, ketones, 
thioamides and alkenes present in various positions between the aromatic nuclei. The 
intermediate alkenes in our synthesis of (±)-NDGA (Chapter 3) fall into this category 
and could be valuable analogues. As noted previously these types of derivatives would 
require alternative protecting groups that could be cleaved easily in the presence of 
sensitive functionalities.
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Solubilisation of NDGA and Derivatives
5.1 Introduction
As mentioned previously NDGA (1) suffers from a lack of solubility in water 
thus greater solubility is essential for in vivo studies. It was our intention to prepare 
covalent conjugates of NDGA which would be more solouble in serum releasing the 
active component over a period of time. In addition to NDGA, it was our objective that 
any promising NDGA analogues should be solubilised using the same procedures.
Initial work in this area was carried out by M c A l l i s t e r ^ ^ l  who attempted to 
esterify triethylene glycol-succinate esters to NDGA using DCC coupling techniques 
with little success (Scheme 55). Attempts to synthesise M-PEG-5000 acetals of 
NDGA also proved unsuccesful hindered by poor solubility of NDGA and PEG- 
aldehyde in common solvents used for Dean-Stark azeotropic distillation.
Scheme 55
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5.2 Towards the Synthesis of Acetals
Although the synthesis of PEG-acetals could be an effective NDGA 
solubilisation tool, we felt that due to their large molecular weights large quantities of 
drugs would have to be administered to be effective. We were interested to re­
investigate the synthesis of acetal conjugates of NDGA albeit of low molecular weight 
containing a polai' tail that would induce water solubility.
Hartzfeld et have reported the reaction of catechol with ethyl
dichloroacetate to afford the ethyl-o-phenylenedioxyacetate (206) in 28% yield. This 
encouraged us to adopt this approach on the bis-catechol NDGA which could be
101
hydrolysed to afford the water soluble acid salt (Scheme 56). Addition of NDGA to 
sodium ethoxide gave a deep green solution to which was added 2 equivalents of ethyl 
dichloroacetate. The reaction mixture became black on reflux and was shown by TLC 
to be a complex mixture of products. The crude product was purified by flash 
chromatography affording the acetal (207) as a yellow oil in low yield. The 
symmetrical nature of (207) was evident from the NMR spectrum showing a single 
doublet at Ô 0.82 for the secondary methyl groups. The acetal methine proton came 
into resonance as a singlet at 6 6.28 and the expected thirteen peaks were observed in 
the NMR spectrum including the ester carbonyl moiety at ô 165.
Scheme 56
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The ester (207) was hydrolysed with ethanolic NaOH at ambient temperature 
affording the acid salt (208) as a brown solid which was readily soluble in water. A 
NMR spectrum run in D2O showed the desired structure; however it was not pure 
enough for testing and attempts to recrystallise this material proved unsuccesful. We 
felt that the initial step of the reaction scheme warranted further investigation to give the 
acetal (207) in high purity to be used in the hydrolysis. The reaction was repeated on a 
number of occasions with varying reactant concentrations and temperatures with little 
success. Indeed on some occasions following the original method failed to give any 
material highlighting the sluggish nature of the reaction. Attempts to carry out the 
acetal formation with milder bases such as triethyl amine and potassium carbonate 
proved unsuccesful giving only starting material. Using the sodium salt of 
dichloroacetic acid as the electrophile was also unsuccesful. It was clear that we could 
carry out the reaction on a large scale to afford a pure enough sample for testing;
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however the expense of the starting material coupled with the inconsistent reaction 
conditions encouraged us to seek an alternative approach.
An attempted transacetalation of catechol with aminoacetaldehyde 
dimethylacetal (209) was attempted as depicted in Scheme 57 with the prospect of 
forming the amine salt (210) to enhance water solubilty. The reaction was however 
unsuccesful with only starting material recovered even when an acid catalyst was used 
and the reaction was heated to drive off MeOH thus displacing the equilibrium.
Scheme 57
MeO 2. HCI, Et^O \ : ^ ^ 0  NH 3 CI
We decided to synthesise aldehyde (212) which could be used directly to 
acetalate our model catechol system prior to forming the amine salt. 
Aminoacetaldehyde dimethylacetal was thus protected as the CBZ derivative following 
the reported procedure of Bischofberger et (Scheme 58). Protected aldehyde 
(211) was isolated in moderate yield as a colourless oil after distillation and gave 
spectroscopic data in agreement with those reported. A 2H benzylic singlet at Ô 5.12 
and a 5H multiplet in the aromatic region of the ^H NMR spectrum were consistent 
with succesful carbamate formation.
Scheme 58
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Oxalic acid induced cleavage of the dimethylacetal functionality of (211) was 
carried out as reported affording aldehyde (212) as a colourless liquid in moderate 
yield. Our first run followed the conditions reported^heating  the reaction at reflux 
for 4 d; however the crude product was shown by ^H NMR spectroscopy to be a 
complex mixture with little signs of the aldehyde (212). In another run the reaction 
mixture was heated for 17 h and TLC showed no signs of starting material and a new
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slower running spot that was stained red with DNP reagent. Using this procedure we 
isolated aldehyde (212) in 57% giving data in agreement with those reported. The 
singlet from the methyl ethers was now absent in the NMR spectrum being
replaced with a deshielded singlet at ô 9.64 for the aldehyde proton. The structure was 
further confirmed by NMR spectroscopy revealing the expected eight resonances 
including the aldehyde moiety at ô 197. We suspect that heating the reaction for too 
long resulted in cleavage of the CBZ group and subsequent polymerisation. We also 
investigated other acetal cleavage conditions including CF3CO2H, CH3CO2H, moist 
silica and p-TsOH; however most just gave starting material highlighting the stability 
of acetal (211).
With aldehyde (212) in hand we attempted to acetalate catechol using the 
general procedure of Chan et employing TMSCl as a dehydrating agent. The 
crude reaction product gave several spots by TLC and a NMR spectrum of the
crude residue obtained showed a complex mixture that was not further investigated. 
We also carried out a reaction with p-TsOH in THF over molecular sieves but this 
method gave only starting material. At this juncture we decided to abandon the acetal 
approach and concentrate on an alternative strategy.
5.3 Synthesis of a Glycine Ester
Singh et have reported the DCC promoted estérification of phenol with 
//-(fgrf-butoxycarbonyl)glycine affording the glycine ester (214) in 96% yield 
(Scheme 59). We decided to apply their reaction conditions to NDGA which could 
then be deprotected under acidic conditions affording the water solouble glycine salt 
(216) as depicted in Scheme 60.
Scheme 59
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Addition of 4.4 equivalents of A-(r^rPbutoxylcarbonyl)glycine was earned out 
as reported under DCC conditions and the reaction mixture was stirred overnight at 
ambient temperature (Scheme 60). After filtration of the insoluble DCU by-product, 
TLC showed that all the starting material had been consumed and a homogeneous 
faster running spot was observed. The crude product was obtained as a foam that was 
shown by ^H NMR spectroscopy to be the desired product contaminated with residual
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DCU. Unfortunately several attempts to crystallise this foam proved unsuccessful with 
the product oiling out on several occasions. Attempts to purify the crude product by 
silica gel chromatography or alumina chromatography resulted in decomposition with 
several spots observed by TLC. The use of alternative coupling agents including EDCI 
and CDI proved worthless giving a variety of spots by TLC that could not be purified 
owing to chromatographic instability of the product. A sample of sufficent purity was 
obtained by taking up the crude residue in the mininum volume of DCM and allowing 
the solution to stand in a freezer overnight. Crystals of DCU were carefully filtered off 
and the mixture was concentrated to give the glycine ester (215) as a foam that was 
used without further purification.
Scheme 60
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The identity of the ester (215) was verified by a number of spectroscopic 
techniques including NMR, IR and accurate mass spectrometry. A 3H doublet at ô 
0.84 was observed for the secondary methyl groups of symmetrical (215) along with a 
18H singlet for the BOC group. The glycidic methylene protons came into resonance 
as a doublet at Ô 4.13 and two non-equivalent amide multiplets were observed at 5 5.6- 
5.7. Peaks at Ô 156.6 and ô 168.7 were observed in the ^^C NMR spectrum for the 
carbamate and ester functionalites respectively which were further confirmed with 
stretches at 1704 and 1786 cm"l, respectively, in the IR spectrum. The incorporation of 
all four ester functionalites was confirmed by accurate mass spectroscopy with an 
observed peak at m/z 953 for (M-i-Na)+* run in the FAB+ mode.
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Deprotection of the BOC groups with subsequent formation of the HCI salt 
was conveniently achieved by bubbling dry HCI into a chilled solution of protected 
ester (215) in anhydrous EtOAc. After a few minutes colourless crystals of the amine 
salt (216) precipitated from the solution and the mixture was stirred until TLC showed 
the consumption of all the starting material. The crude product was further purified by 
washing with EtOAc affording the water soluble amine salt (216) as a powder in 
excellent yield. The removal of the BOC protecting groups was clearly apparent in the 
1h NMR spectrum which showed the absence of the large BOC singlet in the aliphatic 
region and the glycidic methylene protons now came into resonance as a singlet at ô 
4.09. The IR spectrum showed only an ester stretch at 1778 cm"l in that region and the 
structure was further confirmed with a (M+H)+* peak at m/z 531 in the high 
resolution mass spectrum.
5.3.1 Synthesis of a C6-Bridged Glycine Ester
As reported previously the C^-bridged phenolic analogue (156) had been 
shown to be equipotent to NDGA (4.4.2) and we were thus keen to extend our 
solubilisation methodology to this derivative.
The synthesis of the water soluble glycine adduct (218) is depicted in Scheme 
61 starting from the diarylhexane (156), itself obtained in three steps as discussed 
previously (4.1.5). DCC promoted coupling of the diarylhexane (156) with 4.4 
equivalents of A^-(?err-butoxycarbonyl)glycine gave the protected glycine ester (217) in 
quantative yield. Ester (217) could not be recrystallised from a variety of solvents but 
was shown to be homogeneous by TLC. Furthermore, any residual DCU could be 
removed by taking up the crude product in a mininum volume of DCM and allowing 
the solution to stand in a freezer overnight. Filtration and concentration of the resultant 
solution furnished (217) as shiny crystals with no signs of the DCU by-product 
observed in the ^H NMR spectrum. The pertinent feautures of the ^H NMR spectrum 
included a 18H singlet for the BOC methyl protons and a 2H doublet at 5 4.12 for the 
glycine methylene protons. The NMR spectrum highlighted the presence of the 
ester linkages with two resonances observed at ô 168.5 and 5 168.6 and there was a 
stretch at 1788 cm"l in the IR spectrum. A peak at m/z 953 in the mass spectrum was 
recorded for the (M+Na)+* radical giving evidence for the presence of all four ester 
linkages and the identity of (217) was further confirmed by combustion analysis.
Treatment of the protected ester (217) with dry HCI under anhydrous 
conditions resulted in the chemoselective removal of the BOC protecting groups 
affording the water soluble glycine salt (218) as a powder in good yield. A stretch at 
1771 cm"l was observed in the IR spectrum for the ester moiety; however no stretch 
was now observed for the carbamate carbonyl. The ^H NMR spectrum offered
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conclusive evidence that the BOC groups had been successively cleaved. There was no 
resonance detected for the BOC methyl protons and the glycidic methylene protons 
now appeared as two singlets at ô 4.23. The structure was further confirmed by l^C  
NMR and accurate mass spectrometry.
Scheme 61
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We expected that the glycine ester (218) would hydrolyse slowly in water 
under the acidic conditions and decided to check this by monitoring a sample of (218) 
in D2O by NMR spectroscopy after regular intervals. After 1 h there was little signs of 
decomposition but it was clear after 24 h that significant cleavage of the ester linkages 
had been effected. The benzylic methylene triplet at 6 2.58 collapsed to an unresolved 
multiplet with a new multiplet observed in close proximity. The aromatic protons of
(218) were originally observed as a close multiplet between ô 7.18 and ô 7.27; however 
after 24 h in D2O the aromatic region was quite complex showing resonances between 
Ô 6.7 and 5 7.2. After 44 h almost all of the original material had been hydrolysed and 
a solid presumably that of the diarylhexane (156) had precipitated in the NMR tube.
5.4 Attempts Towards Phosphate Esters
We were keen to investigate the synthesis of phosphate and phosphite esters of 
NDGA which could be hydrolysed following the method of Gray and Smith
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affording water soluble salts. As a consequence of having catechol in abundance it was 
decided that initial work in this area should be carried out on that substrate. If 
successful we intended to extend the methodology to the bis-catechol NDGA affording 
a water soluble adduct.
Addition of one equivalent of commercially available methyl dichlorophosphate
(219) to a solution of catechol and two equivalents of triethylamine resulted in the rapid 
precipitation of a white solid (Scheme 62). TLC after 1 h showed consumption of all 
the starting material and a new spot present on the baseline. A NMR spectrum of 
the concentrated solution gave however a very complex spectrum. Further runs of the 
reaction in THF and E t20 at reduced temperatures failed to alleviate the problem and 
the reaction was not further investigated.
Scheme 62
+ Cl^?_oMe - — "}P(0)0
Et3N BU3N
,P— OMe  II I ; P ~ 0 Me -------------------- || | V —O
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We turned our attention to the synthesis of the phosphite ester (221) 
employing the less reactive dichloromethyl phosphite (220). Unfortunately although 
reaction was again clearly evident with precipitation of NEtg.HCl a ^H NMR spectrum 
revealed a complex mixture which was not further investigated. TLC revealed a single 
spot on the baseline and this coupled with the complex NMR spectrum suggested that 
polymerisation was being effected.
5.5 Synthesis of Amine salts
In 1918 Schroeter et al?'^ reported the nitration of the tetramethyl ether of 
NDGA (1) for characterisation purposes. We decided to repeat this work as reduction 
of the nitro group followed by déméthylation would furnish a water soluble derivative.
Commercially available NDGA was methylated following the method of Perry 
et furnishing the tetramethyl ether (47) as fawn crystals in high yield (Scheme 
63). A melting point analysis and ^H NMR spectrum were in agreement with those 
reported.
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Addition of an excess of conc.HNOg to a solution of (47) in glacial AcOH 
gave a yellow solution which deposited crystals after 1.5 h. A modified workup to that 
reported^^ afforded the nitrated diarylbutane (222) as bright orange crystals in high 
yield giving a melting point in agreement with that reported. The regiochemistry of the 
addition was apparent from the NMR spectrum which showed two singlets in the 
aromatic region confirming that nitration had been effected in the 2-position. 
NMR spectroscopy now showed only two aromatic methine protons. The structure of 
(222 ) was confirmed by accurate mass spectrometry and combustion analysis. 
Catalytic hydrogenation over palladium went smoothly affording the amino 
intermediate as a sticky oil after silica gel chromatography. The aromatie singlet at ô
7.54 for the H-3 proton of (222) came into resonance at Ô 6.21 as a result of being 
ortho to two activating groups. Attempted déméthylation of the amino derivative of 
(222) using boron tribromide afforded a crude product that gave a complex NMR 
spectrum. The déméthylation could however be succesfully achieved in refluxing 48% 
HBr affording the amino salt (223) as brown crystals in 76% yield from (222). The 
1 h  NMR spectrum of (223) gave two aromatic singlets and the expected nine 
resonances were observed in the NMR spectrum. Accurate mass spectrometry and 
combustion analysis also confirmed the identity of the water soluble amine salt.
At this stage we had received the results of the enhanced activity of the C4- 
bridged analogue (Chapter 4) and thus set about the synthesis of its amine salt. 
Haworth et aZ.^8 reported the nitration of the diarylbutane (148) in 1934 for
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characterisation purposes; however no suitable experimental details were given. The 
diarylbutane (148) was thus nitrated following the procedure to synthesise (222) 
affording the nitrated compound (224) in good yield as golden crystals that gave a 
melting point in agreement with that reported (Scheme 64). The pertinent 
spectroscopic data included two aromatic singlets in the NMR spectrum, two 
aromatic methine resonances in the NMR spectrum and a parent ion at m/z 420 in 
the mass spectrum.
Scheme 64
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Unlike (222) which had two secondary methyl groups in the aliphatic chain, the 
diarylbutane (224) was insoluble in all the common hydrogenation solvents. A partial 
solubility was observed in dioxane; however an attempted catalytic hydrogenation over 
palladium gave poor conversion. The crude filtered product contained mostly starting 
material by TLC along with the expected product (225) which resided close to the 
baseline and was stained red with Dragendorff reagent. As a consequence of time 
constraints we were unable to investigate the hydrogenation at elevated temperatures or 
a alternative procedure such as dissolving metal reduction.
Concentrating on the C^-bridged analogue we were interested to see if using a 
NH group as an isosteric replacement for one of the bridging methylene moieties could 
afford a water soluble derivative as its HBr salt. Condensation of 3,4- 
dimethoxybenzaldehyde with 2-(3,4-dimethoxyphenyl)ethylamine was carried out in 
refluxing EtOH affording the intermediate imine as an amber oil that was directly 
reduced with an excess of NaBHq (Scheme 65). The crude reaction product was 
recrystallised from 48% HBr affording the secondary amine (226) as its HBr salt in 
quantitative yield. Buck has synthesised amine (226) by a more elaborate procedure
no
while investigating the synthesis of a series of substituted p-phenylethylamines^^^. 
Our material gave a melting point in agreement with that reported and was further 
characterised. The non-symmetrical nature of (226) was clearly evident from the 
NMR spectrum which revealed six clearly defined resonances in the aromatic region. 
The structure was further confirmed by NMR and high resolution mass 
spectrometry.
Scheme 65
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Déméthylation was effected in refluxing 48% HBr depositing the crude 
product as tan coloured crystals which were further purified by trituration in EtOAc 
affording the phenolic amine (227) as its HBr salt in good yield. The ^H NMR 
spectrum showed no signs of the methyl ether functionality and the aliphatic chain was 
shown to be intact giving the expected two hiplets and singlet in the aliphatic region.
5.6 Results and Future Work
The preliminary test data for the water soluble analogues are shown in Table 4. 
The glycine esters appear to be less potent than NDGA; however they have provided 
the first generation of compounds for in vivo studies. The amine salt of NDGA (223) 
was found to be more potent and we still await the results of the C4-bridged analogue 
(227) containing an amine salt in the central bridge.
The encouraging results observed for diamino NDGA (223) suggest that we 
should investigate the synthesis of the racemate along with the C^-bridged analogue 
(225) by overcoming the reduction problems discussed previously. The position of the 
amino group in the C4 -bridged analogue (227) should also be investigated starting 
with commercially available 3,4-dimethoxyaniline. If the test results of these two
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compounds prove encouraging the synthesis of tertiary amine and quaternary 
ammonium salts in both positions should also be undertaken.
Table 4
NDGA Analogue Number IC50 (pmol)
y r r r a : NDGA (1) 3.5
8 4HCI 0 216 10
""ClO 0
218 11
HCr NH, OH .2HBr
223 2.0
.HBr on 227 Unknown
Berlin and N a g a b h u s h a n a m l ^ S  have reported the succesful condensation of 
catechol with phenyldichlorophosphonate affording the bicyclic phosphonate in low 
yield (Scheme 6 6 ). The reaction was carried out in refluxing bromobenzene in the 
absence of a suitable base to mop up the generated HCL Furthermore reaction of the 
ester (228) with one molar equivalent of water resulted in the smooth conversion into 
the acid (229) in quantitative yield. The authors also discuss the synthesis of a further 
two catechol derivatives which are substituted in the 4-position. However in these cases 
the bicyclic esters were not isolated as they underwent cleavage on cooling affording 
the acids as the reaction product.
We feel that attempted synthesis of phosphonate esters, as discussed in 
Section 5.4, warrants further investigation utilising these alternative reaction 
conditions. The presence of the lipophilic phenyl moiety in (228) would clearly be 
disadvantageous with respect to water solubility; however the switch to 
methyldichlorophosphonate could eliminate this problem. One further problem that 
could be envisaged would be a lack of solubility of NDGA in refluxing benzene; 
however if the reaction was successful we expect that the reaction medium would 
become homogeneous.
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A good example of drug solubilisation has been recently reported by Asai et al. 
while investigating the synthesis of water soluble Duocarmycin B1 (DUMBl) 
prodrugs. The limited anti-tumour in vivo activity of DUMBl (230) had been 
attributed to its poor aqueous solubility so three lipophilic groups were attached to the 
free phenolic moeity of (230) as depicted in Scheme 67.
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Of the three derivatives investigated the carbamate (232) and phosphate (233) 
showed excellent water solubility of >20mg / ml. The glycoside (231) was 100 fold 
less soluble in water and unlike the other derivatives was totally resistant to cleavage in 
mouse serum.
In extending this work to NDGA containing four phenolic moieties we feel that 
the synthesis of a tetraglycoside could pose many problems. The reaction would 
undoubtedly generate a mixture of anomers that could be difficult to seperate and 
characterise sufficiently. Furthermore, as discussed previously, if all four groups could
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be successfully introduced one would have a prodrug of considerable mass of which a 
large amount would have to be administered to release a sufficient quantity of the active 
component.
Use of a carbamate derivative on the other hand, such as (232), should be 
investigated especially as it was reported to show the highest potency, Indeed one 
would expect, due to the less sterically demanding nature of the carbamate, that all four 
phenols of NDGA could be succesfully protected. With no stereogenic centres present 
in the protecting groups the product would be easier to characterise and as the tetra 
HCl salt should offer good water solubility.
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Experimental
Reagents were purchased from Aldrich Chemical Company (Gillingham, UK) 
or Lancaster Synthesis (UK) and were used without further purification. Organic 
solvents were obtained from Rhône-Poulenc Rorer and were dried, where necessary, 
using the procedures described by Leonard, Lygo and Procter.93 Melting points were 
recorded in open capillaries using a Gallenkamp apparatus and are uncorrected. and 
l^C NMR spectra were recorded for solutions in CDCI3 with tetramethylsilane as an 
internal standard on a Bruker AM-200 spectrometer operating at 200 and 50 MHz, 
respectively, or on a Bruker DPX/400 spectrometer operating at 400 and 100 MHz, 
respectively, unless otherwise stated. ^^C NMR spectra were assigned with the aid of 
Distortionless Enhancement by Polarisation Transfer (DEPT)-edited spectra. The 
numbering schemes shown are used for ease of assigning the NMR spectra and do not 
refer to the system of nomenclature. All coupling constants are measured in Hz. Thin 
layer chromatography was performed using Merck aluminium-backed silica plates of 
0.25 mm thickness eluting with EtOAc-hexane (1:1), unless otherwise stated. 
Chromatograms were visualised using UV conditions at 254 nm, staining with iodine 
or using a variety of common stains prepared by the methods described in Leonard, 
Lygo and P r o c t e r .^ 3  Column chromatography was carried out on silica gel (particle 
size 70-230 mesh) using the same solvent system as above, unless otherwise stated. 
Mass spectra (MS) were recorded on AEI MS 12 or MS902 spectrometers using the 
electron-impact ionisation (El) mode or, if stated, chemical ionisation (Cl) or fast atom 
bombardment (FAB) modes. Infra-red (IR) spectra were recorded on a Perkin Elmer 
PU 9800 FT-IR spectrometer. Combustion analysis was carried out on a Caiio-Erba 
1106 elemental analyser.
l-(3 ,4“Dimethoxyphenyl)propan-l-oiie (63)
Me O 4
Acylation of veratrole with freshly distilled propionyl chloride on a 45.09 mmol 
scale as previously described^^ afforded ethyl ketone (63) as shiny crystals (7.86 g, 
90%), m.p. 59-61 °C (lit.42 58.5-59.5 °C); Ôr L22 (3H, t, 77.2 Hz, H-9), 2.97 (2H, q,
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J  7.3 Hz, H-8), 3.94 (3H, s, OCH3), 3.95 (3H, s, OCH3), 6.89 (IH, d, J  8.3 Hz, H-5),
7.54 (IH, d, /  1.9 Hz, H-2), 7.59 (IH, dd, J  8.3 Hz and 2.0 Hz, H-6).
2-Bromo-(3,4-dimethoxyplienyl)propaii“l-one (64)
Me O  4
The procedure of Peixy et alA'^ was modified as follows. Bromine (2.48 g, 0.80 
ml, 15.53 mmol) in CHCI3 (15 ml) was added poitionwise under at rt to a solution 
of ketone (63) (3,00 g, 15.5 mmol) in CHCI3 (50 ml) over 30 min with constant 
stirring until TLC showed no signs of starting material. The resultant mixture was 
washed with 10% sodium thiosulpfate (2 x 25 ml) and brine (20 ml) before drying 
over M gS04. Concentration in vacuo gave a light yellow solid which was 
recrystallised from MeOH affording bromoketone (64) as pale white feathers (3,49 g, 
83%), m.p. 83-85 ""C (lit.42 82-82.6 °C); 5h 1.89 (3H, d, J  6.6 Hz, H-9), 3.95 (3H, s, 
OCH3), 3.96 (3H, s, OCH3), 5.31 (IH, q, J  6.6 Hz, H-8), 6.91 (IH, d, 7 8.4 Hz, H-5), 
7.58 (IH, d, J 2.0 Hz, H-2), 7.67 (IH, dd, J  6.4 Hz and 2.0 Hz, H-6).
(±)-l,4-Bis-(3,4-dimethoxyphenyl)-2,3-dimethylbutane-l,4-dione (65)
M cQ.
M eO  4
O M e
O M e
The procedure developed by Perry et a/.42 was used on a 10.99 mmol scale 
affording racemic diketone (65) as crystals (3,56 g, 84%), m.p. 146-148 °C (lit.42 145  ^
146 °C); ÔH 1.31 (3H, d, 7 6.6 Hz, H-9), 3.90 (3H, s, OCH3), 3.95 (3H, s, OCH3), 
6.92 (IH, d, 7 8.4 Hz, H-5), 7.50 (IH, d, 7 1.9 Hz, H-2), 7.72 (IH, dd, 7 8.4 Hz and 1.9 
Hz, H-6).
New data : 8c  16.1 (C-9), 43.3 (C-8), 55.9 and 56.1 (OCH3), 110.1 and 110.6 (C-2 
and C-5), 123.1 (C-6), 129.2 (C-1), 149.0 and 153.2 (C-3 and C-4), 203.0 (C-7).
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(±)-3,4-Dimethyl-2,5-bis-(3,4-dimethoxyplienyl)tetrahydrofuraii (73)
MeO
OMe
OMe
Palladium on charcoal (10%, 100 mg) was added to a stirring solution of 
diketone (65) (250 mg, 0.65 mmol) in EtOH-EtOAc [(5:1), 30 ml] and the mixture was 
stirred under a hydrogen balloon for 17 h at rt. The mixture was filtered through 
Celite® and the residue washed with EtOAc (2x10  ml). Concentration in vacuo gave a 
solid which was recrystallised from ether-hexane affording the title compound (73) as 
crystals (130 mg, 54%), m.p. 119-121 °C (lit.47 121-122 °C); Ôh 0.67 (3H, d, 77.0 Hz, 
H-17 or H-18), 1.07 (3H, d, 7 6.6 Hz, H-17 or H-18), 1.74-1.84 (IH, m, H-3 or H-4), 
2.21-2.30 (IH, m, H-3 or H-4), 3.86 (3H, s, OCH3), 3.88 (3H, s, OCH3), 3.90 (3H, s, 
OCH3), 3.91 (3H, s, OCH3), 4.42 (IH, d, 7 9.3 Hz, H-2 or H-5), 5.14 (IH, d, 7 8.6 Hz, 
H-2 or H-5), 6.83-6.90 (4H, m, Ai'-H), 7.03-7.08 (2H, m, Ar-H).
(±)-l,4-Bis-(3,4-dimethoxyphenyI)-2,3-dimethylbutane-l,4-diol (67)
OH
MeO.
OHMeO 4
OMe
OMe
Reduction of the diketone (65) with LiAlH4 as previously described^^ was 
modified as follows. A solution of diketone (65) (400 mg, 1.04 mmol) in dry THE (25 
ml) was added dropwise to a stirring suspension of LiAlH4 (400 mg, 10.54 mmol) in 
dry THE (10 ml) at rt. After the addition was complete, the grey slurry was stirred at rt 
for 1 h before being quenched cautiously at 0 °C with moist ether. The solids were 
dissolved by the addition of IM HCl with vigorous stirring and the resultant mixture 
transferred to a separating funnel. The layers were separated, the aqueous layer was 
further extracted with EtOAc (2 x 10 ml) and the combined organic extracts were 
washed with brine (15 ml) and dried over MgSOq. Concentration in vacuo afforded 
the title compound (67) as a mixture of diastereoisomers giving an indefinite melting 
point (403 mg, 98.3%); Vmax (KBr)/cm"l 3430 (OH); §h  (360 MHz) (major 
diastereoisomer) 0.59 (3H, d, 7 7.0 Hz, H-9 or H-12), 1.07 (3H, d, 7 6.9 Hz, H-9 or H- 
12), 1.66-1.70 (IH, m, H-8 or H-10), 2.31-2.36 (IH, m, H-8 or H-10), 3.82-3.90 (12H,
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4s, 4 X OCH3), 4.38 (IH, d, J  8.7 Hz, H-7 or H-11), 4.59 (IH, d, J  6.8 Hz, H-7 or H-
11), 6.72-6.95 (6H, m, Ar-H).
(±)-l,4-Bis-(3,4-dimetlioxyplieiiyl)-2,3-dimethylbutane (39)
MeO.
MeO
OMe
OMe
Palladium on charcoal (10%, 850 mg) was added to a stirring solution of the 
diol (67) (l.OOg, 2.56 mmol) in AcOH (50 ml) and the mixture stirred under a 
hydrogen balloon at rt for 72 h. The mixture was filtered through Celite® and the 
residue washed with AcOH (2 x 1 0  ml). Concentration in vacuo followed by silica gel 
flash chromatography afforded a white solid (620 mg). Recrystallisation from MeOH 
afforded (±)-galbulin (78) as a fluffy solid (93 mg), m.p. 132-134 °C (lit.^^ 1 3 5  ^C). 
The ^H NMR spectrum was in excellent agreement with that reported.^3 A second 
crop of material, obtained after chilling the mother liquors in a freezer overnight, 
afforded the title compound (39) as white crystals contaminated with (±)-galbulin (350 
mg, 38.3%), m.p. 77-80 °C (lit.48 7 I °C); 5h 0.83 (3H, d, J 6.7 Hz, H-9), 1.76 (IH, m, 
H -8 ), 2.34-2.62 (2H, m, H-7), 3.82 (3H, s, OCH3), 3.86 (3H, s, OCH3), 6.57-6.83 
(3H, m, Ar-H). This material could not be further purified by recrystallisation or 
column chromatography.
(±)-l,4-Bis-(3,4-dihydroxyplienyi)-2,3-dimetliylbutane (32)
HO.
OH
OH
The general procedure of McOmie et al.^^ was used as follows. Boron 
tribromide (1.89 ml, IM in DCM, 1.89 mmol) was added dropwise to a stirring 
solution of crude diarylbutane (39) (150 mg, 0.42 mmol) in dry DCM (10 ml) at -78 
°C. After the addition was complete, the orange solution was allowed to warm to rt and 
stiiTed for a further 1 h before being poured cautiously into iced-H20 (75 ml). After 
stirring for 15 min, the layers were separated and the aqueous layer was further
118
extracted with DCM (2 x 50 ml). The combined organic extracts were washed with 
brine (25 ml), dried over M gS04 and concentrated affording crude (32) as a light 
yellow oil (170 mg) that could not be purified; ô h  (db-Acet) 0.79 (3H, d, J  6.6 Hz, H- 
9), 1.70-1.80 (IH, m, H-8), 2.23-2.56 (2H, m, H-7), 6.45 (IH, dd, J 8.0 Hz and 1.9 Hz, 
H-6), 6.62 (IH, d, J  1.9 Hz, H-2), 6.71 (IH, d, J  8.0 Hz, H-5).
2-Bromo-l-(3,4-methyleiiedioxyplieiiyl)propan-l-one (81)
The procedure of Biftu et <3/.,48 was modified as follows. Bromine (370 mg, 
0.12 ml, 2.30 mmol) in CHCI3 (5 ml) was added rapidly in portions over 15 min at rt 
to a vigorously stirring solution of l-(3,4-methylenedioxyphenyl)propan-l-one (410 
mg, 2.30 mmol) in CHCI3 (20 ml). After TLC had shown no starting material present, 
the mixture was washed with 10% sodium thiosulfate (2 x 10 ml) and brine (15 ml) 
before drying over MgSO^. Concentration in vacuo gave a yellow solid which was 
recrystallised from MeOH affording the title compound as off-white prisms (369 mg, 
62.4%), m.p. 50-52 °C (lit.48 54,55 °c); ô h  L 88 (3H, d, 7 6.6 Hz, H-9), 5.21 (IH, q, J
6.6 Hz, H-8), 6.06 (2H, s, H-10), 6.87 (IH, d, J  8.2 Hz, H-5), 7.49 (IH, d, 7 1.7 Hz, H- 
2), 7.64 (IH, dd, 7 8.2 Hz and 1.7 Hz, H-6).
(±)-l,4-Bis-(3,4-methyleiiedioxyphenyl)-2,3-dimetIiylbutane-l,4-dione (82)
o
<o
The procedure of Biftu et aZ.,48 was used on a 1.32 mmol scale affording the 
title compound as an off-white solid from EtOH-acetone (364 mg, 77.8%), m.p. 195- 
196 °C (lit.48 206-207 "C (DCM-MeOH)); ÔH L27 (3H, d 7 6.6 Hz, H-9), 3.80-3.89 
(IH, m, H-8), 6.03 (2H, s, H-10), 6.86 (IH, d, 7 8.2 Hz, H-5), 7.42 (IH, d, 7 1.5 Hz, H- 
2), 7.63 (IH, dd, 7 8.2 Hz and 1.6 Hz, H-6).
New data : Vmax (KBr)/cm-l 1670 (C=0), 1611 and 1505 (C=C); ÔC 16.2 (C-9), 43.9 
(C-8), 102.1 (C-10), 108.3 and 108.8 (C-2 and C-5), 125.1 (C-6), 131.3 (C-1), 148.5 
and 152.0 (C-3 and C-4), 202.8 (C-7).
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(±)-l,4-B is-(3,4-m ethylenedioxyphenyl)-2,3-dim ethylbutane-l,4-diol (83)
O H
10
,0 H
O—/
The method of Biftu et was modified as follows. A solution of the
diketone (82) (300 mg, 0.85 mmol) in dry THF (10 ml) was added dropwise to a 
stiring suspension of LiAlH4 (300 mg, 7.91 mmol) and THF (20 ml) at rt. After 
stirring for a further 1 h, the reaction was cooled to 0 °C and quenched by the cautious 
addition of moist ether followed by IM HCl to dissolve all solids. The layers were 
separated and the aqueous layer further extracted with Et2 0  (15 ml). The combined 
organic extracts were washed with brine (15 ml) before drying over MgSOq.. 
Concentration in vacuo gave a solid which was recrystallised from CHClg-hexane 
affording the title compound as a flaky solid (140 mg, 46.2%), m.p. 136-137 °C (lit.48 
141-142 °C) ÔH 0.56 (3H, d, 77.0 Hz, H-9 or H-12), 1.05 (3H, d, 76.9 Hz, H-9 or H-
12), 1.61-1.69 (IH, m, H-8 or H-11), 1.94 (IH, bs, OH), 2.17 (IH, bs, OH), 2.28-2.35 
(IH, m, H -8 or H-11), 4.33 (IH, d, 7 9.2 Hz, H-7 or H-12), 4.54 (IH, d, 7 7.4 Hz, H-7 
or H-12), 5.93 (2H, s, H-10 or H-20), 6.66 (IH, dd, 7 7.6 Hz and 1.6 Hz, H-6 or H- 
19), 6.71 (2H, bs, Ar-H), 6.77 (2H, bs, Ar-H), 6.85 (IH, bs, Ar-H).
(±)-l,4-Bis-(3,4-methylenedioxyphenyI)-2,3-dim ethylbiitane (84)
10
The method of Biftu et was used on a 0.14 mmol scale affording the 
crude title compound as a pale yellow oil that could not be purified; ÔH 0.80 (3H, d, J
6.6 Hz, H-9), 1.67-1.76 (IH, m, H-8), 2.34 (IH, dd, J  13.6 Hz and 8.3 Hz, H-7), 2.54 
(IH , dd, J  13.5 Hz and 6.1 Hz, H-7), 5.91 (2H, s, H-10), 6.54 (IH, dd, 77.8 Hz and 
1.4 Hz, H-6), 6.58 (IH, d, 7 1.4 Hz, H-2), 6.70 (IH, d, 77.9 Hz, H-5).
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4-(3,4-Dimethoxyphenyl)-3-methoxycarbonylbut-3-eiîoic acid (85)
COoMe
The method of Ganeshpure et alP^ was used on a 30.12 mmol scale affording 
the unsaturated half ester (85) as bright yellow crystals from toluene (3.38 g, 40.1%), 
m.p. 145-148 X  (lit.59 149-150 °C {MeOH}); ÔH 3.64 (2H, s, H-2), 3.86 (3H, s, H- 
11), 3.90 (3H, s, OCH3), 3.92 (3H, s, OCH3), 6.89-7.03 (3H, m, Ar-H), 7.87 (IH, s, 
H-4).
4-(3,4-Dimethoxyplienyl)-3-methoxycarboiiylbutanoic acid (86)
CO^Me
MeO 8
The method of Ganeshpure et was used on a 8.93 mmol scale affording 
the saturated half ester (86) as white crystals from toluene (2.12 g, 84.1%), m.p. 107- 
109 °C (lit.59 108-109 °C (benzene-hexane)); ÔH 2.39-2.50 (IH, m, H-3), 2.65-2.76 
(2H, m, H-2 or H-4), 2.96-3.06 (2H, m, H-2 or H-4), 3.68 (3H, s, H-11), 3.86 (3H, s, 
OCH3), 3.86 (3H, s, OCH3), 6.66-6.81 (3H, m, Ar-H). The potassium salt of (86) was 
prepared by the addition of 40% ethanolic KOH to a solution of (86) (500 mg, 1.77 
mmol) in EtOH (4 ml) until basic to phenolphthalein followed by concentration and 
high vacuum drying.
3-(3,4-DimethoxybenzyI)butyrolactone (87)
MeO 8
The method of Ganeshpure et was modified as follows. NaBH4 (201 mg, 
5.31 mmol) was added portion wise via a solid addition funnel to a stirring suspension 
of anhydrous CaCl2 (196 mg, 1.77 mmol) and dry EtOH (20 ml) at 0 °C. After stirring 
for an additional 30 min, a solution of the potassium salt of (86) (1.77 mmol) in dry 
EtOH (5 ml) was added dropwise over 5 min. The mixture was stirred at 0 °C for 1 h, 
allowed to warm to rt and stirred overnight. The resultant white mixture was 
concentrated in vacuo and partioned between CHCI3 (20 ml) and water (20 ml) before 
acidifying the aqueous layer to pH 1-2 with concentrated HCl. The clear solution was
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heated at reflux for 30 min, cooled to rt and the layers were separated. The aqueous 
layer was further extracted with CHCI3 (2 x 1 0  ml). The combined organic extracts 
were washed with saturated NaHCOg (10 ml) and brine (10 ml) before drying over 
MgSOq. Concentration in vacuo gave a crude oil (341 mg) which was purified by 
silica gel flash chromatography affording the lactone (87) as a colourless oil (191 mg, 
45.7%). This material gave a NMR identical to that reported.^^
3,4-DimethoxybenzyI brom ide (93)
MeO 4
The procedure of Torrado and Imperiali^^ was modified as follows. 
Phosphorous tribromide (0.55 g, 0.19 ml, 2.00 mmol) was added dropwise at 0 °C to a 
stirring solution of 3,4-dimethoxy benzyl alcohol (1.02 g, 6.06 mmol) in dry Et2Û (20 
ml). After the addition was complete, the mixture was allowed to reach rt and stirred for 
a further 1 h. The mixture was re-cooled to 0 °C and saturated NaHCOg (10 ml) added 
dropwise. The layers were separated and the aqueous layer was further extracted with 
E t20 (5 ml). The combined organic extracts were washed with brine (10 ml) before 
drying over MgSOq. Concentration in vacuo gave a white solid (1.23 g) which was 
recrystallised from Et20-hexane affording the title compound (93) as a fluffy solid 
(704 mg, 50.3%), m.p. 49-50 °C (lit.60 50-51 °C); ÔH 3.90 (3H, s, OCH3), 3.92 (3H, s, 
OCH3), 4.52 (2H, s, H-7), 6.83 (IH, d, J  8.2 Hz, H-5), 6.93 (IH, d, J  2.0 Hz, H-2), 
6.97 (IH, dd, J  8.2 Hz and 2.1 Hz, H-6).
(£)-l,4-Dibrorao-2,3-dlmethylbut-2-ene (98) :
" K . ,
3
The method of Sweeting et al.^^ was used as follows. A solution of Br2 (1.95 
g, 0.63 ml, 12.20 mmol) in CHCI3 (4 ml) was added dropwise over 30 min to a stirring 
solution of 2,3-dimethylbuta-l,3-diene (1.00 g, 1.38 ml, 12.17 mmol) in CHCI3 (5 ml) 
at -10 °C. After the addition was complete, the light yellow solution was concentrated in 
vacuo to give a pale brown liquid which solidified on standing. Recrystallisation from 
light petroleum-ether afforded the title compound as cream crystals (1.90 g, 64.4%), 
m.p. 45-47.5 °C (lit.63 47.0-47.5 °C); ÔH 1.90 (3H, s, H-3), 4.02 (2H, s, H-1); 6c  17.6 
(C-1), 35.5 (C-3), 132.3 (C-2).
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l,2-Dimethoxy-4-Iodo-benzene (105) ;
MeO
MeO 1
The general method of Skulski et al.^^ was modified as follows. Lead 
tetraacetate (4.88 g, 11.00 mmol) was added to a stirring solution of 1% (2.55 g, 10.04 
mmol) and 1,2-dimethoxybenzene (2.78 g, 2.56 ml, 20.12 mmol) in glacial AcOH (50 
ml). After stirring at rt for 22 h, the light yellow reaction mixture was concentrated to 
ca, 15 ml and H2O (20 ml) was added. The mixture was extracted with Et2Û (2 x 25 
ml) and the combined organic extracts were washed with 10% NaHSOq (3 x 10 ml) 
and brine (20 ml) before drying over MgSOq. The mixture was concentrated in vacuo 
to give a yellow oil (5.41 g) which was crystallised from chilled EtOH affording the 
title compound (3.80 g, 71.6%), m.p. 34.5-35.5 °C (lit.64 34-35 °C); ÔR 3.85 (3H, s, 
OCH3), 3.86 (3H, s, OCH3), 6.62 (IH, d, 78.4 Hz, H-6), 7.12 (IH, d, 7 1.7 Hz, H-3), 
7.22 (IH, dd, 7 8.4 Hz and 1.8 Hz, H-5).
3,3 %4,4 ’ -Tetramethoxybiphenyl (109)
OMe
MeO OMe
n-BuLi (0.90 ml, 1.4 M in hexanes, 1.26 mmol) was added dropwise to a 
stirring solution of 4-bromo-1,2-dimethoxybenzene (250 mg, 0.15 ml, 1.15 mmol) in 
dry THE (10 ml) at -78 °C. After stirring for 10 min, a solution of bromide (98) (167 
mg, 0.69 mmol) in dry THE (2 ml) was added dropwise and the mixture was stirred at 
-78 °C for 30 min. The light yellow solution was allowed to warm to rt and stirred for 
15 h before diluting with Et20 (25 ml). The organic solution was washed with H2O (2 
X 20 ml) and brine (20 ml) before drying over MgSOq. Concentration in vacuo gave a 
pale yellow solid which was purified by silica gel flash chromatography affording the 
title compound as crystals, m.p 123-125 °C (lit.^^ 124-126 °C); ÔR 3.94 (3H, s, 
OCH3), 3.98 (3H, s, OCH3), 6.96 (IH, d, 7 8.3 Hz, H-5), 7.08 (IH, d, 7 2.0 Hz, H-2),
7.12 (IH, dd, 7 8.2 Hz and 2.1 Hz); 6c  56.4 (OCH3), 56.4 (OCH3), 110.7 and 111.8 
(C-2 and C-5), 119.5 (C-6), 134.6 (C-1), 148.7 and 149.5 (C-3 and C-5); LRMS : m/z 
= 274.1 (M +\ 100%).
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l-(3,4-dimethoxyphenyl)-2,3-dimethyl-6-7-dimethoxynapthalene (127) :
MeO
13 OMe
OMe
The method of Carroll et was used on a 2,57 mmol scale affording the 
crude product as an amber coloured oil (2.38 g). Crystallisation of this oil from EtOH 
afforded the title compound (127) as orange crystals (171 mg, 37.8%), m.p. 175-178 
°C (lit.82 177-178 °C); ÔH 2.07 (3H, s, H-17 or H-18), 2.28 (3H, s, H-17 or H-18),
3.78 (3H, s, OCH3), 3.87 (3H, s, OCH3), 3.93 (3H, s, OCH3), 3.94 (3H, s, OCH3), 
6.64-6.67 (2H, m, H-12 and H-16), 6.87 (IH, d, J 8.0 Hz, H-15), 7.01 (IH, s, ArH), 
7.15 (IH, s, ArH), 7.38 (IH, s, ArH); 6c  15.2 and 20.1 (C-17 and C-18), 54.2 
(OCH3), 101.9 (CH), 104.7 (CH), 109.4 (CH), 111.2 (CH), 120.0 (CH), 122.8 (CH),
123.0 (C), 127.0 (C), 128.8 (C), 131.4 (C), 132.9 (C), 136.8 (C), 146.0, 147.1, 147.3 
and 147.5 (C-3, C-4, C-13 and C-14); LRMS : m/z = 352 (M +\ 100%).
/weso-l,4“Bis-(3,4-dimetlioxyplienyl)-2,3-dimethyl-2,3-butanediol (132) :
OHMeO
MeO 4 OH
OMe
OMe
The procedure of Takeya et al.^^ was modified as follows. Activated zinc dust 
(2.00 g, 30.60 mmol) was added in portions to a stirring mixture of 3,4- 
dimethoxyphenylacetone (2.00 g, 1.8 ml, 10.30 mmol) and TiCl/j. (2.92 g, 1.69 ml, 
15.38 mmol) in dry THF (60 ml) at 0 °C. The resultant dull green mixture was allowed 
to warm to rt and then heated at reflux for 3 h whereupon the mixture became a deep 
red homogeneous solution. After cooling to rt the mixture was quenched with saturated 
K2 CO 3 solution (15 ml) and stirring was continued for a further 1 h. After the 
resultant thick slurry was filtered through Celite® and the residue washed with CHCI3 
(4 X 30 ml), the light yellow organic solution was washed with water (80 ml) and brine 
(30 ml) before drying over MgSOq. Concentration in vacuo afforded a yellow oil 
which was crystallised from ether affording a 4:3 ratio (^H NMR) of diastereoisomeric 
pinacols as a colourless solid (1.47 g, 73.5%). Recrystallisation of this product three 
times from EtOH afforded the me^o-pinacol (132) as shiny crystals (439 mg, 22.0%),
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m.p. 156-159 °C; Vmax (KBr)/cm-l 3547 (OH), 1588 and 1514 (C=C); 8h  1.14 (3H, 
s. H-9), 2.00 (IH, s, OH), 2.68 (IH, d, J  13.4 Hz, H-7), 3.12 (IH, d, J  13.4 Hz, H-7),
3.89 (3H, s, OCH3), 3.90 (3H, s, OCH3), 6,79-6.86 (3H, m, Ar-H); 5 c  20.9 (C-9),
40.4 (C-7), 55.0 (OCH3), 75.8 (C-8), 110.1 and 113.3 (C-2 and C-5), 122.0 (C-6),
129.2 (C-1), 146.9 and 147.7 (C-3 and C-4); (Found: C 67.82%; H 7.84%; M+", 
390.2042. C22H30O6 requires C 67.7%; H 7.69%; M, 390.2043).
(±)-l,4-Bis-(3,4“dimethoxypheiiyl)-2,3-dimetliyl-2,3-butaiiediol (133) :
OHMeO.
OHMeO 4
OMe
OMe
The mother liquors from above were concentrated in vacuo and recrystallised 
from ether affording the title compound (133) as a mixture of diastereoisomers 
[{±y.meso -  2:1] (787 mg, 39.4%), m.p. 136-139 °C; Vmax (KBr)/cm'l 3513 (OH), 
1590 and 1514 (C=C); ô h  (major diastereoisomer) 1.18 (3H, s, H-9), 2.01 (IH, s, 
OH), 2.67 (IH, d, /  13.5 Hz, H-7), 3.09 (IH, d, J  13.4 Hz, H-7), 3.88 (3H, s, OCH3),
3.89 (3H, s, OCH3), 6.77-6.86 (3H, m, Ar-H); ÔC 21.8 (C-9), 42.1 (C-7), 77.1 (C-8),
111.4 and 114.7 (C-2 and C-5), 123.4 (C-6), 130.5 (C-1), 148.2 and 149.0 (C-3 and 
C-4); (Found: C 67.75%; H 7.82%; M+*, 390.2041. C22H30O6 requires C 67.7%; H 
7.69%; M, 390.2042).
(£^)-l,4-Bis-(3,4-dimethoxyphenyl)-2,3-dimetIiyl-2-butene (96) ;
MeO.
MeO 4
OMe
OMe
The procedure of Takeya et al.^^ was modified as follows. A mixture of the 
pinacol (133) (400 mg, 1.03 mmol), triethyl orthoformate (430 mg, 0.48 ml, 2,90 
mmol) and benzoic acid (85 mg, 0.70 mmol) was heated in a distillation apparatus 
under nitrogen at 110 *^ C for 2 h. After cooling, additional benzoic acid (43 mg, 0.35 
mmol) was added and heating was continued at 180 °C for 2 h at atmospheric pressure 
followed by 15 min under vacuum (rotary pump) while EtOH was distilled over. The
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resultant yellow solution was allowed to cool to rt, taken up in DCM (30 ml) and 
washed successively with sat. NaHCOg (15 ml) and brine (10 ml) before drying over 
M gS04. Concentration in vacuo gave an oil which solidified on standing. Excess 
triethyl orthoformate was removed by column chromatography eluting with ether- 
hexane (2:1) and the resultant yellow solid was recrystallised from EtOH affording the 
title compound (96) as colourless needles (255 mg, 69.9%), m.p. 121-123 °C; Vmax 
(KBr)/cm-l 1589 and 1515 (C=C); 8h  1.76 (3H, s, H-9), 3.41 (2H, s, H-7), 3.82 (3H, 
s, OCH3), 3.86 (3H, s, OCH3), 6.70-6.80 (3H, m, Ar-H); 8c  19.0 (C-9), 40.2 (C-7),
56.1 and 56.3 (OCH3), 111.5 and 112.1 (C-2 and C-5), 120.6 (C-6), 129.3 and 133.8 
(C-1 and C-8), 147.6 and 149.2 (C-3 and C-4); (Found: C 74.01%; H 7.91%; M +', 
356.1985. C22H28O4 requires C 74.16%; H 7.87%; M, 356.1987).
(±)-l,4-Bis-(3,4“dimethoxyplieiiyl)“2,3"dimethylbutane (39) ;
MeO.
MeO 4
OMe
OMe
Platinum (IV) oxide (25 mg, 0.11 mmol) was added to a stimng solution of the 
(E)-alkene (96) (150 mg, 0.42 mmol) in glacial AcOH (20 ml) and the mixture was 
stirred under a hydrogen balloon, after degassing the solvent three times, for 1 h. The 
mixture was filtered through Celite®, the residue washed with CHClg (2 x 10 ml) and 
the colourless solution concentrated in vacuo. Saturated by-products were removed by 
column chromatography eluting with ether-hexane (3:1) affording a colourless oil (104 
mg) which crystallised on standing. Recrystallisation from MeOH afforded pure 
racemic (39) as needles (46 mg, 30.5%), m.p. 70-72 (lit.,^^ 71 °C); ô h  0.83 (3H, d,
J  6.6 Hz, H-9), 2.40 (IH, dd, J 13.6 Hz and 7.8 Hz), 2.56 (IH, dd, J  13.6 Hz and 6.8 
Hz), 1.74-1.78 (IH, m, H-8), 3.82 (3H, s, OCHg), 3.86 (3H, s, OCHg), 6.59 (IH, d, J
1.8 Hz, H-2), 6.63 (IH, dd, 7 8.1 Hz and 1.8 Hz, H-6), 6.76 (IH, d, J 8.1 Hz, H-5).
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(±)-l,4-Bis-(3,4-diliydroxyphenyl)“2,3-dimethylbutane (32)
HO.
HO 4
OH
OH
A mixture of (39) (58 mg, 0.16 mmol) and 48% HBr-AcOH (2:1) (3 ml) was 
heated at reflux under nitrogen for 6 h. After cooling to rt, the light pink mixture was 
poured into water (10 ml) and extracted into EtOAc (2 x10  ml). The combined organic 
extracts were washed with brine (10 ml), dried over MgSÜ4 and concentrated in vacuo 
to give a light yellow oil that crystallised on standing. Purification by column 
chromatography afforded the title compound as a light brown solid (40 mg, 81.6%), 
m.p. 155-157 °C (lit.,44 157-160 °C).
New data. Vmax (KBr)/cm-l 3474 and 3377 (OH). 1610 and 1527 (C=C); 5 h  (dô- 
DMSG) 0.73 (3H, d, 7 6.5 Hz, H-9), 1.62-1.67 (IH, m, H-8), 2.20 (IH, dd, J  13.2 Hz 
and 8.4 Hz, H-7), 2.41 (IH, dd, J  13.2 Hz, and 5.6 Hz, H-7), 6.34 (IH, dd, J  7.9 Hz 
and 1.8 Hz, H-6), 6.48 (IH, d, J  1.8 Hz, H-2), 6.60 (IH, d, 77 .9  Hz, H-5), 8.55 (IH, 
bs, OH), 8.65 (IH, bs, OH); 8c  (ds-DMSO) 14.1 (C-9), 38.2 (C-8), 40.6 (C-7), 115.7 
and 116.5 (C-2 and C-5), 119.8 (C-6), 132.4 (C-1), 143.3 and 145.2 (C-3 and C-4); 
(Found: C 71.35%; H 7.34%; M+*, 302.1516. C 18H22O4 requires C 71.52%; H 
7.28%; M, 302.1518).
(Z)-l,4-Bis-(3,4-dimethoxyphenyl)-2,3-dimethyl-2-butene (131) :
MeO.
MeO
OMe
OMe
This compound was prepared by the method used to prepare (96) using the 
me^o-pinacoi (132) (400 mg, 1.03 mmol) affording the title compound as feathers 
(290 mg, 79.5%), m.p. 78-80 °C; Vmax (KBr)/cm-l 1588 and 1514 (C=C); 8h  1.69 
(3H, s, H-9), 3.48 (2H, s, H-7), 3.82 (3H, s, OCH3), 3.86 (3H, s, OCH3), 6.67 (IH, d, 
7 2.0 Hz, H-2), 6.71 (IH, dd, 7 8.0 and 2.0 Hz, H-6), 6.79 (IH, d, 7 8.0 Hz, H-5); 8c
18.6 (C-9), 39.7 (C-7), 55.8 (OCH3), 55.9 (OCH3), 111.1 and 112.0 (C-2 and C-5),
120.4 (C-6), 128.7 and 133.3 (C-1 and C-8), 147.2 and 148.9 (C-3 and C-4); (Found:
127
c 74.15%; H 7.91%; M+*, 356.1990. C22H28O4 requires C 74.16%; H 7.87%; M, 
356.1987).
meso-l,4-Bis-(3,4-dimethoxyphenyl)-2,3-dimethylbutane (47) :
MeO,
MeO 4
OMe
OMe
Platinum (IV) oxide (20 mg, 0.09 mmol) was added to a stirring solution of the 
(Z)-alkene (131) (200 mg, 0.56 mmol) and the mixture was stirred under a hydrogen 
balloon at rt, after degassing the solvent three times. After 1 h, when TLC showed no 
signs of stalling material, the mixture was filtered through Celite® and the residue was 
washed with CHCI3 (2 x 10 ml). Concentration in vacuo afforded a pale yellow oil 
which solidified on standing and was recrystallised two times from MeOH affording 
the title compound as shiny crystals (75 mg, 37.3%), m.p. 99-100 °C (lit.,42 100-102 
°C); ÔH 0.85 (3H, d, J 6.6 Hz, H-9), 1.75-1.80 (IH, m, H-8), 2.30 (IH, dd, J  13.5 Hz 
and 9.3 Hz, H-7), 2.75 (IH, dd, J  13.5 Hz and 5.0 Hz, H-7), 3.85 (3H, s, OCH3), 3.86 
(3H, s, OCH3), 6.65 (IH, d, /  1.7 Hz, H-2), 6.70 (IH, dd, J 8.1 Hz and 1.7 Hz, H-6),
6.79 (IH, d ,7  8.1 Hz, H-5).
meso-l,4-BiS“(3,4-liydroxyphenyI)-2,3-dimethylbutane (NDGA) (1) ;
HO.
HO 4
OH
OH
A mixture of (47) (60 mg, 0.17 mmol) and 48% HBr-AcOH (2:1) (3 ml) was 
heated at reflux under nitrogen for 6 h. After cooling to rt, the light pink mixture was 
poured into water (10 ml) and extracted into EtOAc (2 x 10 ml). The combined organic 
extracts were washed with brine (10 ml), dried over MgSÜ4 and concentrated in vacuo 
to give a light yellow oil that crystallised on standing. Recrystallisation from Et20- 
hexane afforded NDGA (1) as shiny brown crystals (40 mg, 78.4%), m.p. 184-186 °C 
(lit.,42 1 84.5-186); 5 h  0.75 (3H, d, J  6.6 Hz, H-9), 1.60-1.62 (IH, m, H-8), 2.10 (IH, 
dd, J  13.2 and 9.2 Hz, H-7), 2.57 (IH, dd, J  13.3 and 4.8 Hz, H-7), 6.39 (IH, dd, J  8.0
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and 1.9 Hz, H-6), 6.53 (IH, d, J  1.9 Hz, H-2), 6.62 (IH, d, 77.9 Hz, H-5), 8.57 (IH, 
bs, OH), 8.64 (IH, bs, OH).
2-(3,4-Dimethoxyphenyl)-l,3-ditliiane (137)
M eO ^ 3
MeO 4
The method of Seebach et was modified as follows : Dry HCl was 
bubbled into a solution of 3,4-dimethoxybenzaldehyde (2.00 g, 12.00 mmol) and 1,3- 
propanedithiol (1.21 ml, 12.10 mmol) in dry CHCI3 (5 min) at 0 °C for 5 min. The 
mixture was stirred for 30 min then washed successively with H2O (2 x 5  ml), 10% 
KOH (2 x 5  ml) and H2O ( 2 x 5  ml) before drying over MgSOq.. Concentration in 
vacuo gave a pale yellow solid (2.91 g) which was recrystallised from EtOH affording 
dithiane (137) as crystals (2.56 g, 83.1 %), m.p. 92-92.5 °C (lit.94 92-93 °C); ÔH 1.82-
2.21 (2H, m, H-10), 2.85-3.14 (4H, m, H-8 and H-9), 3.87 (3H, s, OCH3), 3.90 (3H, s, 
OCH3), 5.13 (IH, s, H-7), 6.82 (IH, d, J 8.8 Hz, H-5), 7.01-7.05 (2H, m, H-2 and H- 
6).
l,5-Bis-(3,4-dimethoxyplienyI)pentane-l,5-bis dithiane (138)
M eO. 3 ,  OMe
MeO 4 OMe
The method of Fliedner et alP^ was used as follows : n-BuLi (1.60 ml, 1.35 M 
in hexanes, 2.16 mmol) was added dropwise at -35 °C to a stirring solution of dithiane 
(137) (500 mg, 1.95 mmol) in dry THE (25 ml). The resultant yellow solution was 
stirred for 1.5 h, allowed to warm to -15 °C and a solution of 1,3-propanedithiol (0.10 
ml, 0.99 mmol) in dry THE (1 ml) was introduced dropwise. After standing in a fridge 
overnight the solution was re-cooled to -35 °C and queched by the cautious addition of 
H2O (0.5 ml) and the mixture concentrated in vacuo. The residue was suspended in 
H2 O (5 ml), the mixture acidified to pH 2-3 by the addition of c.HCl and extracted 
with CHCI3 (30 ml). The organic layer was washed succesively with 5 % NaHS03 (3 
X 10 ml), 5 % KOH (3 x 10 ml) and H2 O (3 x 10 ml) before drying over MgSOq. 
Concentration in vacuo gave a pale yellow oil which was purified by silica gel flash 
chromatography affording the title compound (138) as a pale yellow solid (369 mg,
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68.6 %), m.p. 111-114 °C (lit.94 115-117 °C); ÔR 1.24-1.34 (2H, m, H-9), 1.83-1.91 
(4H, m, H-8 and H-12), 2.62-2.69 (4H, m, H-10 and H-11), 3.86 (3H, s, OCH3), 3.89 
(3H, s, OCH3), 6.79 (IH, d, J 8.3 Hz, H-5), 7.31-7.38 (2H, m, H-2 and H-6).
Ethyl-(3,4-dimethoxypheiiyl)benzoate (139)
MeO 4
The method of Choshi et al.^^ was modified as follows : Concentrated H2SO4 
(2 drops) was added to a stirring suspension of 3,4-dimethoxybenzoic acid (1.00 g, 
5.49 mmol) and EtOH (5 ml) and the whole mixture heated at reflux for 18 h. After 
cooling to rt, the solution was poured into water (30 ml) and extracted into EtOAc (2 x 
20 ml). The combined organics were washed with IM NaOH (10 ml) and brine (10 
ml) before drying over MgS04. Concentration in vacuo gave a yellow oil which was 
distilled under reduced pressure affording the title compound as a viscous oil (705 mg, 
61.3%), b.p. 134-136 °C (>1 mniHg) (lit.,96 152-153 °C/6 mmHg); Ô r 1.38 (3H, t, J
7.1 Hz, H-9), 3.91 (3H, s, OCH3), 3.93 (3H, s, OCH3), 4.35 (2H, q, 7 7.1 Hz, H-8), 
6.87 (IH, d, J  8.4 Hz, H-5), 7.55 (IH, d, J  1.9 Hz, H-2), 7.67 (IH, dd, J  8.4 Hz and 2.0 
Hz, H-6); ÔC 14.7 (C-9), 56.2 (OCH3), 61.0 (C-8), 110.5 and 112.2 (C-2 and C-5),
123.3 (C-1), 123.8 (C-6), 148.9 and 153.2 (C-3 and C-4), 166.6 (C-7).
l,3-Bis-(3,4-dimethoxyphenyl)propan-l,3-dione (141)
OMe 
OMe
The method of Choshi et aL^^ was modified as follows : A solution of 3,4- 
dimethoxyacetophenone (180 mg, 1.00 mmol) in PhCH3 (3 ml) was added dropwise 
to a stirring suspension of NaH (50 mg, 60% in oil, 1.25 mmol) (pre-washed in hexane 
(2 x 2  ml)) and ester (139) (231 mg, 1.10 mmol) in dry PhCH3 (8 ml) at rt. After the 
addition complete the mixture was heated at reflux for 16 h, cooled to rt and quenched 
by the cautious addition of 10% HCl (5 ml). The mixture was extracted with EtOAc (2 
X 10ml) and the combined organics washed with brine (10 ml) before drying over 
MgS04. Concentration in vacuo gave an orange solid which was recrystallised from 
EtOH affording the diketone (141) as orange crystals (104 mg, 30.2 %), m.p. 127-129 
°C (lit.,94 100.5-101 ""C (ether)); v^ax. (KBr)/cm"l, 1600 (C=0); 5 r  3.97 (6H, s,
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MeO 4
0CH3), 3.99 (6H, s, OCH3), 6.75 (IH, s, H-8), 6.94 (2H, d, J  8.4 Hz, H-5), 7.56 (2H, 
d, 71.9 Hz, H-2), 7.61 (2H, dd, 7 8.4 Hz and 2.0 Hz, H-6), 14.4 (IH, bs, OH).
New data : ÔC 56.4 (OCH3), 92.1 (C-8), 110.1 and 110.9 (C-2 and C-5), 121.4 (C-6),
128.8 (C-1), 149.5 and 153.1 (C-3 and C-4), 184.9 (C-7); (Found: M+°, 344.1259. 
C 19H20O6 requires M, 344.1260),
l,3-Bis-(3,4-dimethoxyphenyl)propane (142)
MeO 4
OMe
OMe
Palladium on charcoal (10 %, 150 mg) was added to a solution of the diketone 
(141) (250 mg, 0.73 mmol) in MeOH (50 ml) and the mixture stirred under a 
hydrogen balloon at rt for 72 h. The mixture was filtered through Celite®, the catalyst 
washed with MeOH (2 x 20 ml) and the solvent removed on a rotary evaporator. Flash 
chromatography of the residue afforded the title compound (142) as a powder (160 
mg, 70 %), m.p. 61-63 °C (lit.,97 62-63 °C).
New data : Vmax. (CDCl3)/cm-i, 1509 and 1588 (C=C); ô r  1.88-1.96 (2H, m, H-8),
2.60 (4H, t, 77.6 Hz, H-7), 3.86 (6H, s, OCH3), 3.87 (6H, s, OCH3), 6.71 (2H, d, 7 1.8 
Hz, H-2), 6.73 (2H, dd, 7 8.2 Hz and 1.9 Hz, H-6), 6.80 (2H, d, 7 8.0 Hz, H-5); ô c
33.7 (C-8), 35.4 (C-7), 56.2 (OCH3), 56.3 (OCH3), 111.6 and 112.2 (C-2 and C-5),
120.6 (C-6), 135.3 (C-1), 147.5 and 149.2 (C-3 and C-4); (Found: M+*, 316.1675. 
C 19H24O4 requires M, 316.1675).
l ,3 “Bis-(3,4-dihydroxyphenyl)propane (143)
HO 4
OH
OH
The general procedure of McOmie et was used as follows : Boron 
tribromide (1.71 ml, IM in DCM, 1.71 mmol) was added dropwise to a stirring 
solution of diaryIpropane (142) (120 mg, 0.38 mmol) in dry DCM (8 ml) at -78 °C. 
After the addition complete, the orange solution was allowed to come to rt and stirred 
for Ih before pouring into iced-H20 (50 ml). The resultant mixture was extracted with 
EtOAc (2 X 25 ml) and the combined organics washed with brine (10 ml) and dried 
over MgS04. Concentration in vacuo afforded a light orange oil which was purified by 
silica gel dry flash column chromatography giving the title compound (143) as a 
colourless oil that solidified on standing (90 mg, 91.2 %), m.p. 115-117 °C (lit.,^7 \
119 °C); (Found : C 68.91%; H 6.07%. C 15H 16O4 requires C 69.23%; H 6.15%).
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New data; v^ax. (KBr)/cm-l, 3425 and 3367 (OH), 1608, 1560 and 1526 (C=C); ÔR 
(CD3OD) 1.95-2.06 (2H, m, H-8), 2.64 (4H, t, 77.4 Hz, H-7), 5.06 (4H, bs, OH), 6.67 
(2H, dd, 7 8.0 Hz and 2.0 Hz, H-6), 6.79 (2H, d, 7 1.9 Hz, H-2), 6.85 (2H, d, 7 8.0 Hz, 
H-5); ÔC (CD3OD) 35.3 (C-8), 36.0 (C-7), 116.5 and 116.8 (C-2 and C-5), 121,0 (C-
6), 135.7 (C-1); 144.4 and 146.3 (C-3 and C-4); (Found: M+", 260.1043. C15H 16O4 
requires M, 260.1049).
3,4-Dimethoxybenzyl triplienylpliosphonium  brom ide (144)
MeO 7 PPh-,Br
MeO 4
A mixture of triphenylphosphine hydrobromide (2.04g, 5.95 mmol) and 3,4- 
dimethoxybenzyl alcohol (1.00 g, 5.95 mmol) in dry CH3CN (100 ml) was heated at 
reflux for 12 h. After cooling to rt the mixture was concentrated in vacuo to give a pale 
yellow solid which was recrystallised from EtOH affording (144) as white crystals 
(2.26 g, 77.0%), m.p. 235-237 °C; Vmax (KBr)/cm-l 1588 and 1515 (C=C); 5 h  3.54 
(3H, s, OCH3), 3.79 (3H, s, OCH3), 5.36 (2H, d, 7h-P 13.8 Hz, CH2), 6.60 (IH, d, J
8.3 Hz, H-6), 6.64-6.67 (IH, m, H-5), 6.85-6.86 (IH, m, H-3), 7.60-7.78 (15H, m, 
PPh3); 8c  30.6 (d, 7c-P 46.1 Hz, CH2), 56.2 and 56.4 (OCH3), 111.3, 115.3 and
115.4 (CH), 117.8, 118.7 and 119.4 (C), 124.1, 130.4, 130.5, 134.9, 135.0 and 135.2 
(CH), 149.1 and 149.2 (C-1 and C-2); 5p (81 Hz, CDC13) 22.4; (Found; C 65.54%; H
5.29%; M+°(-HBr), 412.1591. C27H26B1O2P requires C 65.72%; H 5.27%; M(- 
HBr), 412.1592).
3-(3,4-Dim ethoxyphenyl)propan-l-ol
5  OH
MeO 4
The method of Frydman et was modified as follows : A solution of 3- 
(3,4-dimethoxyphenyl)propionic acid (1.50 g, 7.14 mmol) in dry THF (5 ml) was 
added dropwise to a stirring slurry of LiAIH4 (0.41 g, 10.70 mmol) and THF (20 ml) 
at 0 °C. After stirring at rt for 3.5 h the reaction was quenched by the cautious addition 
of moist ether followed by IM HCl to dissolve the inorganic solids. The layers were 
separated, the aqueous layer extracted with EtOAc (25 ml) and the combined organics 
washed with brine (15 ml) before drying over M gS04. Concentration in vacuo 
followed by distillation afforded the title compound as a viscous oil (0.93 g, 66.5%) 
giving b.p. 150-152 °C / > 1 mmHg, (lit., 100 134-142 °C / 0.5 mmHg), Ôr 1.82-1.89
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(2H, m, H-8), 2.22 (IH, bs, OH), 2.64 (2H, t, J 1.5 Hz, H-7), 3.65 (2H, t, J  6.5 Hz, H- 
9), 3.84 (3H, s, OCH3), 3.85 (3H, s, OCH3), 6.71-6.83 (3H, m, Ai-H).
3-(3,4-Dimethoxyphenyl)propioiialdehyde (146)
MeO 4
9 H
The method of Padwa et was modified employing the general procedure 
of Swern et as follows : A solution of DMSO (438 mg, 0.40 ml, 5.62 mmol) in 
dry DCM (2 ml) was added dropwise to a stirring solution of oxalyl chloride (356 mg, 
0.24 ml, 2.80 mmol) in dry DCM (20 ml) at -60 °C. After 2 min a solution of the 
alcohol (500 mg, 2.56 mmol) in dry DCM (4 ml) was introduced dropwise at the same 
temperature and stirring continued for 15 min. EtgN (1.29 g, 1.78 ml, 12.76 mmol) 
was added dropwise to the cloudy solution and the mixture allowed to warm to rt over 
45 min when TLC showed no signs of starting material. Water (20 ml) was added and 
the resultant two layers separated with the aqueous layer further extracted with DCM 
(15 ml). The combined organics were washed with 10% HCl (10 ml) and brine (20 ml) 
before drying over MgSOq, Concentration in vacuo afforded the title compound (146) 
as a light yellow oil (486 mg, 98.2%) pure enough to be used without further 
purification. ÔH 2.77 (2H, t, J  7.2 Hz, H-7 or H-8), 2.91 (2H, t, J  7.4 Hz, H-7 or H-8), 
3.85 (3H, s, OCH3), 3.87 (3H, s, OCH3), 6.72-6.74 (2H, m, H-2 and H-6), 6.80 (IH, 
d, J  8.6 Hz, H-5), 9,82 (IH, bs, CHO); ô c  27.6 (C-7), 45.4 (C-8), 55.7 (OCH3), 55.8 
(OCH3), 111.2 and 111.5 (C-2 and C-5), 120.0 (C-6), 132.9 (C-1), 147.3 and 148.8 
(C-3 and C-4), 201.7 (C-9).
l,4-Bis-(3,4-dim ethoxyphenyl)but-l-ene (147)
MeO.
‘3 OMe
OMe
To a stirring suspension of (144) (1.25 g, 2.54 mmol) in dry THF (25 ml) was 
added /r-BuLi (1.74 ml, 1.6 M in hexanes, 2.79 mmol) dropwise at 0 °C. After stirring 
the dark red solution for a further 15 min aldehyde (146) (469 mg, 2.42 mmol) in THF 
(5 ml) was introduced dropwise at the same temperature. The resultant fawn coloured 
suspension was stirred at 0 °C for 30 min allowed to warm to rt and stirred for a
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further 1 h before pouring into iced water (50 ml). The mixture was extracted into 
EtOAc (3 X 25 ml) and the combined organics washed with brine (25 ml) before 
drying over MgS04. Concentration in vacuo gave a yellow solid which was purified 
by column chiomatography affording alkene (147) as a mixture of geometrical isomers 
(630 mg, 79.5%, Z:E = 1.9-1), m.p. 150-156 ^C; Vmax (KBr)/cm"l 1590 and 1600 
(C=C); ÔH (A-isomer) 2.47-2.52 (2H, m, CH2), 2.71-2.75 (2H, m, CH2), 3.84-3.94 
(12H, m, OCH3), 6.13 (IH, dt, J  15.8 Hz and 6.8 Hz, H-8), 6.35 (IH, d, J  15.6 Hz, H-
7), 6.71-6.89 (6H, m, Ar-H), (Z-isomer) 2.63-2.68 (2H, m, CH2), 2.71-2.75 (2H, m, 
CH2), 3.84-3.94 (12H, m, OCH3), 5.62 (IH, dt, 711.6 Hz and 7.1 Hz, CH), 6.38 (IH, 
d, 7 11.6 Hz, Ar-CH), 6.71-6.89 (6H, m, Ar-H); 5 c  30.9, 35.5, and 36.0 (CH2), 56.2 
and 56.3 (OCH3), 109.0, 111.3, 111.6, 112.2, 112.3, 112.5, 119.3, 120.6, 121.6, 128.5,
129.5 and 130.4 (CH), 130.9 (C), 131.0 (CH), 131.3 , 134.7, 134.9, 147.6, 148.2, 
148.7, 148.9, 149.2 and 149.4 (C); (Found: M+°, 328.1674. C20H24O4 requires M, 
328.1675).
l ,4 “Bis-(3,4-dimetlioxypheiiyl)butane (148)
MeO
OMe
OMe
Palladium on charcoal (10%, 50 mg) was added to a stirring solution of (147) 
(578 mg, 1.76 mmol) in MeOH-EtOAc (5:1) (50 ml) and the mixture stirred under a 
hydrogen balloon at room temperature for 72 h. The mixture was filtered through 
Celite® and the residue washed with ethyl acetate (2 x 10 ml). Concentration in vacuo 
gave a white solid which was recrystallised from aqueous MeOH affording the 
diaiylbutane (148) as crystals (489 mg, 84,2%), m.p. 89-90 °C (lit.,^^ 90 °C).
New data : Vmax (KBr)/cm’l 1606, 1589 and 1517 (C=C); ÔH 1.62-1.66 (2H, m, H-
8), 2.58 (2H, t, 7 6.6 Hz, H-7), 3.85 (3H, s, OCH3), 3.86 (3H, s, OCH3), 6.69-6.71 
(2H, m, H-2 and H-6), 6.78 (IH, d, 7 7.8 Hz, H-5); 5 c  31.6 and 35.8 (C-7 and C-8),
56.2 (OCH3), 56.3 (OCH3), 111.6 and 112.1 (C-2 and C-5), 120.6 (C-6), 135.6 (C-1),
147.5 and 149.2 (C-3 and C-4); (Found: M+°, 330.1833. C20H 26O4 requires M, 
330.1822).
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l,4-Bis-(3,4-dihydroxyphenyl)butane (149)
HO
OH
OH
A mixture of the diarylbutane (148) (300 mg, 0.91 mmol), 48% HBr (5 ml) and 
glacial AcOH (2 ml) was heated at reflux under N2 for 6 h. After cooling to rt, the 
mixture was poured into water (50 ml) and extracted with EtOAc (2 x 20 ml). The 
combined organics were washed with brine (2 x 10 ml), dried over M gS04 and 
concentrated in vacuo to give an off-white solid. Recrystallisation from ether-hexane 
afforded the title compound (149) as tan coloured crystals (199 mg, 79.9%), m.p. 136- 
138 °C (lit.,98 141-142 °C {aq. MeOH)).
New data : Vmax (KBr)/cm-l 3385 and 3268 (OH), 1619, 1610 and 1530 (C=C); 5h  
(d6-DMSO) 1.47 (2H, bs, H-8), 2.39 (2H, bs, H-7), 6.39 (IH, dd, J  8.0 Hz and 1.8 Hz, 
H-6), 6.53 (IH, d, J  1.8 Hz, H-2), 6.60 (IH, d, 77.9 Hz, H-5), 8.55 (IH, bs, OH), 8.66 
(IH, bs, OH); 5 c  (dg-DMSO) 31.2 and 34.7 (C-7 and C-8), 115.7 and 116.0 (C-2 
and C-5), 119.1 (C-6), 133.4 (C-1), 143.4 and 145.3 (C-3 and C-4); (Found: M+°, 
274.1207. C16H 18O4 requires M, 274.1205).
l,5-Bis-(3,4“dimethoxyphenyl)-penta-l,4-dien-3-oiie (150)
OMe 
OMe
The method of Haworth et al. 1^ 2 was used on a 12.04 mmol scale affording the 
unsaturated ketone (150) as bright yellow feathers (1.63 g, 83.6 %), m.p. 84-85 °C 
(lit ,102 84 °C); ÔH 3.92 (3H, s, OCH3), 3.94 (3H, s, OCH3), 6.89 (IH, d, J  8.3 Hz, H- 
5), 6.96 (IH, d, /  15.9 Hz, H-8), 7.14-7.21 (2H, m, H-2 and H-6), 7.70 (IH, d, J  15.8 
Hz, H-7).
MeO 4
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l,5-Bis-(3,4-dimethoxyphenyl)pentan-3-one (151)
OMe
MeO 4 ^  OMe
The procedure of Haworth et was modified as follows : Palladium on
charcoal (10 %, 50 mg) was added to a solution of the unsaturated ketone (150) (810 
mg, 2.29 mmol) in EtOAc (20 ml) and the mixture stirred under a hydrogen balloon 
for 1 hr. The resultant colourless mixture was filtered through Celite®, the catalyst 
washed with EtOAc (2 x 1 0  ml) and the solvent was removed on a rotary evaporator. 
Recrystallisation of the residue from EtOH gave (151) as crystals (457 mg, 55.8 %), 
m.p. 80-82 °C (lit.,^02 g5 °C); Ôh 2.64-2.88 (4H, m, H-7 and H-8), 3.85 (3H, s, 
OCH3), 3.86 (3H, s, OCH3), 6.66-6.80 (3H, m, Ar-H).
l,5-Bis-(3,4-dimethoxyphenyl)pentane (152)
MeO 4
OMe
OMe
The method of Haung-Minlonl^^ ^as modified as follows : Hydrazine hydrate 
(146 mg, 0.14 ml, 2.92 mmol) was added dropwise to a stirring mixture of the ketone 
(151) (500 mg, 1.40 mmol) and powdered KOH (206 mg, 3,68 mmol) in diethylene 
glycol (6 ml). After the addition complete, the mixture was heated at 165 °C for 4 h 
under a N2 atmosphere before allowing to cool to rt and pouring into water (40 ml). 
The resultant mixture was extracted with Et20 (2 x 20 ml) and the combined organics 
washed with water (2 x 20 ml) and brine (10 ml) before drying over M gS04. 
Concentration in vacuo gave a yellow oil which was purified by silica gel flash column 
chromatography affording diarylpentane (152) as a powder (280 mg, 58.3 %), m.p. 50- 
53 °C (lit.,102 56-57 °C); Ôh 1.38-1.45 (2H, m, H-9), 1.56-1.71 (4H, m, H-8), 2.56 
(4H, t, 77.3 Hz, H-7), 3.86 (6H, s, OCH3), 3.87 (6H, s, OCH3), 6.69-6.73 (4H, m, H-2 
and H-6), 6.79 (2H, d, J  8.6 Hz, Ar-5).
l,5-Bls-(3,4-dihydroxyphenyl)pentane (153)
HO 4
OH
OH
The method of Haworth et was modified employing the general method 
of McOmie et on a 0.61 mmol scale as outlined for compound (149). The
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diarylpentane (153) was isolated as a tan coloured solid after flash column 
chromatography (158 mg, 90.0 %), m.p. 130-132 °C (lit.,^1)  ^129-130 °C).
New data: Vmax. (KBr)/cm-i, 3473 and 3377 (OH), 1608 and 1519 (C=C); ô h  
(CD3OD) 1.28-1.38 (2H, m, H-9), 1.48-1.63 (4H, m, H-8), 2.43 (4H, t, 77.3 Hz, H-7),
4.90 (4H, bs, OH), 6.45 (2H, dd, 7 8.0 Hz and 2.0 Hz, H-6), 6.58 (2H, d, 7 1.9 Hz, H-
2), 6.64 (2H, d, 7 8.0 Hz, H-5); ÔC (CD3OD) 30.15 (C-9), 33.13 (C-8), 36.53 (C-7),
116.4 and 116.8 (C-2 and C-5), 120.9 (C-6), 136.0 (C-1), 144.3 and 146.3 (C-3 and 
C-4); (Found: M+", 288.1361. C17H20O4 requires M, 288.1362).
l,6-Bis-(3,4-dimethoxyphenyl)liexan-l,6-dione (154)
OMe
OMe
The procedure of Fliedner et al.^^ was adopted using dry CHCI3 and freshly 
distilled adipoyl dichloride on a 7.24 mmol scale affording diketone (154) as feathers 
(1.03 g, 81.1%), m.p. 148-150 °C (lit.,94 149-150 °C); ÔH 1.82-1.87 (2H, m, H-9),
3.00 (2H, m, H-8), 3.94 (3H, s, OCH3), 3.95 (3H, s, OCH3), 6.89 (IH, d, 7 8.4 Hz, H-
5), 7.53 (IH, d, 7 1.9 Hz, H-2), 7.59 (2H, dd, 7 8.3 Hz and 2.0 Hz, H-6).
MeO 4
1.6-Bis-(3,4-dimethoxyphenyl)hexane (155)
^  , OMe
2 o I IIMeO^ OMe| i  8
MeO''» 5
Palladium-charcoal (10 %, 200 mg) was added to a solution of the diketone 
(154) (500 mg, 1.3 mmol) in glacial AcOH (100 ml) and the mixture stirred under a 
hydrogen balloon overnight. The mixture was filtered through Celite®, the catalyst was 
washed with AcOH ( 2 x 1 0  ml) and the solvent was removed on a rotary evaporator. 
Recrystallisation of the residue from MeOH afforded the diarylhexane (155) as plates 
(317 mg, 68.2 %), m.p. 76-77 °C (lit.,97 78-79 °C); Ôh 1.34-1.40 (2H, m, 0 % ) , 1.56-
1.60 (2H, m, CH2), 2.55 (4H, t, 7 7.2 Hz, H-7), 3.85 (3H, s, OCH3), 3.87 (3H, s, 
OCH3), 6.69-6.73 (2H, m, H-2 and H-6), 6.79 (2H, d, 7 8.6 Hz, H-5).
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l,6-Bis-(3,4-dihydroxyphenyl)hexane (156)
HO 4
OH
OH
The general procedure of McOmie et was used on a 0.70 mmol scale, as 
outlined for compound (149), to give the diarylhexane (156) from EtOAc-hexane (200 
mg, 94.8 %), m.p. 131-133 °C (lit.,97 132-133 °C).
New data: Vmax. (KBr)/cm'l, 3452 and 3398 (OH); 6h (d^-Acet) 1.15-1.23 (2H, m, 
CH2), 1.34-1.44 (2H, m, 0 % ) , 2.31 (2H, t, 77.2 Hz, H-7), 6.37 (IH, dd, J  8.0 Hz and
2.0 Hz, H-6), 6.54 (2H, d, 7 2.0 Hz, H-2), 6.57 (2H, d, 7 8.0 Hz, H-5), 7.46 (4H, bs, 
OH); ÔC (dg-Acet) 29.7 (C-9), 32.5 (C-8), 35.8 (C-7), 115.8 and 116.2 (C-2 and C-5),
120.3 (C-6), 135.2 (C-1), 143.7 and 145.8 (C-3 and C-4); (Found: C 71.65; H 7.38 %; 
M + \ 302.1520. C18H22O4 requires C 71.52; H 7.28 %; M, 302.1518).
l,7-Bis-(3,4-dimethoxyphenyl)heptan-l,7-dione (157)
MeO 4
OMe
OMe
The method of Fliedner et was adopted using dry CHCI3 on a 3.62 mmol 
scale affording diketone (157) as crystals (282 mg, 39.0 %), m.p. 90-92 °C (lit.,^^ 91- 
93 °C); ÔH 1.18-1.88 (6H, m, 3 x CH2 ), 2.96 (4H, t, 7 7.1 Hz, H-8), 3.94 (6H, s, 
OCH3), 3.95 (6H, s, OCH3), 6.89 (2H, d, 7 8.4 Hz, H-5), 7.55 (2H, dd, 7 7.4 Hz and
2.0 Hz, H-6), 7.61 (2H, d, 7 2.0 Hz, H-2).
l,7-Bis-(3,4-dimethoxyplienyI)heptane (158)
MeO OMe
OMe
Palladium on charcoal (10%, 50 mg) was added to a stirring solution of 
diketone (158) in MeOH (75 ml) and the mixture stirred under a hydrogen balloon 
overnight. The resultant mixture was filtered through Celite® and the residue washed 
with MeOH (2 x 25 ml). The combined organics were concentrated in vacuo to give an 
oil which was crystallised from aqueous MeOH affording the diaryIheptane (158) as 
crystals (179 mg, 76.8%), m.p. 52-53 °C (lit.,1^^ 56 °C).
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l,7-Bis-(3,4-dihydroxyphenyl)heptane (159)
H o^ ^  ^  ^  ^  ^  ^  .on
HO 4 ^  ^  OH
The general procedure of McOmie et was used on a 0.44 mmol scale, as 
outlined for compound (149), affording the phenolic diarylheptane (159) from PhCHg 
as a cream powder (58 mg, 41.7%), m.p. 100-102 °C (lit., 105 iq6 °C).
New data : Vmax (KBr)/cm'l 3399 (OH), 1613, 1601 and 1515 (aromatic); 5h  1.20-
1.22 (6H, m, H-9 and H-10), 1.40-1.46 (4H, m, H-8), 2.33 (4H, t, /7 .8  Hz, H-7), 4.79 
(4H, s, OH), 6,35 (2H, dd, J  8.0Hz and 2.1 Hz, H-6), 6.49 (2H, d, J  2.0 Hz, H-2), 6.55 
(2H, d, J  8.0 Hz, H-5); 6c  30.2, 30.5 and 32.9 (C-8, C-9 and C-10), 36.3 (C-7), 116.2 
and 116,5 (C-2 and C-5), 120.6 (C-6), 135.7 (C-1), 144.0 and 146.0 (C-3 and C-4); 
(Found: C 72.12%; H 7.60%; M+*, 316.1661. C 19H24O4 requires C 72.15%; H 
7.59%; M, 316.1674).
l,4-Bis-(3,4-dimethoxybenzoyl)benzeiie (161)
MeO 4
OMe
OMe
To a stirring suspension of aluminium chloride (0.72g, 5.43 mmol) in dry 
CHCI3 (25 ml) was added veratrole (0.50g, 0.46 ml, 3.62 mmol) dropwise at 0 ^C 
followed by terephthaloyl chloride (0.37g, 1.81 mmol) via solid addition funnel at the 
same temperature. The mixture was allowed to warm to rt stirred for a further 1 h then 
heated at reflux for 4 h whereupon a brown solid separated. The mixture was allowed 
to cool to rt then poured cautiously into acidified iced-water and extra CHCI3 added to 
ensure two clear layers. The aqueous layer was extracted with CHCI3 (2 x 20 ml) and 
the combined organics washed successively with water (2 x 20 ml), saturated NaHCOg 
(2 X 20 ml) and brine (1 x 10 ml) before drying over MgSOq.. Concentration in vacuo 
afforded a yellow solid which was recrystallised from glacial AcOH affording the 
diketone (161) as lemon coloured crystals (0.405g, 55.1%), m.p. 187-188 °C (lit.,1^6
193.5-194.5 °C).
New data : Vmax (KBr)/cm-l 1647 (C=0), 1595, 1581 and 1510 (Ar); 5 h  3.97 (6H, s, 
OCH3), 3.98 (6H, s, OCH3), 6.92 (2H, d, J  8.4 Hz. H-6), 7.40 (2H, dd, J  8,3 Hz and
2.0 Hz, H-5), 7.56 (2H, d, J  2.0 Hz, H-3), 7.85 (4H, s, H-9); 5 c  56.7 and 56.8 
(OCH3), 110.5 and 112.6 (C-2 and C-5), 126.4 (C-6), 130.0 (C-9), 130,3 (C-1), 141.7
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(C-8), 149.9 and 154.1 (C-3 and C-4), 195.6 (C-7); (Found: M+% 406.1417. 
C24H22O6 requires M, 406.1416).
l,4-Bis-(3,4-dihydroxybenzyI)benzene (162)
HO 4
Palladium on charcoal (10%, 50 mg) was added to a stirring solution of the 
diketone (161) (200 mg, 0.49 mmol) in THF (50 ml) and the mixture stiired under a 
hydrogen balloon at rt for 72 h. The mixture was filtered through Celite® and the 
residue washed with EtOAc. Concentration in vacuo afforded a yellow oil which was 
taken up in dry DCM (10 ml) and treated dropwise with boron tribromide (2.12 ml, 
IM in DCM, 2.12 mmol) at -78 °C. The orange solution was allowed to warm to rt 
and stirred for 1 h before being poured cautiously into iced-water. The resultant 
mixture was extracted into EtOAc (50 ml), the aqueous layer further extracted with 
EtOAc (2 xlO ml) and the combined organic extracts washed with brine (10 ml) before 
drying over MgSOq. Concentration in vacuo afforded a beige solid which was 
recrystallised from PI1CH3 to give (162) as an cream powder (103 mg, 64.8% from X), 
m.p. 209-211 °C (lit.,106 212-214 ^C).
New data : Vmax (KBr)/cm-l 3462 and 3314 (OH), 1624, 1597 and 1518 (Ar); ÔH 
4.83 (4H, s, OH), 6.39 (2H, dd, J  8.0 Hz and 1.9 Hz, H-5), 6.46 (2H, d, /  1.9 Hz, H-3), 
6.55 (2H, d, J  8.0 Hz, H-6), 6.95 (4H, s, CH2); 6c  41.8 (C-7), 116.2 and 117.0 (C-3 
and C-6), 121.1 (C-5), 129.8 (C-9), 134.5 and 140.7 (C-4 and C-8), 144.4 and 146.1 
(C-1 and C-2); (Found: M+*, 322.1212. C20H 18O4 requires M, 322.1205).
4-Methoxybenzyl triphenylphosphonium bromide (164)
PPh.Br
MeO 4
A solution of j9-anisaldehyde (300 mg, 0.27 mmol, 2.20 mmol) in dry THF (2 
ml) was added dropwise to a stirring slurry of L1A1H4 (125 mg, 3.31 mmol) and dry 
THF (10 ml) at 0 °C. After the addition complete, the mixture was allowed to warm to 
rt and stirred for a further 16 h before being quenched by the cautious addition of 
moist ether at 0 °C. The solids were filtered through Celite® and the residue washed 
with EtOAc ( 2 x 1 0  ml). The combined organic extracts were washed with water (20 
ml) and brine (20 ml) before drying over MgS04. Concentration in vacuo afforded a 
yellow oil which was taken up in dry CH3CN (10 ml) and heated at reflux in the
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presence of triphenylphosphine hydrobromide (793 mg, 2.31 mmol) for 20 h. After 
cooling to rt, the mixture was concentrated giving a white foam which was 
recrystallised from i-PrOH affording the title compound (164) as a powder (790 mg, 
77.6%), m.p. 227-228 °C (lit.,*07 236-238 °C); Vmax (KBr)/cm-l 1606, 1585 and 
1511 (Ar); Sh 3.72 (3H, s, OCH3), 5.26 (2H, d, 7h-P 13.7 Hz, H-5), 6.64 (2H, d, J  8.5 
Hz, H-3), 7.01 (2H, dd, J  8.5 Hz and 2.1 Hz, H-2), 7.61-7.79 (15H, m, Ph-H); 5 c  30.5 
(d, /c-p 46.4 Hz, C-5), 55.6 (OCH3), 114.6 (d, J  3.0 Hz, CH), 118.2 (d, J  84.8 Hz, C),
118.8 (d, J  8.6 Hz, C), 130.5 (d, J  12.5 Hz, CH), 133.0 (d, J  5.5 Hz, CH), 134.7 (d, J
9.6 Hz, CH), 135.4 (d, J 2.5 Hz, CH), 160.0 (d, J  3.7 Hz, C); 8p (81 Hz) 22.4 (Found: 
M+* (-HBr), 382.1485. C26H24BrOP requires M (-HBr), 382.1487).
3-(4-m ethoxyphenyl)propionaldehyde (166)
MeO 4
The method of Semmelhack et was modified as follows. A solution of 3- 
(4~methoxyphenyl)propionic acid (l.OOg, 5.55 mmol) in dry THF (5 ml) was 
introduced dropwise to a stirring slurry of LiAIH4 (0.32 g, 8.32 mmol) and dry THF 
(25 ml) at 0 °C. After the addition complete, the mixture was allowed to warm to rt and 
stirred for a further 20 h before being quenched by the cautious addition of moist ether 
at 0 °C. The solids were removed thi'ough Celite®, the residue washed with EtOAc (2 x 
10 ml) and the combined organics washed with brine (20 ml) before drying over 
MgS04. Concentration in vacuo afforded a pale yellow oil (0.85 g, 5.13 mmol) which 
was taken up in dry DCM (6 ml) and added dropwise at 0 °C to a stirring slurry of 
freshly prepared PDC^^^ (2.51 g, 6.67 imnol) and dry DCM (25 ml). The mixture was 
allowed to warm to rt and stirred for a further 19 h before filtering through a silica plug 
eluting with EtOAc. The organics were washed with brine (2 x 15 ml), dried over 
MgS0 4  and concentrated in vacuo to give a brown oil which was subjected to column 
chromatography affording aldehyde (166) as a light yellow oil (0.37 g, 40.7%), Vmax 
(neat)/cm-l 1732 (CHO), 1612, 1584 and 1517 (Ar); 5 h  2.74 (2H, t, 77.8 Hz, H-5 or 
H-6), 2.90 (2H, t, J  7.5 Hz, H-5 or H-6), 3.78 (3H, s, OCH3), 6.83 (2H, d, /  8.4 Hz, H-
3), 7.11 (2H, d, J  8.4 Hz, H-2), 9.80 (IH, t, J  1.6 Hz, CHO); 5 c  27.7 (C-5), 45.9 (C-6),
55.6 (OCH3 ), 114.4 (C-3), 129.6 (C-2), 132.7 (C-1), 158.5 (C-4), 202.2 (C-7); 
(Found: M"^ *, 164.0839. C10H 12O2 requires M, 164.0837),
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l,4-Bis-(4-methoxyphenyl)but-l-ene (167)
2 5
MeO 4
OMe
M-BuLi (LOO ml, L6M in hexanes, 1.60 mmol) was added dropwise at 0 °C to 
a stirring suspension of the phosphonium salt (164) (672 mg, 1.45 mmol) and dry 
THF (15 ml). After stirring for a further 10 min, aldehyde (166) (238 mg, 1.45 mmol) 
in dry THF (3 ml) was introduced dropwise to the blood red homogeneous solution 
and the mixture stirred for 30 min at 0 °C then allowed to warm to rt. After stirring for 
1 h at rt, the light orange reaction mixture was poured into iced-water (50 ml) and 
extracted into EtOAc (2 x 25 ml). The combined organic extracts were washed with 
brine (20 ml), dried over MgS04 and concentrated in vacuo giving a cream solid which 
was recrystallised from MeOH affording the pure (E)-isomer (167) as shiny plates 
(175 mg, 45.0%), m.p. 110-112 °C; Vmax (KBr)/cm"l 1607 and 1511 (C=C), 828 and 
849 (p<3ra-disubstituted benzene); ÔH 2.44-2.50 (2H, m, H-7), 2.72 (2H, t, J  7.3 Hz, 
H-8), 3.79 (3H, s, OCH3), 3.79 (3H, s, OCH3), 6.10 (IH, dt, J  15.8 Hz and 6.8 Hz, H-
6), 6.35 (IH, d, J  15.8 Hz, H-5), 6.83 and 6.84 (4H, 2 x d, J  8.8 Hz, H-3 and H-11),
7,13 (2H, d, J  8.4 Hz, H-2 or H-10), 7.26 (2H, d, J 8.8 Hz, H-2 or H-10); ôc  35.5 (C-
7), 35.5 (C-8), 55.6 (0CH3), 55.7 (0CH3), 114.1 and 114.3 (C-3 and C-11), 127.4, 
128.3, 129.7 and 130.0 (C-2, C-5, C-6 and C-10), 131.0 and 134.4 (C-1 and C-9),
158.2 and 159.1 (C-4 and C-12); (Found; M+*, 268.1463. C18H20O2 requires M, 
268.1463). The mother liquors were concentrated and subjected to silica gel column 
chromatography eluting with hexane-ether (3:1) affording an oil (116 mg, 29.8%, Z\E 
= 12:1). (Z)-isomer : Vmax (neat)/cm“l 1608 and 1513 (C=C), 839 (pa/'fl-disubstituted 
benzene); ÔH 2.58-2.64 (2H, m, H-7), 2.68-2.72 (2H, m, H-8), 3.77 (3H, s, OCH3),
3.79 (3H, s, OCH3), 5.59 (IH, dt, 711.6 Hz and 6.8 Hz, H-6), 6.36 (IH, d, 711.6 Hz, 
H-5), 6.81-6.85 (4H, m, H-3 and H-11), 7.10 (2H, d, 7 8.4 Hz, H-2 or H-10), 7.18 (2H, 
d, 7 8.4 Hz, H-2 or H-10); ÔC 31.1 and 35.6 (C-7 and C-8), 55.6 (OCH3), 55.6 
(OCH3), 114.0 and 114.2 (C-3 and C-11), 129.1, 129.7, 130.3 and 130.7 (C-2, C-5, C- 
6 and C-10), 134.3 (C-1 and C-9), 158.2 and 158.6 (C-4 and C-12); (Found: M+", 
268.1461. C 18H20O2 requires M, 268.1464).
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l,4-Bis-(4-methoxyphenyl)butane (169)
MeO 4
^ 1 ^
OM e
Method 1 : Palladium on charcoal (10%, 50 mg) was added to a solution of the 
(E)-alkene (167) (125 mg, 0.47 mmol) in MeOH-EtOAc (2:1, 30 ml) and the mixture 
stirred under a hydrogen balloon for 21 h at rt. The catalyst was filtered through 
Celite®, washed with EtOAc (2 x5  ml) and the mixture concentrated in vacuo to give a 
solid which was recrystallised from aq.MeOH affording the title compound as shiny 
plates (82 mg, 65.1%), m.p. 77-78 °C (lit.,"! 78-79 °C); Vmax (KBr)/cm-l 1611,1582 
and 1513 (Ar); 8 r  1.59-1.63 (2H, m, H-6 ), 2.55-2.56 (2H, m, H-5), 3.78 (3H, s, 
OCH3 ), 6.81 (2H, d, J  8.4 Hz, H-3), 7.07 (2H, d, J  8.4 Hz, H-2); 8 c  31.7 and 35.3 (C- 
5 and C-6 ), 55.6 (OCH3 ), 114.1 (C-3), 129.6 (C-2), 135.1 (C-1), 158.0 (C-4); (Found; 
M+", 270.1619. C18H2 2 O2 M, 270.1620).
Method 2 : Palladium on charcoal (10%, 25 mg) was added to a solution of the 
alkene (168) (Z:E = 12:1, 100 mg, 0.37 mmol) in MeOH-EtOAc (2:1, 15 ml) and the 
mixture stirred under a hydrogen balloon for 16 h at rt. The catalyst was filtered 
through Celite®, washed with EtOAc ( 2 x 5  ml) and concentrated in vacuo to give a 
white solid. Recrystallisation from aq.MeOH afforded the title compound as shiny 
crystals (65 mg, 64.5%) giving a m.p. and NMR spectrum identical with those 
reported in method 1.
l,4-Bis-(4-hydroxyphenyI)butane (170)
HO 4
OH
The general procedure of McOmie et al.^^ was used on a 0.22 mmol scale, as 
outlined for compound (149), affording the diarylbutane (170) as fawn crystals from 
ether-hexane (39 mg, 72.4%), m.p. 153-155 °C (lit.,m  158-159 °C); Vmax (KBr)/cm' 
1 1614 and 1512 (Ar), 816 (pa/'a-disubstituted benzene); ÔH (d^-DMSO) 1.49 (2H, 
bs, H-6), 2.46 (2H, bs, H-5), 6.65 (2H, d, J  8.4 Hz, H-3), 6.94 (2H, d, J  8.4 Hz, H-2),
9.09 (IH, bs, OH); ÔC (d^-DMSO) 31.2 and 34.5 (C-5 and C-6), 115.3 (C-3), 129.4
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(C-2), 132.6 (C-1), 155.5 (C-4); (Found: M+% 242.1307. C 16H 18O2 requires M, 
242.1307).
l,5-Bis-(4-methoxypheiiyl)penta-l,4"dien-3-one (173)
M eO 4 O M e
The method for the synthesis of ketone (150) was followed employing 
anisaldehyde (1.63 g, 1.46 ml, 12.00 mmol), acetone (0.32 g, 0.40 ml, 5.52 mmol) and 
10% NaOH (1.00 ml). The unsaturated ketone (173) was isolated as bright yellow 
feathers from EtOH (1.14 g, 70.4%), m.p. 128-130 (lit.,113 136-138 °C); ô h  3.84 
(3H, s, OCH3), 6.92 (4H, d, J  8.6 Hz, H-3), 6.95 (2H, d, J  15.7 Hz, H-6), 7.56 (4H, d, J
8.7 Hz, H-2), 7.69 (2H, d, J  15.8 Hz, H-5).
l,5-Bis-(4-methoxyphenyl)pentan-3-one (174)
M eO  4 OM e
Palladium on charcoal (10%, 50 mg) was added to a stirring solution of the 
unsaturated ketone (173) (1.00 g, 3.40 mmol) in EtOAc (30 ml) and the mixture stirred 
under a hydrogen balloon at rt for 1 h. The resultant colourless solution was filtered 
through Celite® and the residue washed with EtOAc (2 x 10 ml). The combined 
organics were concentrated in vacuo to give a colourless oil which crystallised on 
scratching. Recrystallisation from MeOH afforded the title compound (174) as fine 
needles (0.69 g, 68.2%), m.p. 52-54 °C ( li t ., '"  55.0-55.2 °C); Vmax (KBr)/cm-l 1687 
(C=0); 8h  2.66 (2H, t, 7 7.6 Hz, H-5 or H-6), 2.82 (2H, t, J  7.6 Hz, H-5 or H-6), 3.77 
(3H, s, OCH3), 6.80 (2H, d, J  8.5 Hz, H-3), 7.06 (2H, d, J  8.5 Hz, H-2); 5 c  29.3 and
45.2 (C-5 and C-6), 55.6 (OCH3), 114.3 (C-3), 129.6 (C-2), 133.5 (C-1), 158.3 (C-4),
209.9 (C-7).
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l,5-Bis-(4-methoxyphenyl)pentane
M eO  4 OM e
A mixture of the saturated ketone (174) (500 mg, 1.68 mmol), powdered KOH 
(248 mg, 4.42 mmol) and hydrazine hydrate (175 mg, 0.17 ml, 3.50 mmol) was heated 
in diethylene glycol (6 ml) at 175 °C for 4 h under N2 - After cooling to rt the mixture 
was poured into water (40 ml), the resultant suspension extracted into Et2Ü (2 x 20 ml) 
and the combined organics washed with brine (20 ml) before drying over MgS04. 
Concentration in vacuo gave a cloudy oil that was purified by dry flash column 
chromatography eluting with ether-hexane (1:1) affording the diarylpentane as a 
colourless oil (167 mg, 35.0%); ÔH 1.32-1.39 (2H, m, H-7), 1.56-1.64 (4H, m, H-6), 
2.53 (4H, t, 77,6 Hz, H-5), 3.77 (6H, s, OCH3), 6.81 (4H, d, /  8.6 Hz, H-3), 7.07 (4H, 
d, J  8.6 Hz, H-2); ÔC 29.3 (C-7), 32.1 (C-6), 35.4 (C-5), 55.6 (OCH3), 114.1 (C-3),
129.7 (C-2), 135.3 (C-1), 158.0 (C-4).
l,5-Bis-(4-hydroxyphenyl)pentane (175)
HO 4  ^  OH
The general procedure of McOmie et al.^^ was used on a 0.59 mmol scale, as 
outlined for compound (149), affording the title compound (175) as an off-white solid 
from PhCHs (104 mg, 69%), m.p. 100-103 “C ( l i t . , " '  104-105 °C); Vmax (KBr)/cnrl 
3539 (OH), 1612, 1598 and 1514 (Ar); 5 h  (dg-DMSO) 1.22-1.30 (2H, m, H-7), 1.51 
(4H, qt, /7 .6  Hz, H-6), 2.43 (4H, t, J  8.0 Hz, H-5), 6.65 (4H, d, J  8.4 Hz, H-3), 6.94 
(4H, d, J 8.3 Hz, H-2), 9.08 (2H, bs, OH); 8c  (dg-DMSO) 28.5 (C-7), 31.5 and 34.6 
(C-5 and C-6), 115.3 (C-3), 129.4 (C-2), 132.7 (C-1), 155.5 (C-1); (Found: (M4-H)+'. 
257.1540. C 17H20O2 requires (M+H), 257.1541).
l,6-Bis-(4-methoxyphenyl)hexaii-l,6-dione (176)
M eO  4
OM e
The method of Fliender et alP^ was adopted using anisole (744 mg, 0.75 ml, 
6.88 mmol), AICI3 (1.01 g, 7.58 mmol) and freshly distilled adipoyl dichloride (567
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mg, 0,45 ml, 3.10 mmol) in dry CHCI3 (15 ml). The 1,6-diketone (176) was isolated as 
a solid from MeOH (0.92 g, 91.0%), m.p. 143-144 °C (lit.,94 144-146 °C {EtOAc}); 
5 h  1.74-1.89 (2H, m, H-7), 2.95-3.01 (2H, m, H-6), 3.86 (3H, s, OCH3), 6.93 (2H, d, 
J  8.9 Hz, H-3), 7.94 (2H, d, J  8.9 Hz, H-2); 5 c  24.6 (C-7), 38.5 (C-6), 55.8 (OCH3),
114.1 (C-3), 130.5 and 130.7 (C-1 and C-2), 163.8 (C-4), 199.1 (C-5).
l,6-Bis-(4-methoxyphenyI)hexane (177)
M eO  4
OM e
To a stirring solution of the 1,6-diketone (176) (350 mg, 1.07 mmol) in glacial 
AcOH (50 ml) was added palladium on charcoal (10 %, 100 mg) and the mixture 
stirred under a hydrogen balloon overnight at rt. The catalyst was filtered through 
Celite®, washed with AcOH (2 x 10 ml) and the mixture concentrated. The resultant 
yellow solid (424 mg) was recrystallised from EtOH affording the diarylhexane (177) 
as plates (242 mg, 66%), m.p. 66-69 °C (lit.,1^^ 64.5-65.5 °C); Vmax (KBr)/cm"l 1611 
and 1511 (Ar); ÔH 1.32-1.57 (8H, m, 4 x CH2), 2.53 (4H, t, J7 .9  Hz, H-5), 3.78 (6H, 
s, OCH3), 6.82 (4H, d, J  8.7 Hz, H-3), 7.08 (4H, d, J  8.6 Hz, H-2); (Found : M+’, 
298.1935. C20H26O2 requires M, 298.1932).
l,6-Bis-(4-hydroxyphenyl)hexane (178)
no 4
OH
The general method of McOmie et was used on a 0.67 mmol scale, as 
outlined for compound (149) using BBrg (2.01 ml, IM in DCM, 2.01 mmol), 
affording the diarylhexane (178) from PI1CH3 as an amorphous solid (153 mg, 
84.5%), m.p. 143-144 °C (lit.,lH 144.5-145.5 °C).
New data : Vmax (KBr)/cm~l 3402 (OH), 1512, 1599 and 1613 (aromatic); ÔH 
(CD3OD) 1.22-1.25 (4H, m, H-7), 1.44 (4H, m, H-6), 2.38 (4H, t, 77.2 Hz, H-5), 4.83 
(2H, s, OH), 6.57 (4H, d, J  8.4 Hz, H-3), 6.86 (4H, d, J  8.4 Hz, H-2); ÔC (db-Acet)
29.7 and 32.6 (C-6 and C-7), 35.5 (C-5), 115.8 (C-3), 130.0 (C-2), 134.1 (C-1), 156.1 
(C-4); (Found : M +', 270.1621. C18H22O2 requires M, 270.1620).
146
A'^ -(3,4“dimethoxybenzyI)-3%4^-dimethoxyphenyl acetamide (181)
MeO.
'2 OM e
OM e
EDCI (0.25g, 1.33 mmol) was added in one portion to a stirring solution of
3,4-dimethoxybenzylamine (0.20g, 0.18 ml, 1.20 mmol), 3,4-dimethoxyphenylacetic 
acid (0.26g, 1.33 mmol) and DMAP (16 mg, 0.13 mmol) in dry DCM (10 ml) at rt. 
After stirring for 18 h, H2O (10 ml) was added and the layers separated. The organic 
extracts were washed successively with 5 % NaHCOs (5 ml), 5 % citric acid (5 ml) 
and brine (5 ml) before drying over M gS04. Concentration in vacuo gave a light 
yellow solid (339 mg) which was recrystallised from MeOH affording amide (181) as 
fine white needles (0.24 g, 59 %), m.p. 133-135 ‘^ C (lit.,114 127-129 °C {EtOAc})
New data : Vmax (KBr)/cm"l 3310 (NH), 1639 (amide); ÔH 3.56 (2H, s, H-7), 3.81 
(3H, s, OCH3), 3.85 (6H, s, 2 x OCH3), 3.86 (3H, s, OCH3), 4.34 (2H, d, J  5.8 Hz, H-
9), 5.79 (IH, um, NH), 6.71-6.83 (6H, m, Ar-H); ÔC 43.7 (CH2), 43.8 (CH2), 56.2 
(CH3), 56.3 (CH3), 111.2 (CH), 111.4 (CH), 111.8 (CH), 112.7 (CH), 120.1 (CH),
121.9 (CH), 127.6 (C), 131.1 (C), 148.7 (C), 149.4 (C), 149.6 (C), 171.5 (C); (M +\ 
345.1579. C 19H23NO5 requires M, 345.1577).
A-(3,4-dihydroxybenzyl)-3’,4’-dihydroxyplienyl acetamide (182)
HO.
OH
A solution of amide (181) (150 mg, 0.43 mmol) in dry DCM (2 ml) was added 
dropwise to a stimng solution of boron tribromide (2.83 ml, IM in DCM, 2.83 mmol) 
in dry DCM (10 ml) at -78°C. The mixture was allowed to warm to rt, stirred for a 
further 1 h then quenched by pouring into iced-water (20 ml). The resultant mixture 
was extracted with EtOAc (1 x 35 ml and 1x10  ml) and the combined organic extracts 
washed with brine (20 ml) before drying over MgSOq. Concentration in vacuo gave a 
light yellow sticky oil (66 mg) which was crystallised from acetone-ether-hexane 
affording the phenolic amide (182) as a light brown solid (29 mg, 23%), m.p. 179-182 
°C; Vmax (KBr)/cm-l 3450 (OH), 1600 (amide); 5h  (dg-DMSO) 3.23 (2H, s, H-7),
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4.05 (2H, d, J  5.6 Hz, H-9), 6.46-6.50 (2H, m, Ar-H), 6.61-6.67 (4H, m, Ar-H), 8.24 
(IH, m, NH), 8.69 (IH, s, OH), 8.76 (IH, s, OH), 8.80 (IH, s, OH), 8.85 (IH, s, OH); 
ÔC (d6-DMSO) 42.1 and 42.3 (C-7 and C-9), 115.3 (CH), 115.6 (CH), 116.8 (CH),
118.6 (CH), 120.1 (CH), 127.5 and 130.6 (C-1 and C-10), 144.1, 144.5, 145.2 and
145.4 (C-3, C-4, C-12 and C-13), 170.7 (C-8); (Found: M+*, 289.0952. C 15H 15NO5 
requires M, 289.0950).
A^-(3,4-dimethoxyplienyl)-3-(3%4’-(limethoxyplienyl)propanam ide (185)
M eO . N.
1
â
MeO"
O M e
EDCI (274 mg, 1.43 mmol) was added in one portion to a stirring solution of
3,4-dimethoxyaniline (200 mg, 1.31 mmol), DMAP (20 mg, 0.16 mmol) and 3-(3,4- 
dimethoxyphenyl)propionic acid (300 mg, 1.43 mmol) in dry DCM (15 ml) at rt. After 
stirring for 16 h, the mixture was washed successively with saturated NaHC0 3  (10 
ml), 5% citric acid (10 ml) and brine (10 ml) before drying over M gS04. 
Concentration in vacuo gave a mauve coloured solid (372 mg) which was recrystallised 
from MeOH affording the title compound (185) as fine pale pink needles (244 mg, 
54 .0%), m.p. 116-118 “C; Vmax (KBr)/cm-l 3294 (NH), 1655 (amide); ÔH 2.69 (2H, 
t, J 7.6 Hz, H-9), 3.07 (2H, t, J 7.6 Hz, H-8), 3.90 (3H, s, OCH3), 3.92 and 3.93 (9H, 2 
X s, 3 X OCH3), 6.83-6.89 (5H, m, Ai'-H), 7.36 (IH, d, ]  1.6 Hz, H-11); Sc 31.7 (C-9),
40.2 (C-8), 56.2, 56.3 and 56.4 (OCH3), 105.2 (CH), 111.5 (CH), 111.7 (CH), 112.1 
(CH), 112.2 (CH), 120.6 (CH), 131.8 and 133.7 (C-1 and C-10), 146.1, 147.9 and
149.3 (C-3, C-4, C-12 and C-13), 170.8 (C-7); (Found; M+', 345.1575. C19H23NO5 
requires M, 345.1576).
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iV-(3,4-dihydroxyphenyl)-3-(3’,4’-diliydroxyphenyl)propanamide (186)
HO. N.
1
6
HO'
O H
Boron tribromide (2.83 ml, IM in DCM, 2.83 mmol) was introduced dropwise 
to a stirring solution of amide (185) (150 mg, 0.43 mmol) in dry DCM (15 ml) at -78 
°C. The light orange solution was allowed to warm to 0 °C and stirred for a further 30 
min before pouring into iced-H20 (20 ml). The resultant suspension was extracted 
with EtOAc (45 ml) and the organic extracts washed with brine (20 ml) before drying 
over MgS04. Concentration in vacuo gave a fawn coloured solid (81 mg) which was 
recrystallised from acetone-CHClg affording the phenolic amide (186) as an off-white 
solid (57 mg, 45.2%), m.p. 193-195 °C; Vmax (KBr)/cm-l 3429 (OH), 1636 (amide); 
8h  2.44 (3H, t, 77.2 Hz, H-9), 2.69 (2H, t, 77.2 Hz, H-8), 6.46 (IH, d, 77.6 Hz, H-5), 
6.60-6.62 (3H, m, Ar-H), 6.75 (IH, dd, J  8.4 Hz and 1.6 Hz, H-6), 7.13 (IH, d, J 2.0 
Hz, H-11), 8.56 (IH, s, OH), 8.64 (IH, s, OH), 8.73 (IH, s, OH), 8.92 (IH, s, OH), 
9.51 (IH, s, NH); 5 c  30.8 (C-9), 38.7 (C-8), 108.2 (CH), 110.6 (CH), 115.5 (CH),
115.7 (CH), 116.0 (CH), 119.1 (CH), 131.7 and 132.5 (C-1 and C-10), 141.4, 143.6,
145.2 and 145.3 (C-3, C-4, C-12 and C-13), 170.1 (C-7); (Found; M+’, 289.0950. 
C15H 15NO5 requires M, 289,0951).
/7-[2-(3,4-dimethoxypheiiyl)ethyl]-3%4’-dimethoxybenzamide (189)
M eO .
7 N H
O M e
EDCI (0.23 g, 1.21 mmol) was added in one portion to a stirring solution of 2- 
(3,4-dimethoxyphenyl)ethyl amine (0.2 g, 0.18 ml, 1.10 mmol), 3,4-dimethoxybenzoic 
acid (0.22 g, 1.21 mmol) and DMAP (15 mg, 0.12 mmol) in dry DCM (15 ml) at rt. 
Stirring was continued for a further 16 h then the mixture transferred to a separating 
funnel and washed successively with saturated NaHCOg (10 ml), 5 % citric acid (10 
ml), and brine (10 ml) before drying over MgSOq. Concentration in vacuo gave a 
cream solid which was recrystallised from i-PrOH affording the title compound (189)
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as a flaky solid (0.25 g, 65,8%), m.p. 139-140 °C (lit.,115 140-142 °C {DCM-ether}); 
Vmax (KBr)/cm-l 3296 (NH), 1629 (amide); ÔH 2.88 (2H, t, J 6.9 Hz, H-9), 3.66-3.71 
(2H, m, H-8), 3.84 (3H, s, OCH3), 3.87 (3H, s, OCH3), 3.91 (3H, s, OCH3), 3.92 (3H, 
s, OCH3), 6.09 (IH, bs, NH), 6.75-6.84 (4H, m, Ar-H), 7.15 (IH, dd, J  8.4 Hz and 2.0 
Hz, H-6), 7.39 (IH, d, J  2.0 Hz, H-2).
New data : 5 c  35.7 and 41.7 (C-8 and C-9), 56.2, 56.3 and 56.4 (OCH3), 110.6 (CH), 
110.9 (CH), 111.7 (CH), 112.3 (CH), 119.5 (CH), 121.1 (CH), 127.6 and 131.9 (C-1 
and C-10), 148.1, 149.3, 149.4 and 152.0 (C-3, C-4, C-12 and C-13), 167.5 (C-7); 
(Found M+*, 345.1575. C 19H23NO5 requires M, 345.1576).
A-[2-(3,4-dihydroxypheiiyl)ethyI]-3’,4’-dihydroxybenzamide (190)
H O .
s'
10,
15
14
O H
O H
Boron tribromide déméthylation was used on a 0.36 mmol scale, as outlined for 
compound (149), affording the crude amide (190) as a tan coloured foam (100 mg) 
that could not be recrystallised from a variety of solvents. Column chromatography 
(silica, 2:1 EtOAc-acetone + 2% AcOH) gave a tan coloured solid (39 mg) which was 
not pure enough for testing as shown by ^H NMR spectroscopy.
A"Methyl"(3,4-dimethoxyphenyl)benzylamme (192)
M eO ,
M eO
Methylamine (0.82 ml, 8.03M in EtOH, 6.62 mmol) was added dropwise to a 
stirring solution of 3,4-dimethoxybenzaldehyde (1.00 g, 6.02 mmol) in dry EtOH (10 
ml) at rt. After heating at reflux for 26 h, the resultant yellow solution was concentrated 
in vacuo to give a yellow syrup which solidified on standing, 5 h  3.50 (3H, d, 7 1.5 Hz, 
NMe), 3.92 (OCH3), 3.94 (OCH3), 6.88 (IH, d, J  8.2 Hz, Ar-H), 7.12 (IH, dd, J  8.2 
Hz and 1.8 Hz, Ar-H), 7.41 (IH, d, J  1.8 Hz, Ar-H), 8.20 (IH, s, ArCH). The resultant 
solid was taken up in MeOH (20 ml) and hydrogenated over palladium on charcoal 
(10%, 100 mg) at an initial pressure of 60 p.s.i. for 24 h. The mixture was filtered 
tlirough Celite®, the residue washed with MeOH (2 x 10 ml) and concentrated to give 
the amine (192) as a colourless oil (798 mg, 73.2%) b.p. 92-98 °C / 0.22 mmHg; Vmax
150
(neat)/cm"i 3325 (NH), 1607, 1592 and 1515 (aromatic); 6h  1.51 (IH, bs, NH), 2.46 
(3H, s, H-9), 3.69 (2H, s, H-7), 3.87 (3H, s, OCH3), 3.89 (3H, s, 0CH3), 6.80-6.89 
(3H, m, Ar-H); 5 c  36.1 (C-9), 55.8 (OCH3), 55.9 (OCH3), 56.0 (C-7), 110.9 and
111.3 (C-2 and C-5), 120.2 (C-6), 132.9 (C-1), 148.0 and 148.9 (C-3 and C-4); 
(Found M+*, 181.1101. C 10H 15NO2 requires M, 181.1103).
A-Methyl-A-(3,4-dimethoxybenzyl)-3,4-dimetlioxyphenylacetamide
(193)
M eO .
M eO
O M e
O M e
EDCI (247 mg, 1.29 mmol) was added in one portion to a stirring solution of 
amine (192) (213 mg, 1.18 mmol), 3,4-dimethoxyphenylacetic acid (254 mg, 1.29 
mmol) and DMAP (16 mg, 0.13 mmol) in dry DCM (15 ml) at rt. After stirring for 18 
h, the mixture was washed successively with saturated NaHC03 (10 ml), 5% citric acid 
(10 ml) and brine (10 ml) before drying over MgS04. Concentration in vacuo gave a 
light yellow oil which was crystallised from acetone-Et20 affording amide (193) as 
shiny crystals (293 mg, 69.2%), m.p. 87-90 °C; Vmax (KBr)/cm"l 1631 (amide), 1590 
and 1515 (aromatic); 5 h  2.91 (3H, s, H-8), 3.72 and 3.73 (H-10), 3.76, 3.79, 3.85,
3.86 and 3.87 (12H, OCH3), 4.50 and 4.54 (2H, 2 x s, H-7), 6.45-6.87 (6H, m, Ar-H); 
5 c  34.0 and 35.5 (C-8), 40.9 and 41.2 (C-10), 51.0 and 53.8 (C-7), 56.2 and 56.3 
(OCH3), 109.8 (CH), 111.2 (CH), 111.6 (CH), 112.1 (CH), 119.2 (CH), 120.8 (CH),
121.2 (CH), 127.8, 128.1, 129.2 and 130.3 (C-1 and C-11), 148.3 (C), 148.9 (C),
149.5 (C), 171.7 and 171.9 (C-9); (Found M+', 359.1736. C20H25NO5 requires M, 
359.1733).
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A^-Metliyl-A^-(3,4-dihydoxybenzyl)-3,4-dihydoxyphenylacetamide (194)
HO,
O H
O H
Boron tribromide déméthylation was carried out as reported for compound 
(149) on a 0.35 mmol scale affording the phenolic amide (194) as shiny fawn crystals 
from acetone-CHClg (70 mg, 66%), m.p. 151-154 °C; Vmax (KBr)/cm"l 3406 (OH), 
1586 (amide); ÔH 2.74 and 2.82 (3H, 2 x s, H-8), 3.51 and 3.53 (2H, 2 x s, H-10), 
4.30 and 4.36 (2H, 2 x s, H-7), 6.39-6.70 (6H, m, Ar-H), 8.72-8.95 (4H, m, OH); ôc
33.5 and 35.0 (C-8), 39.6 and 39.8 (C-10), 49.8 and 52.6 (C-7), 114.4 (CH), 115.6 
(CH), 115.7 (CH), 115.8 (CH), 116.0 (CH), 116.5 (CH), 116.6 (CH), 117.9 (CH),
119.1 (CH), 119.9 (CH),126.6, 126.8, 128.4 and 128.9 (C-1 and C-11), 144.1 (C),
144.2 (C), 144.7 (C), 144.8 (C), 145.4 (C), 145.5 (C), 145.8 (C), 171.0 and 171.1 (C-
9); (Found M + \ 303.1110. C16H 17NO5 requires M, 303.1106).
A-Metliyl-(4-methoxyphenyl)beiizylainine (196)
MeO" "
Methylamine (1.00 ml, 8.03M in EtOH, 8.03 mmol) was added dropwise to a 
stirring solution of p-anisaldehyde (1.00 g, 0.89 ml, 7.34 mmol) in dry EtOH (10 ml) 
at rt. After heating at reflux for 24 h, the resultant yellow solution was concentrated in 
vacuo to give a yellow syrup which was taken up in MeOH (20 ml) and hydrogenated 
over palladium on charcoal (10%, 100 mg) at an initial pressure of 60 p.s.i. for 24 h. 
The mixture was filtered through Celite®, the residue washed with MeOH (2 x 1 0  ml) 
and concentrated to give the title compound (196) as a colourless oil (806 mg, 73.3%) 
b.p. 76-80 °C/>1 mmHg; Vmax (neat)/cm"l 3321 (NH), 1612, 1585 and 1517 (Ar), 
815 (p(3ra-disLibstituted benzene); ÔH 1.77 (IH, bs, NH), 2.42 (3H, s, H-6), 3.67 (2H, 
s, H-5), 3.79 (3H, s, OCH3), 6.86 (2H, d, J  8.8 Hz, H-3), 7.22 (2H, d, J  8.4 Hz, H-2); 
ÔC 36.3 (C-6), 55.6 (OCH3), 55.8 (C-5), 114.2 (C-3), 129.7 (C-2), 132.7 (C-1), 159.0 
(C-4); (Found: M +', 150.0917. C9H 12NO requires M, 150.0919).
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A^-Methyl-A'^-(4-hydroxybenzyl)-4-hydroxyphenylacetamide (198)
HO'
OH
EDCI (342 mg, 1.78 mmol) was added in one portion to a stirring solution of 
amine (196) (243 mg, 1.62 mmol), 4-methoxyphenylacetic acid (296 mg, 1.78 mmol) 
and DMAP (20 mg, 0.162 mmol) in dry DCM (25 ml) at rt. After stirring for 60 h, the 
mixture was washed successively with saturated NaHCOg (20 ml), IM HCl (10 ml) 
and brine (10 ml) before drying over MgS04. The resultant solution was concentrated 
in vacuo to give a cloudy oil (396 mg) which was taken up in dry DCM (25 ml) and 
treated portionwise with boron tribromide (6.62 ml, IM in DCM, 6.62 mmol) at -78 
°C. After the addition complete, the dark brown mixture was allowed to slowly warm to 
0 °C and stirred at this temperature for 30 min before being poured cautiously into 
iced-H 20 (100 ml) and extracted into EtOAc (2 x 25 ml). The combined organic 
extracts were washed with brine (20 ml), dried over MgS04 and concentrated in vacuo 
to give a foam (364 mg). The crude product was purified by column chromatography 
eluting with EtOAc-acetone (2:1) to give a pale yellow solid which was recrystallised 
from acetone-CHClg affording the title compound (198) as a flaky solid (122 mg, 
34.0% from 196), m.p. 194-196 °C; Vmax (KBr)/cm-l 3365 (OH), 1624 (amide), 
1596 and 1515 (Ar); 5 h  2.72 and 2.85 (3H, 2 x s, H-6), 3.60 (2H, s, H-8), 4.37 and
4.45 (2H, 2 X s, H-5), 6.68-6.74 (4H, m, Ar-H), 6.93-7.02 (4H, m, Ar-H), 9.24 (bs, 
OH), 9.30 (bs, OH), 9.38 (bs, OH); Sc 33.4 and 35.0 (C-6), 39.1 and 39.5 (C-8), 49.7 
and 52.6 (C-5). 115.4 (CH), 115.5 (CH), 115.7 (CH), 126.1, 126.3, 127.7 and 128.3 
(C-1 and C-9), 128.5 (CH), 129.3 (CH), 130.2 (CH), 156.1, 156.2, 156.8 and 156.9 
(C-4 and C-12), 171.1 (C-7); (Found: M+’, 271.1207. C 16H 17N O 3 requires M, 
271.1208).
3,4-Dibenzyloxybenzaldehyde (200)
Ph. 8
Ph 9 O 4
The method of Barrero et alM ^  was used as follows. Benzyl bromide (1.44 g, 
1.0 ml, 8.42 mmol) was added dropwise to a stirring suspension of 3,4- 
dihydroxybenzaldehyde (0.50 g, 3.62 mmol) and K2CO3 (1.00 g, 7.24 mmol) in
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acetone (20 ml) at rt. After the addition complete the mixture was heated at reflux for 
17 h, cooled to rt and filtered through Celite®. The resultant solution was concentrated 
in vacuo to give an orange oil which crystallised with scratcliing. Recrystallisation from 
Et20-acetone afforded the aldehyde (200) as a lemon coloured solid (0.78 g, 68%), 
m.p. 86-88 °C (lit.,117 87 °C); ÔH 5.21 (2H, s, H-8 or H-9), 5.26 (2H, s, H-8 or H-9),
7.02 (IH, d, J  8.2 Hz, H-5), 7.30-7.51 (12H, m, H-2, H-6 and Ph-H), 9.79 (IH, s, H-n
A-Me-3,4-dibenzyloxybenzylamiiie (201)
7 NHMe
Ph 9 0  4
The method of Neidigh et was modified as follows. A mixture of 
aldehyde (200) (0.50 g, 1.57 mmol) and methylamine (0.22 ml, 8.03M in EtOH, 1.77 
mmol) in dry EtOH (10 ml) was heated at reflux for 15 h. After cooling to rt, the 
yellow solution was concentrated to give an amber oil which was taken up in fresh 
EtOH (25 ml) to which was added NaBH/j. (0.30 g, 7.85 mmol) portionwise via a solid 
addition funnel. The mixture was heated at reflux for 2 h then cooled and stined at rt 
for 24 h before pouring into H2O (100 ml). The resultant suspension was extracted 
with Et20 (2 X  20 ml) and the combined organic extracts washed with IM HCl (2 x 20 
ml). The aqueous layer was basified with 2M NaOH then extracted with CHCI3 (2 x 
20 ml), the organic solution dried over MgSOq and concentrated to give the amine 
(201) as a yellow oil (0.44 g, 84,6%); ÔH 2.39 (3H, s, NMe), 3.63 (2H, s, H-7), 5.12 
(2H, s, H-8 or H-9), 5.15 (2H, s, H-8 or H-9), 6.80 (IH, dd, J 8.2 Hz and 1.9 Hz, H-6),
6.87 (IH, d, /  8.1 Hz, H-5), 6.96 (IH, d, J  1.9 Hz, H-2), 7.26-7.45 (lOH, m, Ph-H); 8c
36.2 (NMe), 56.1 (C-7), 71.7 and 71.9 (C-8 and C-9), 115.6 (CH), 121.6 (CH), 127.7 
(CH), 127.8 (CH), 128.1 (CH), 128.8 (CH), 133.9 (C-1), 137.8 (C), 137.9 (C), 148.5 
and 149.4 (C-3 and C-4).
3,4-Dibenzyloxyphenylacetic acid (204)
10 ,  O HPhv. 8
The procedure of He et alM ^  was used on a 2.38 mmol scale affording acid 
(204) as a fawn solid (781 mg, 94.3%), m.p. 106-107 °C (aq. EtOH) (lit.,^1^ 106-108 
°C); ÔH 3.52 (2H, s, H-7), 5.12 (2H, s, H -8 or H-9), 5.13 (2H, s, H -8 or H-9), 6.78 
(IH, dd, J 8.2 Hz and 1.8 Hz, H-6), 6.88 (IH, d, J  8.4 Hz, H-5), 6.89 (IH, d, 72.0 Hz,
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H-2), 7.27-7.44 (lOH, m, Ph-H); ô c  40.9 (C-7), 71.8 (C-8 and C-9), 115.5 and 116.7 
(C-2 and C-5), 122.8 (C-6), 126.8 (C), 126.9 (CH), 127.7 (CH), 127.8 (CH), 128.2 
(CH), 128.9 (CH), 137.5 (C), 137.7 (C), 148.8 and 149.4 (C-3 and C-4), 178.3 (C-10); 
(Found: M+*, 348.1362. C22H20O4 requires M, 378.1362).
A^-Methyl-A^-(3,4-dibenzyIoxybenzyI)-3,4-dibenzyloxyphenylacetamide (205)
17
18
G. Ph
Pli
EDCI (68 mg, 0.36 mmol) was added in one portion to a stirring solution of 
amine (201) (108 mg, 0.32 mmol), acid (204) (124 mg, 0.36 mmol) and DMAP (4 mg, 
0.03 mmol) in dry DCM (20 ml) at rt. After stirring at rt for 48 h, the mixture was 
washed with H2O (10 ml), saturated NaHCOg (10 ml) and brine (10 ml) before drying 
over MgSOq. Concentration in vacuo gave a cloudy oil (210 mg) which was purified 
by silica gel flash chromatography affording the tertiai’y amide (205) as a colourless oil 
(168 mg, 78.1%); Vmax (CDCl3)/cnr^ 1637 (amide); ÔH 2.71 and 2.80 (3H, 2 x s, H- 
8), 3.59 and 3.61 (2H, 2 x s, H-10), 4.30 and 4.44 (2H, 2 x s, H-7), 5.02, 5.05, 5.07, 
5.08, 5.10 and 5.12 (8H, 7 x s, H-17, PI-18, H-19 and H-20), 6.51-6.90 (6H, m, Ar-H), 
7.21-7.51 (20H, m, Ph-H); ÔQ 34.1 and 35.4 (C-8), 40.8 and 41.1 (C-10), 50.9 and 
53.7 (C-7), 71.6, 71.7 and 71.8 (C-17, C-18, C-19 and C-20), 113.7 (CH), 115.3 (CH),
115.5 (CH), 115.7 (CH), 115.9 (CH), 116.0 (CH), 120.0 (CH), 121.6 (CH), 122.1 
(CH), 127.7 (CH), 127.8 (CH), 127,9 (CH), 128.2 (CH), 128.3 (CH), 128.7 (CH),
128.8 (CH), 128.9 (CH), 130.0 (C), 131.1 (C), 137.4 (C), 137.6 (C), 137.7 (C), 137.8 
(C), 148.3 (C), 148.7 (C), 149.5 (C), 149.7 (C), 171.5 and 171.8 (C-9); (Found: M + \ 
663.2983. C44H41NO5 requires M, 663.2985).
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A^-Methyl-A^-(3,4-diliydroxybenzyl)-3,4-dihydroxyphenylacetamide (194)
HO.
OH
OH
Palladium on charcoal (10%, 30 mg) was added to a solution of amide (205) 
(168 mg, 0.25 mmol) in MeOH-EtOAc (3:1, 20 ml) and the mixture stirred under a 
hydrogen balloon at rt for 48 h. The catalyst was filtered through Celite®, the residue 
washed with EtOAc (2 x 1 0  ml) and the combined extracts concentrated to give an oil. 
Purification by silica gel flash chromatography (2; 1 EtOAc-acetone) gave a colourless 
oil which was crystallised from acetone-CHClg affording the title compound as a solid 
(57 mg, 74.0%). This material gave a TEC and melting point analysis identical to that 
prepared from the tetramethylether.
7«^sO“l , 4 -BiS“(ethoxycarboiiylmetIiiiiyI-3 ,4 -dioxyphenyl)-2 ,3 -dimethylbutane
(207)
EtOjC-
The method of Hartzfeld et was modified as follows. NDGA (150 mg, 
0.50 mmol) in anhydrous EtOH (2 ml) was added dropwise to a stirring solution of 
sodium ethoxide (from sodium {46 mg, 2,00 mmol)) in EtOH (5 ml) at 0 °C. After 
stirring for 15 min, ethyl dichloroacetate (157 mg, 0.12 ml, 1.00 mmol) was added 
dropwise to the dark green solution and the mixture allowed to warm to rt. The 
resultant brown solution was stirred at rt for 1 h, heated at reflux for 6 h then allowed 
to cool to rt before concentrating in vacuo. The brown solid so obtained was taken up 
in E t20 (20 ml), washed with 5% NaHCOs (10 ml) and water (10 ml) before drying 
over M gS04. Concentration in vacuo afforded the title compound (207) as a crude 
yellow oil (65 mg, 28%). A purified sample was obtained by silica gel flash 
chromatography collecting the fraction at Rf 0.65; ÔH 0.82 (3H, d, J  6.6 Hz, H-10), 
1.33 (3H, t, 7 7.1 Hz, OCH2CH3), 1.72 (IH, m, H-9), 2.20-2.32 (IH, m, H-8), 2.66- 
2.75 (IH, m, H-8), 4.32 (2H, q, 7 7.1 Hz, OCH2CH3), 6.28 (IH, s, H-7), 6.61-6.80
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(3H, m, Ar-H); ô c  14.0 and 16.0 (C-10 and CH3), 38.9 (C-8), 39.3 (C-9), 62.4 (C% ),
102.8 (C-7), 108.1 and 109.4 (C-2 and C-5), 122.3 (C-6), 136.2 (C-1), 144.6 and
146.6 (C-3 and C-4); m/z (CI/NH3) 488 (M+NH4)+*.
m^j:o-l,4-Bis-(ethoxycarbonylraethinyl-3,4-dioxyphenyI)-2,3-dimethylbutane 
disodium sait (208)
To a stirring solution of NaOH (5 mg, 0.13 mmol) in EtOH (2 ml) was added 
ester (207) (25 mg, 0.05 mmol) in EtOH (2 ml) dropwise at rt. After stirring for 1 h, 
the resultant precipitate was collected by centrifuge and washed several times with 
EtOH affording the acid salt (208) as a pale brown solid (17 mg, 70%); ô h  (D2O) 
0.61 (3H, d, 7 6.4 Hz, H-10), 1.52 (2H, m, H-9), 2.13 (IH, m, H-8), 2.52 (IH, m, H-8),
5.98 (IH, s, H-7), 6.56-6.68 (3H, m, Ar-H); Umax. (KBr)/cm"l, 1640 (C=0).
A^-(BenzyIoxycarbonyl)aminoacetaIdehyde dimethylacetal (211)
OMe 
OMe
The method of Bischofberger et was used as follows. Benzyl
chloroformate (4.23 g, 3.54 ml, 24.81 mmol) was added dropwise to a stirring solution 
of aminoacetaldehyde dimethylacetal (2.00g, 2.07 ml, 19.02 mmol) in dry (1:1) EtOAc- 
pyridine (12 ml) at 0 °C, After the addition was complete, the mixture was allowed to 
warm to rt and stirred for 4 h. The resultant mixture was filtered through a sinter funnel 
and the residue extracted with EtOAc (3 x 10 ml). The combined organic extracts were 
washed successively with H2O (20 ml), IM KOH (2 x 15 ml), 5% citric acid (4 x 20 
ml) and brine (20 ml) before drying over MgS04. Concentration in vacuo gave a light 
yellow oil (4.27 g) which was purified by distillation under reduced pressure giving 
carbamate (211) as a colourless oil (2.23 g, 49.0%), b.p 132-140 °C / 0.02 mmHg 
(lit.,123 145 °c / 0.03 mmHg); Umax. (neat)/cm-l 3342 (NH), 1716 (C=0); 8h  3.35 
(2H, t, J  5.7 Hz, H-3), 3.40 (6H, s, OCH3), 4.40 (IH, t, J 5.3 Hz, H-4), 5.12 (2H, s, H-
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1), 7.31-7.40 (5H, m, Ar-H); ô c  42.9 (C-3), 54.7 (OCH3), 67.2 (C-1), 103.2 (C-4), 
128.5 and 128.9 (CH), 136.8 (C), 156.8 (C-2).
A “(Benzyloxycarbonyl)ammoacetaldehyde (212)
o
. o ,N
The method of Bischofberger et was used as follows. A mixture of acetal
(211) (500 mg, 2.09 mmol) and oxalic acid (42 mg, 0.47 mmol) in (2:1) THF-H2O (6 
ml) was heated at reflux for 17 h. After cooling to rt, the mixture was transferred to a 
separating funnel containing Et20 (30 ml) and washed with 5% NaHCOg (15 ml) and 
brine (10 ml) before drying over MgS04. Concentration in vacuo gave a clear oil (363 
mg) which was purified by silica gel flash chromatography affording the aldehyde
(212) as a colourless liquid (228 mg, 56.6%); ôh 4.14 (2H, d, 7 5.1 Hz, H-3), 5.14 
(2H, s, H-1), 5.56 (IH, s, NH), 7.32-7.42 (5H, m, Ar-H), 9.64 (IH, s, CHO); ô c  52.0 
(C-3), 67.6 (C-1), 128.5, 128.7 and 129.0 (CH), 136.5 (C), 156.7 (C-2), 197.0 (CHO).
m^so-l,4-Bis-(3,4-di-{A-^erfbutoxycarbonyl}aminoacetoxyphenyl)-2,3- 
dimethylbutane (215)
O ^ N
O H
10
0
15
NH
NH
To a stirring solution of me^o-NDGA (100 mg, 0.33 mmol) and N-{tei't- 
butoxycarbonyl)glycine (255 mg, 1.46 mmol) in dry EtOAc (5 ml) was added pyridine 
(0.12 ml, 1.46 mmol) dropwise. The mixture was cooled to 0 °C and DCC (300 mg,
1.46 mmol) was added in one portion and the mixture allowed to warm to rt and stiiTed 
for 16 h. The resultant suspension was filtered through Celite® and the residue washed 
with EtOAc (2 x 20 ml). The filtrate was washed successively with 5 % NaHCOg (2 x 
20 ml), 5 % citric acid (2 x 20 ml) and brine (1 x 10 ml) before drying over MgS04.
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The resultant mixture was allowed to stand at 0 °C overnight to precipitate any 
remaining DCU which was filtered off and the solvent removed in vacuo to yield the 
glycine ester (215) as pale yellow crystals of indefinite melting point (308 mg, 100 %); 
Dmax. (KBr)/cm"l, 1704 (carbamate), 1786 (ester); ÔH 0.84 (3H, d, J  6.4 Hz, H-9),
1.46 (18H, s, H-14 and H-19), 1.78 (IH, m, H-8), 2.34-2.39 (IH, m, H-7), 2.69-2.74 
(IH, m, H-7), 4.13 (4H, d, 7 5.9 Hz, H-11 and H-16), 5.59 (IH, s, NH), 5.67 (IH, s, 
NH), 6.86-7.10 (3H, m, Ar-H); ÔC 16.2 (C-9), 26.6 (C-8), 28.3 (C-14 and C-19), 38.2 
(C-7), 42.3 (C-11 and C-16), 80.0 and 80.3 (C-13 and C-18), 122.8, 123.3 (C-2 and 
C-5), 127.4 (C-6), 139.7, 140.8 and 141.4 (C-1, C-3 and C-4), 156.2 (C-12 and C-17),
168.3 (C-10 and C-15); (Found m /z  {FAB + }, {M+Na)+* 9 5 3 .4 3 7 4 . 
C46H66N40i6Na requires M, 953.4372).
meso-l,4-Bis-(3,4-diammoniumacetoxyphenyl)-2,3-dimethylbutane 
tetrachloride (216)
10O
12
Dry HCl was bubbled into an ice cold solution of the protected ester (215) 
(150 mg, 0.16 mmol) in dry EtOAc (10 ml) for 3 min whereupon a white precipitate 
soon separated from the reaction mixture. The mixture was allowed to slowly warm to 
rt and stirred for a further 1 hr before being concentrated in vacuo. The resultant solid 
was washed with EtOAc (2 x 1 0  ml) to give the glycine ester (216) as a white solid 
(106 mg, 97 %), m.p. 205-210 °C dec.; 'Umax. (KBr)/cm-l, 1778 (ester); § h  (D^O) 
0.64 (6H, d, 7 6.5 Hz, H-9), 1.62 (IH, m, CH), 2.20-2.31 (IH, m, H-7), 2.64-2.71 (IH, 
m, H-7), 4.09 (4H, s, H-11), 7.06-7.09 (3H, m, Ar-H); (Found m/z {FAB+}, 
{M+H}+* 531.2452. C26H35N4O8 requires M, 531.2455).
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l,6-Bis-(3,4-di-{A^-^^r^butoxycarbonylamino)acetoxyphenyl)hexane (217)
H OO H
1 5 ,  N .  14 o
O O
Pyridine (116 mg, 0.12 ml, 1.46 mmol) was added to a stirring solution of 
diarylhexane (156) (100 mg, 0.33 mmol) and A^-(fôrf-butoxycai'bonyl)glycine (256 mg,
1,46 mmol) in dry EtOAc (8 ml) at 0 °C. After stirring for 5 min, DCC (300 mg, 1.46 
mmol) was added in one portion and the mixture allowed to waim to rt and stirred for a 
further 16 h. The mixture was filtered through Celite® and the residue extracted with 
EtOAc (2 x 1 0  ml). The combined organic extracts were washed successively with 5% 
N aH CO s (10 ml), 5% citric acid (10 ml) and brine (10 ml) before drying over 
MgS04. Concentration of the organic exrtracts gave an oily residue which was taken 
up in DCM (2 ml) and allowed to stand in a freezer overnight. Filtration and 
concentration in vacuo afforded the title compound as shiny crystals (307 mg, 100%), 
m.p. 58-65 °C; Dmax. (KBr)/cm-l, 1788 (ester), 1702 (carbamate); ÔH 1.33 (2H, m, 
CH2), 1.46 (18H, s, H-12 and H-17), 1.59-1.61 (2H, m, CH2), 2.58 (2H, t, 7 7.5 Hz, 
H-7), 4.12 (4H, d, 74.6 Hz. H-9 and H-14), 5.49-5,51 (2H, m, NH), 6.98-7.08 (3H, m, 
Ar-H); 5 c  28.7 (C-12 and C-17), 29.2 (CH2), 31.2 (CH2), 35.5 (C-7), 42.8 (C-9 and 
C-14), 80.6 (C-11 and C-16), 123.1 and 123.3 (C-2 and C-5), 127.2 (C-6), 139.9 (C- 
1), 141.8 and 142.4 (C-3 and C-4), 156.6 (C-10 and C-15), 168.5 and 168.6 (C-8 and 
C-13); (Found: C 59.41; H 7.28; N 6.04; (M+Na)+* (FAB+), 953.4374. 
C46H66N4 0 i 6Na requires C 59.35; H 7.10; N 6.02; M, 953.4372).
l,6-Bis-(3,4-diammoniumacetoxyphenyl)hexane tetrachloride (218)
NHjCiC1H,N
C l H s N . i i ^  /k :  ^  NH3CI
10 0
5
Dry HCl was bubbled into a solution of the protected amine (217) (220 mg,
0.24 mmol) in dry EtOAc (7 ml) at 0 °C for 2 min. A white solid quickly precipitated 
and the mixture was allowed to warm to rt and stirred for a further 20 min. The solid 
was collected by filtration, washed with Et2 0  (2 x 10 ml) and dried over P2O5 to 
afford the amine salt (218) as a powder (124 mg, 78%), m.p 185-190 '"C; Dmax. 
(KBr)/cm'l, 2771 (ester); ÔH 1.25 (2H, bs, CH2), 1.53 (2H, bs, CH2), 2.58 (2H, t, 7
7.4 Hz, H-7), 4.23 (4H, 2 x s, H-9 and H-11), 7.18-7.27 (3H, m, Ar-H); 6c  28.2 and
30.6 (CH2), 34.7 (C-7), 40.5 (C-9 and C-11), 123.3 and 123.4 (C-2 and C-5), 128.6
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(C-6), 138.4 (C-1), 140.4 and 144.6 (C-3 and C-4), 167.1 and 167.2 (C-8 and C-10); 
(Found: (M+H)+* (FAB-h), 531.2453. C26H35N40sNa requires M, 531.2455.
(j»eio)-l,4-Bis-(3,4-dimethoxypheiiyl)-2,3-dimethylbutane (47)
McO,
MeO 4
OMe
OMe
The procedure of Perry et was modified as follows : A solution of KOH 
(210 mg, 3.75 mmol) in MeOH (0.65 ml) and water (1 ml) was added dropwise to a 
stirring solution of NDGA (250 mg, 0,83 mmol) in MeOH (2 ml). To the resultant 
green solution was added dimethyl sulfate (840 mg, 0.63 ml, 6.66 mmol) dropwise and 
the mixture stirred for a further 23 h ensuring the mixture was maintained at pH 8-9 by 
periodical addition of more KOH solution. Ammonia solution (35%, 5 ml) was added 
to the tan coloured suspension and the mixture stirred for a further 30 min. The 
resultant mixture was extracted with EtOAc (30 ml) and the organic extracts washed 
with water (10 ml) and brine (10 ml) before drying over MgS04. Concentration in 
vacuo gave a fawn coloured solid (285 mg) which was recrystallised from aq. MeOH 
affording the protected diaryl butane (47) as shiny tan coloured crystals (249 mg, 
83.8%), m.p. 99-101 °C (lit,42 100-102 X ); by  0.78 (6H, d, 76.6 Hz, H-9), 1.68-1.72 
(2H, m, H-8), 2.20-2.26 (2H, dd, J  13.2 and 9.2 Hz, H-7), 2.66-2.70 (2H, dd, J  13.2 
and 4.8 Hz, H-7), 6.65 (2H, d, J  1.8 Hz, H-2), 6.70 (2H, dd, J  8.1 and 1.8 Hz, H-6),
6.79 (2H, d, 7 8.1 Hz, H-5).
(meso)-l,4-Bis-(4,5-dimetlioxy-2-iiitropheiiyl)-2,3-dimethylbutaiie (222)
NO2
Me*
OMe
Mel
OMe
The procedure of Schroeter et was modified as follows. Concentrated 
HNO3 (0.19 ml, d 1.42, 4.22 mmol) was added dropwise at rt to a stirring solution of 
diarylbutane (47) (400 mg, 1.12 mmol) in glacial AcOH (2.5 ml). A yellow solid 
precipitated from the solution and stirring was continued for a further 1.5 h at rt. Water
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(15 ml) was added, the mixture extracted with CHCI3 (50 ml) and the organic extracts 
washed with saturated NaHCOg (20 ml) and brine (15 ml) before drying over 
M g S 0 4 , Concentration in vacuo gave a orange solid (233 mg) which was 
recrystallised from MeOH affording the nitrated diarylbutane (222) as orange crystals 
(203 mg, 81.2%), m.p, 149-151 °C (lit.,37 150-151 “C).
New data : Vmax (KBr)/cm'l 1523 and 1335 (NOg); 5 h  0.80 (3H, d, J  6.7 Hz, H-9), 
1.79-1.81 (IH, m, H-8), 2.58-2.63 (IH, dd, J  13.2 and 9.2 Hz, H-7), 3.27-3.31 (IH, dd, 
J  13.2 and 4.0 Hz, H-7), 3.86 (3H, s, OCH3), 3.91 (3H, s, OCH3), 6.68 (IH, s, H-6), 
7.54 (IH, s, H-3); 8c  16.6 (C-9), 37.3 (C-7), 39.3 (C-8), 56.6 (OCH3), 56.8 (OCH3),
108.8 and 114.9 (C-3 and C-6), 132.7 (C-1), 141.7 and 147.5 (C-2 and C-4), 153.0 
(C-5); (Found: C 58.88%; H 6.36%; N 6.20%; M+", 448.1844. C22H 28N 2O 8 
requires C 58.93%; H 6.25%; N 6.25%; M, 448.1846).
(/Keso)-l,4-BiS“(4,5“dihydroxy-2-am inophenyl)-2,3-dim ethylbutane diHBr
(223)
HO'
OH
HO'
OH
Palladium on charcoal (10%, 150 mg) was added to a stirring solution of (222) 
(325 mg, 0.73 mmol) in EtOAc (20 ml) and the mixture stirred at rt under a hydrogen 
balloon overnight. The catalyst was removed through Celite® and the residue extracted 
with EtOAc (3 X 10 ml). Concentration in vacuo afforded a sticky white solid which 
was purified by flash column chromatography eluting with EtOAc affording the free 
amine as a sticky off-white solid (0.26 g, 91%); ôfj 0.85 (3H, d, J  6.6 Hz, H-9), 1.79-
1.84 (IH, m, H-8), 2.19 (IH, dd, J  14.0 Hz and 9.6 Hz, H-7), 2.59 (IH, dd, J  14.0 Hz 
and 4.8 Hz, H-7), 3.72 (3H, s, OCH3), 3.75 (3H, s, OCH3), 6.21 (IH, s, H-5), 6.51 
(IH, s, H-2). The protected amine was taken up in 48% hydrobromic acid (5 ml) and 
heated at reflux for 2 h. After cooling to rt the precipitated brown solid was filtered and 
washed with 48% HBr (10 ml) affording the amine salt (223) as a tan solid (279 mg, 
76% from 222), m.p. > 250 °C; Vmax (KBr)/cm"l 1619, 1570 and 1532 (aromatic); 
ÔH (D2O) 0.73 (3H, d, 76.4 Hz, H-9), 1.73 (IH, m, H-8), 2.30 (IH, dd, 7 14.4 Hz and
10.4 Hz, H-7), 2.66 (IH, dd, 7 14.5 Hz and 4.1 Hz, H-7), 6.74 (IH, s, H-3 or H-6),
6.79 (IH, s, H-3 or H-6); 6c  (D2O) 15.3 (C-9), 32.8 (C-7), 38.0 (C-8), 111.5 and
118.3 (C-3 and C-6), 120.8 and 127.5 (C-1 and C-2), 143.2 and 144.9 (C-4 and C-5);
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(Found; C 42.57%; H 5.30%; N 5.44%; M+*, 332.1735. C 18H24N2O4 .H2O requires 
C 42.19%; H 5.47%; N 5.47; M, 332.1736).
l,4-Bis-(4,5-dimethoxy-2-iiitropheiiyl)butane (224) :
NO2
MeO
NO2OMe
Me<
OMe
Concentrated HNO3 (0.15 ml, 3.39 mmol) was added dropwise to a stirring 
solution of diarylbutane (148) (150 mg, 0.45 mmol) in glacial AcOH at rt resulting in 
precipitation of a yellow solid. The resultant suspension was stirred for a further 1.5 h 
before water (20 ml) was added and the mixture extracted into CHCI3 (2 x 20 ml). The 
combined organic extracts were washed with saturated NaHC03 (20 ml) and brine (15 
ml) before drying over MgSÜ4 . Concentration in vacuo gave an orange solid (173 mg, 
91%) which was recrystallised from /-PrOH affording the nitrated diarylbutane (224) 
as golden crystals (130 mg, 68.1%), m.p. 183-184 °C (lit.,38 184-185 °C {AcOH}); 
Vmax (KBr)/cm"ll581 and 1518 (aromatic), 1325 (NO2); ÔH L76 (2H, bs, H-8),
2.98 (2H, bs, H-7), 3.93 (3H, s, OCH3), 3.98 (3H, s, OCH3), 6.74 (IH, s, H-6), 7.59 
(IH, s, H-3); ÔC 31.0 and 34.0 (C-7 and C-8), 56.7 (OCH3), 56.8 (OCH3), 108.6 (C- 
3), 113.6 (C-6), 133.3 (C-1), 141.4 (C-2), 147.5 (C-4), 153.4 (C-5); (Found: M+* 
420.1533. C20H24N2O8 requires M, 420.1533).
l,4-Bis-(4,5-dimethoxy-2-amiiîophenyl)butane (225)
MeO"
OMe
Mel
OMe
Palladium on carbon (10%, 25 mg) was added to a solution of the diarylbutane
(224) (95 mg, 0.23 mmol) in dioxane (15 ml) and the mixture stirred under a hydrogen 
balloon overnight. The mixture was filtered through Celite® and the residue extracted 
with CHCI3 ( 2 x 5  ml) to give a lilac coloured solution. TLC of this mixture showed 
mostly starting material and a minor lower running spot that gave a positive result with 
Dragendorff stain. The reaction mixture was not further investigated.
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A^-(3,4-Dimetlioxybenzyl)-A'^-(2-{3,4-dimethoxyphenyl)ethylammoiiium
bromide (226)
MeO
12 OMe
OMe
2-(3,4-Dimethoxyphenyl)ethylamine (0,57 g, 0.53 ml, 3.16 mmol) was added 
to a solution of 3,4-dimethoxybenzaldehyde (0.50 g, 3.01 mmol) in anhydrous EtOH 
(15 ml) and the mixture heated at reflux under nitrogen for 18 h. After cooling to rt the 
mixture was concentrated in vacuo to gave the intermediate imine as an amber coloured 
oil; ÔH 8.05 (CH=N). The crude imine was taken up in fresh EtOH (20 ml) and treated 
portionwise with NaBH4 (569 mg, 15.04 mmol) via a solid addition funnel. The 
mixture which almost became colourless was heated at reflux for 1 h allowed to cool 
and stirred overnight at rt. The resultant mixture was poured into water (60 ml), 
extracted with CHCI3 (2 x 20 ml) and the combined organic extracts washed with 
water (20 ml) and brine (20 ml) before drying over MgS04. Concentration in vacuo 
gave a white solid which was recrystallised from 48% HBr to give the amine salt (226) 
as a tan coloured solid (1.24 g, 100%), m.p. 184-186 °C (lit.,1^^ 187 °C); Vmax 
(KBr)/cm-l 1596 and 1519; 8h  (dg-DMSO) 2.91 (2H, t, J 9.1 Hz, H-9), 3.08-3.12 
(2H, m, H-8), 3.72 (3H, OCH3), 3.75 (3H, OCH3), 3.76 (3H, s, OCH3), 3.78 (3H, s, 
OCH3), 4.11 (2H, t, J 5.6 Hz, H-7), 6.75 (IH, dd, J  8.1 Hz and 1.9 Hz, H-6 or H-I5),
6.85 (IH, d, 7 1,9 Hz, H-2 or H-11), 6.90 (IH, d, J  8.2 Hz, H-5 or H-14), 6.99 (IH, d, 
J  8.3 Hz, H-5 or H-14), 7.04 (IH, dd, J  8.2 Hz and 1.9 Hz, H-6 or H-15), 7.23 (IH, d, 
J 1.8 Hz, H-2 or H-11), 8.34 (2H, bs, NH2); 5 c  (de-DMSO) 31.3 (C-8), 47.7 and
50,2 (C-7 and C-9), 55.8, 55.9 and 56,0 (OCH3), 111,9, 112.4, 112.8 and 114.0 (C-2, 
C-5, C-11 and C-14), 120.9 and 123.0 (C-6 and C-15), 124.3 and 129.8 (C-1 and C-
10), 148.0, 149,0, 149.2 and 149,6 (C-3, C-4, C-12 and C-13); (Found; M +’ 
331.1781. C 19H24NO4 requires M, 331.1784).
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A'^-(3,4-Dihydroxybenzyl)-A^-(2-{3,4-dihydroxyphenyl)ethylammonium 
bromide (227)
HO
12 OH
OH
A mixture of the amine salt (226) (250 mg, 0.61 mmol) and 48% HBr (10 ml) 
was heated at reflux under nitrogen for 18 h. After cooling to rt the light orange 
solution was concentrated in vacuo to give a brown solid which was triturated with 
EtOAc affording the title compound (227) as a light brown powder (151 mg, 70.0%), 
m.p.> 250 °C; 5 h  (D^O) 2.79 (2H, t, 7 7.5 Hz, H-9), 3.15 (2H, t, 77.4 Hz, H-8), 4.00 
(2H, s, H-7), 6.62 (IH, dd, 7 8.1 Hz and 2.1 Hz, H-6 or H-15), 6.70 (IH, d, 7 2.0 Hz, 
H-2 or H-11), 6.76-6.86 (4H, m, Ar-H).
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